Compositions of hydroxypropyl-beta-cyclodextrin and methods of purification thereof
By preparing a hydroxypropyl-β-cyclodextrin composition with a specific isomer ratio, the shortcomings of the hydroxypropyl-β-cyclodextrin mixture in the prior art in selective dissolution and delivery are solved, and specific The efficient dissolution and delivery of molecules is suitable for the treatment of a variety of diseases.
Patent Information
- Application Number
- CN202380025132.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-18
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-08
AI Technical Summary
Existing overall mixtures of hydroxypropyl-β-cyclodextrins are difficult to selectively dissolve or deliver specific guest molecules in certain applications and are difficult to isolates by conventional chromatography, resulting in pharmacological or chemical applications. Not effective.
By preparing a mixture containing less than 0.05% unsubstituted and a small amount of hydroxypropyl substituted beta-cyclodextrin, using nanofiltration and pH adjustment, compositions with specific isomer ratios are prepared for selection or delivery agent.
The selective dissolution and delivery of specific guest molecules is achieved, and the therapeutic effect is improved, such as the affinity for cholesterol, and is suitable for the treatment of type C Nieman-Pick disease, liver disease and cardiovascular disease, etc.
Smart Images

Figure BDA0005023996650000271 
Figure BDA0005023996650000272 
Figure BDA0005023996650000281
Abstract
Description
Technical Field
[0001] This application claims priority to U.S. Provisional Application No. 63 / 311,661, filed February 18, 2022, entitled “COMPOSITIONS OF HYDROXYPROPYL-BE TA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SA ME,” the entire contents of which are incorporated herein by reference. The present disclosure relates to mixtures of β-cyclodextrin molecules. The present disclosure also relates to compositions comprising mixtures of β-cyclodextrin molecules. Thus, the present disclosure relates to the fields of chemistry and pharmacy. Background Art
[0002] Hydroxypropyl-B-cyclodextrin ("HPBCD") is a common organic molecule with a variety of industrial applications. Such applications include pharmaceutical excipients, polymers, solubilizers, chelating agents, drug delivery vehicles, and various other uses. HPBCD is manufactured commercially on a large scale. HPBCD is typically produced by subjecting B-cyclodextrin to propylene oxide in the presence of a base to alkylate the cyclodextrin ring with hydroxypropyl groups. Alkylation (or addition of hydroxypropyl groups) can potentially occur at any available site on the cyclodextrin ring where an alcohol is present. On an industrial scale, this alkylation process is largely uncontrolled, and the resulting HPBCD product is typically a mixture of HPBCD molecules ranging from a single hydroxyl substituent to a fully alkylated molecule, where all 21 possible alkylation sites are occupied by hydroxypropyl groups, and every possible substitution combination in between. Furthermore, subsequent alkylation can occur at any or all of the 21 available hydroxyl sites on the cyclodextrin structure, resulting in a vast array of possible substitution patterns. In fact, it has been determined that there are 117,655 possible isomeric configurations that can be generated only on the primary face of the cyclodextrin ring structure. & Zhang, Yongmin & Sollogoub, Matthieu. (2021). Programmed Synthesis of Hepta-Differentiated β-Cyclodextrin: 1 out of 117655 Arrangements. Angewandte Chemie (International Edition, English). 60.10.1002 / anie.202102182. Even more strikingly, the number of possible substitution patterns considering all 21 positions becomes exponentially greater.
[0003] In most applications of HPBCD, the commercially available bulk mixture is acceptable for its intended purpose, and there is generally no technical or economic reason to expend resources to separate or isomerically purify the mixture into more concise groups or individual compounds. However, there are certain HPBCD applications that require a more refined mixture or even a single isomer. For example, it may be desirable to selectively solubilize or chelate a specific guest molecule found in a solution or suspension containing numerous substituents (e.g., cholesterol-containing blood or spinal fluid). While the bulk HPBCD mixture may dissolve the guest molecule in its presence, it may also dissolve certain spectator molecules that do not require solubilization or chelation. Conversely, it may be desirable to selectively solubilize a guest molecule (e.g., a pharmaceutical agent) or deliver it to a specific environment or internal organ. While a bulk HPBCD mixture may be highly capable of carrying a guest molecule, it may not be able to selectively deliver or release the guest molecule to a specific environment or organ. On the other hand, a specific HPBCD isomer or group of isomers may be able to selectively solubilize or deliver a desired guest molecule to a desired environment or organ. Alternatively, if a concise set of HPBCD isomers or individual compounds can be identified, isolated, and / or enriched that can selectively solubilize, sequester, deliver, or clamp a specific guest molecule of interest at the expense of other components in the mixture, unique chemical qualities that are not typically accessible using the bulk HPBCD mixture can be enhanced and utilized. The specific guest molecule of interest can be cholesterol. The specific guest molecule of interest can be one or more lipids.
[0004] Therefore, given the shortcomings described above with respect to the overall mixture of commercially available HPBCD, it is desirable in certain applications to fine-tune the selectivity of HPBCD so as to bind, deliver, or solubilize a guest or target molecule using a specific HPBCD molecule or a concise set of HPBCD isomers that can be separated from the overall commercial HPBCD mixture. A concise set of HPBCD isomers can include similar HPBCD molecules separated into groups based on, for example, molecular weight, alkylation or substitution pattern, or some other chemical property or characteristic.
[0005] The present invention provides for the isolation and use of a series of specific, similar isomers of HPBCD as selective solubilizing or chelating agents, allowing for fine-tuning of selectivity. These isolated groups of HPBCD molecules with similar chemical properties can then be used for very specific purposes. While the overall mixture can provide some generalized results, the use of isomerically similar groups of HPBCD molecules can lead to more precise pharmacological or chemical results. For example, the present invention provides for the isolation and use of specific mixtures of HPBCD molecules to selectively solubilize or chelate cholesterol. The increased affinity for cholesterol exhibited by the mixtures of the present invention is beneficial for the treatment or prevention of diseases or conditions such as Niemann-Pick disease Type C, liver disease, cardiovascular disease, familial hypercholesterolemia, and cholesterol deposition.
[0006] The preparative chromatography method previously used to purify hydroxypropyl-β-cyclodextrin molecules and related substances uses direct phase silica gel, which separates the main hydroxypropyl-β-cyclodextrin components based on the hydrophilic interaction between the OH groups of the silica gel and the OH groups of the hydroxypropyl-β-cyclodextrin components. However, this method fails to separate the different hydroxypropyl-β-cyclodextrin isomers. One reason for this is that the size and molecular weight distribution of the different isomers can be distributed within a very narrow range. The hydroxypropylation of the β-cyclodextrin molecule does not add OH groups to the β-cyclodextrin molecule; in fact, it only replaces the OH groups of the β-cyclodextrin with the OH groups of the hydroxypropyl side chain. The net charge of the molecule does not change because no ionic groups are added to the β-cyclodextrin molecule. These technical factors mentioned above make it technically infeasible and / or economically impractical to perform isomeric separations via conventional chromatographic means (e.g., ion exchange, size exclusion, reverse phase or normal phase silica gel). Summary of the Invention
[0007] Provided herein is a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"), the composition comprising an average degree of substitution of 6.02-7.98, wherein the composition is suitable for intrathecal, intravenous, oral, or intraventricular administration to a patient in need thereof. In some embodiments, the pH of the composition is between 6.0 and 7.9. In some embodiments, the true density of the composition is about 1.096-1.098 g / cm 3. In some embodiments, the weight molar osmotic concentration of the composition is about 635–695 mOs / kg. In some embodiments, the composition further comprises a container and invisible particulate matter, and the amount of invisible particulate matter having a size ≥25 microns is ≤600 / container. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by HPLC. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by gas chromatography. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by the PG / EG ratio of propylene glycol to ethylene glycol. In some embodiments, the composition comprises no more than 1 ppm propylene oxide.
[0008] In certain embodiments, the pharmaceutical composition comprises no more than ("NMT") 5 EU / g β-cyclodextrin mixture, NMT 4 EU / g β-cyclodextrin mixture, NMT 3 EU / g β-cyclodextrin mixture, or no more than 2 EU / g β-cyclodextrin mixture. In preferred embodiments, the pharmaceutical composition comprises NMT 1.5 EU / g β-cyclodextrin mixture. In certain embodiments, the pharmaceutical composition comprises NMT 1.4 EU / g β-cyclodextrin mixture, NMT 1.3 EU / g β-cyclodextrin mixture, NMT 1.2 EU / g β-cyclodextrin mixture, NMT 1.1 EU / g β-cyclodextrin mixture, or NMT 1.0 EU / g β-cyclodextrin mixture.
[0009] In some embodiments, the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC. In some embodiments, the concentration of the composition is from about 10 mg / mL to about 200 mg / mL. In some embodiments, the concentration of the mixture of β-cyclodextrin molecules of the composition is from about 10 mg / mL to about 200 mg / mL. In some embodiments, the composition exhibits a ratio of Cyclo low toxicity. In some embodiments, the conductivity of the composition is about ≤200 μS / cm. In some embodiments, the composition is stable for at least 6 months. In some embodiments, the composition further comprises at least one of the following: a pharmaceutical excipient, a carrier, a pharmaceutically acceptable diluent, a pH adjuster, and a buffer. In some aspects, the pH adjuster is sodium hydroxide. In some aspects, the buffer comprises sodium dihydrogen phosphate and disodium hydrogen phosphate.
[0010] Further provided herein is a method for preparing a mixture of purified β-cyclodextrin suitable for intrathecal, intravenous, oral, or intracerebroventricular administration to a patient in need thereof, the method comprising nanofiltering the β-cyclodextrin to achieve a mixture of purified β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"), and wherein the average degree of substitution is 6.02-7.98, and adjusting the pH of the nanofiltered purified β-cyclodextrin mixture to achieve a pH of 6.0 to 7.8. In some embodiments, the pH is adjusted with 0.1 M sodium hydroxide.
[0011] Further provided herein is a method of treating Niemann-Pick disease type C, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with a hydroxypropyl group at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"), the composition comprising an average degree of substitution of 6.02-7.98, wherein the composition is suitable for intrathecal, intravenous, oral, or intracerebroventricular administration to a patient in need thereof. Also provided herein is a composition for use in a method for treating Niemann-Pick disease type C, the method comprising administering a therapeutically effective amount of a composition to a patient in need thereof, wherein the composition comprises a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, and wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"), the composition comprising an average degree of substitution of 6.02-7.98, wherein the composition is suitable for intrathecal, intravenous, oral, or intraventricular administration to a patient in need thereof. Alternatively, the method may be a method for treating liver disease, cardiovascular disease, familial hypercholesterolemia, or cholesterol deposition. In some embodiments, the method comprises administering to the patient about 50 mg to about 2000 mg of the β-cyclodextrin mixture. In some embodiments, about 50 mg to about 300 mg of the β-cyclodextrin mixture is administered. In some embodiments, the method comprises administering the composition at intervals of 1 day, 2 days, or 3 days. In some embodiments, the method includes administering the composition once a week. In some embodiments, the composition is administered once every two weeks. In some embodiments, the administration includes administering about 200 mg / kg to about 4100 mg / kg of a β-cyclodextrin mixture intravenously to the patient. In some embodiments, the administration causes one or more lipids (e.g., one or more low-density lipoproteins (LDL) and / or triglycerides) to decrease by 75% ± 5%, 80% ± 5%, 85% ± 5%, 90% ± 5% or 95% ± 5%. In some embodiments, the administration prevents NPC progression compared to no administration or administration of a placebo. In some embodiments, the administration is sufficient to maintain or reduce one or more domain scores of the NPC Severity Scale (NPC Severity Scale), wherein the one or more domain scores are selected from: walking, fine motor skills, cognition, speech, swallowing, eye movement, memory, hearing and epileptic seizures. In some embodiments, the administration is carried out within 4 hours. In some embodiments, the duration of administration (which is preferably intravenous administration) is about 4 hours or less.
[0012] Further provided herein is a composition comprising a mixture of β-cyclodextrin molecules, wherein the mixture of β-cyclodextrin molecules comprises β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"); β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"); β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"); β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"); β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"); β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"); hydroxypropyl substituted β-cyclodextrin ("DS-9"); β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"); β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"); β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"); β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"); and β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"); and wherein the mixture of β-cyclodextrin molecules comprises less than 1% DS-4. In some embodiments, the composition has Figure 4 In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules has an HPLC-CAD average retention time of about 13.5 minutes. In some embodiments, the mixture of β-cyclodextrin molecules has Figure 3DEPT-edited HSQC spectra of β-cyclodextrin molecules. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 0.5% w / w to about 1% w / w DS-4. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 2% w / w to about 5% w / w DS-5. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 7% w / w to about 13% w / w DS-6. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 21% w / w to about 27% w / w DS-7. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 23% w / w to about 29% w / w DS-8. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 15% w / w to about 21% w / w DS-9. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 6% w / w to about 12% w / w DS-10. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 2% w / w to about 6% w / w DS-11. In some embodiments, the mixture of β-cyclodextrin molecules comprises about 0.5% w / w to about 4% w / w DS-12. In some embodiments, the mixture of β-cyclodextrin molecules comprises less than about 1% w / w DS-13. In some embodiments, the composition does not contain DS-0, DS-1, DS-2 and / or DS-3. In some embodiments, the mixture of β-cyclodextrin molecules is suitable for intravenous, intrathecal or intracerebroventricular administration. In some embodiments, the composition is suitable for intravenous, intrathecal or intracerebroventricular administration. In some embodiments, the amount of DS-1, DS-2, DS-3, DS-4, DS-5, DS-6, DS-7, DS-8, DS-9, DS-10, DS-11, DS-12 and DS-13 in the mixture of β-cyclodextrin molecules is determined by MALDI-TOF-MS. In some embodiments, DS-8 has the highest concentration in the mixture of β-cyclodextrin molecules compared to the concentrations of DS-1, DS-2, DS-3, DS-4, DS-5, DS-6, DS-7, DS-9, DS-10, DS-11, DS-12, and DS-13. In some embodiments, the β-cyclodextrin molecules are substituted at the 2-O-position with a substitution rate of 35%-55%, substituted at the 3-O-position with a substitution rate of 45%-65%, and substituted at the 6-O-position with a substitution rate of 0%-20%. In some embodiments, the substitution rates at the 2-O-, 3-O-, and 6-O-positions are determined by HSQC edited by DEPT. These positions (2-O-, 3-O-, and 6-O-) on each glucose unit of β-cyclodextrin are confirmed as follows. In some embodiments, the average degree of substitution of the composition is between about 7 and about 9.In an exemplary embodiment, the composition has an average degree of substitution of about 7.7. In some embodiments, the composition has. Figure 1 In some embodiments, the true density of the composition is about 1.095 g / cm 3 to about 1.100g / cm 3 . In some embodiments, the weight molar osmotic concentration of the composition is about 600mOs / kg to about 750mOs / kg. In some embodiments, the composition is a clear and colorless solution. In some embodiments, the pH of the composition is about 4.0 to about 6.0. In some embodiments, the viscosity of the composition at 20°C is 1.5cP to about 3.0cP. In some embodiments, the composition contains less than or equal to about 0.05% impurities. In some embodiments, the composition contains less than 600 particles / container having a diameter greater than or equal to 25 microns. In some embodiments, the composition contains less than 6000 particles / container having a diameter greater than or equal to 10 microns.
[0013] Further provided herein is a composition comprising a mixture of β-cyclodextrin molecules, wherein the composition has 1 H-NMR spectrum, which comprises at least one peak at about 5.0-5.4 ppm corresponding to the anomeric protons of the β-cyclodextrin molecule; at least one peak at about 3.2-4.2 ppm corresponding to the protons in the core region of the β-cyclodextrin molecule; and at least one peak at about 1.0-1.2 ppm corresponding to the methyl protons of the side chains of the β-cyclodextrin molecule. In some embodiments, the composition may have Figure 2 of 1 H-NMR.
[0014] Fraction 1 mixture
[0015] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, the mixture comprising less than 1% β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"). In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the weight percentage. In some embodiments, the composition comprises less than 1% β-cyclodextrin substituted with three hydroxypropyl groups ("DS-3"), β-cyclodextrin substituted with two hydroxypropyl groups ("DS-2"), and β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 5% β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 7% to about 13% hexahydroxypropyl-substituted β-cyclodextrins ("DS-6"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 8% to about 12% DS-6. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 16% to about 22% heptahydroxypropyl-substituted β-cyclodextrins ("DS-7"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 17% to about 21% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 26% to about 32% octahydroxypropyl-substituted β-cyclodextrins ("DS-8"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 27% to about 31% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 22% to about 28% β-cyclodextrins substituted with nine hydroxypropyl groups ("DS-9"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 23% to about 27% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 11% to about 17% β-cyclodextrins substituted with ten hydroxypropyl groups ("DS-10"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrins comprises from about 12% to about 16% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises less than 1% β-cyclodextrins substituted with eleven hydroxypropyl groups ("DS-11").In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises less than 1% β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"), β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"), and β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrins is from about 6.4 to about 7.0. In an exemplary embodiment, the average degree of substitution is about 6.69. In some embodiments, from about 52% to about 58% of the hydroxypropyl substitutions in the hydroxypropyl β-cyclodextrin molecules are located at the 3-O-position. In some aspects, from about 55% to about 56% of the hydroxypropyl substitutions in the β-cyclodextrin molecules are located at the 3-O-position. In some embodiments, from about 41% to about 47% of the hydroxypropyl substitutions in the hydroxypropyl β-cyclodextrin molecules are located at the 2-O-position. In some aspects, about 43% to about 45% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some embodiments, the concentration of the composition will not substantially change the time required for nanofiltration. In some aspects, the duration of the nanofiltration composition is in the range of 1.04 to 1.20 hours / diafiltration volume (kg soln / m2-hr / L soln). In some embodiments, compared to before nanofiltration, no substantial differences are observed in the HPLC-ELSD after nanofiltration of the composition. In some embodiments, compared to before nanofiltration, no substantial differences are observed in the NMR after nanofiltration of the composition. In some embodiments, the electrical conductivity of the composition is between 0 and 8.0 μS / cm, between 0 and 4.5 μS / cm, between 0 and 3 μS / cm, or between 0 and 1.5 μS / cm. In some embodiments, the weight molar osmotic concentration of the composition is about 600mOs / kg to about 750mOs / kg. In some embodiments, the composition has a true density of about 1.095 g / cm². 3 to about 1.100g / cm 3 In some embodiments, the pH of the composition is from about 4.0 to about 8.0. In some embodiments, the viscosity of the composition at 20° C. is from about 1.5 cP to about 10,000 cP.
[0016] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"); β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"); β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"); β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"); β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"); and β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"), wherein the composition comprises less than 1% β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4") and less than 1% β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"). In some embodiments, the composition comprises 0.0 to 1.0% of three hydroxypropyl-substituted β-cyclodextrin ("DS-3"), 0.0 to 1.0% of two hydroxypropyl-substituted β-cyclodextrin ("DS-2"), and 0.0 to 1.0% of one hydroxypropyl-substituted β-cyclodextrin ("DS-1"). In some embodiments, the composition comprises less than 1% of twelve hydroxypropyl-substituted β-cyclodextrin ("DS-12"), thirteen hydroxypropyl-substituted β-cyclodextrin ("DS-13"), and fourteen hydroxypropyl-substituted β-cyclodextrin ("DS-14"). In some embodiments, DS-8 has the highest concentration in the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules compared to DS-5, DS-6, DS-7, DS-9, and DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 5% DS-5. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 7% to about 13% DS-6. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 16% to about 22% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 26% to about 32% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 22% to about 28% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 11% to about 17% DS-10. In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is from about 6.4 to about 7.0. In an exemplary embodiment, the average degree of substitution is about 6.69. In some embodiments, about 52% to about 58% of the hydroxypropyl substitution in the hydroxypropyl beta-cyclodextrin molecules is located at the 3-O-position. In some embodiments, about 41% to about 47% of the hydroxypropyl substitution in the hydroxypropyl beta-cyclodextrin molecules is located at the 2-O-position. In an exemplary embodiment, the composition has Figure 8In an exemplary embodiment, the HPLC-CAD average retention time of the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules is about 10.1 minutes. In some embodiments, the composition has an -ESI-MS spectrum with peaks at about 653 m / z, about 682 m / z, about 711 m / z, about 741 m / z, about 769 m / z, about 799 m / z, about 828 m / z, and about 857 m / z, and a +ESI-MS spectrum with peaks at about 686 m / z, about 715 m / z, about 744 m / z, about 773 m / z, about 802 m / z, about 832 m / z, about 861 m / z, and about 890 m / z. In an exemplary embodiment, the composition has Figure 9 In some embodiments, the composition has a MALDI-TOF spectrum with peaks at about 1436 m / z, about 1495 m / z, about 1555 m / z, about 1614 m / z, about 1674 m / z, and about 1733 m / z. In an exemplary embodiment, the composition has Figure 10 In one exemplary embodiment, the composition has Figure 6 of 1 H-NMR spectrum. In one exemplary embodiment, the composition has Figure 7 DEPT edited HSQC spectrum of . In some embodiments, the weight molar osmotic concentration of the composition is about 635-695 mOs / kg. In some embodiments, the true density of the composition is about 1.096-1.098 g / cm 3 . In some embodiments, the conductivity of the composition is between 0 and 8.0 μS / cm. In some embodiments, the pH of the composition is from about 4.0 to about 8.0. In some embodiments, the viscosity of the composition at 20°C is from about 1.5 cP to about 10,000 cP. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by HPLC. In some embodiments, the composition comprises no more than 1 ppm propylene oxide. In some embodiments, the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC. In some embodiments, the composition further comprises chloride between 0 and 10 ppm. In some embodiments, the composition is nanofiltered. In some embodiments, no substantial difference is observed in the HPLC-ELSD after nanofiltration of the nanofiltered composition compared to before nanofiltration. In some embodiments, no substantial difference is observed in the NMR after nanofiltration of the nanofiltered composition compared to before nanofiltration.
[0017] Fraction 2 mixture
[0018] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising less than 1% hydroxypropyl β-cyclodextrin with five hydroxypropyl groups ("DS-5"). In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the weight percentage. In some embodiments, the composition comprises less than 1% β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"), β-cyclodextrin substituted with three hydroxypropyl groups ("DS-3"), β-cyclodextrin substituted with two hydroxypropyl groups ("DS-2"), and β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules does not contain DS-1, DS-2, DS-3, and / or DS-4. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 0% to about 6% hydroxypropyl β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"). In some aspects, the mixture of isomerically purified β-hydroxypropyl cyclodextrin molecules comprises from about 1% to about 5% DS-6. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 8% to about 14% hydroxypropyl β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 9% to about 13% DS-7. In some embodiments, the mixture of isomerically purified β-hydroxypropyl cyclodextrin molecules comprises from about 19% to about 25% hydroxypropyl β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 20% to about 24% DS-8. In some embodiments, the mixture of isomerically purified β-hydroxypropyl cyclodextrin molecules comprises from about 23% to about 29% hydroxypropyl β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 24% to about 28% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 17% to about 23% hydroxypropyl β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"). In some aspects, the mixture of isomerically purified β-hydroxypropyl cyclodextrin molecules comprises from about 18% to about 22% DS-10. In some embodiments, the mixture of isomerically purified β-hydroxypropylcyclodextrin molecules comprises from about 9% to about 15% hydroxypropyl β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"). In some aspects, the mixture of isomerically purified β-cyclodextrin molecules comprises from about 10% to about 14% DS-11.In some embodiments, the mixture of isomerically purified β-cyclodextrin molecules comprises from about 2% to about 8% hydroxypropyl β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"). In some aspects, the mixture of isomerically purified β-cyclodextrin molecules comprises from about 3% to about 7% DS-12. In some embodiments, the mixture of isomerically purified β-cyclodextrin molecules comprises less than 1% hydroxypropyl β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13") and / or less than 1% hydroxypropyl β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is free of DS-13 and / or DS-14. In some embodiments, the average degree of substitution of the mixture of isomerically purified β-cyclodextrin molecules is from about 7 to about 8. In an exemplary embodiment, the average degree of substitution is about 7.42. In some embodiments, about 36% to about 42% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 3-O-position. In some aspects, about 37% to about 41% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 3-O-position. In some embodiments, about 58% to about 64% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some aspects, about 59% to about 63% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. In some aspects, the duration of the nanofiltration composition is in the range of 1.04 to 1.20 hours / diafiltration volume (kg soln / m2-hr / L soln). In some embodiments, no substantial difference in composition is observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration. In some embodiments, no substantial difference in the composition is observed in NMR after nanofiltration compared to before nanofiltration. In some embodiments, the conductivity of the composition is between 0 and 8.0 μS / cm, between 0 and 4.5 μS / cm, between 0 and 3 μS / cm, or between 0 and 1.5 μS / cm. In some embodiments, the pH of the composition is from about 4.0 to about 8.0. In some embodiments, the viscosity of the composition at 20° C. is from about 1.5 cP to about 10,000 cP.
[0019] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"); β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"); β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"); β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"); β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"); β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"); and β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"), wherein the composition comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5") and the composition comprises less than 1% β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"). In some embodiments, the composition comprises less than 1% of four hydroxypropyl substituted β-cyclodextrin ("DS-4"), three hydroxypropyl substituted β-cyclodextrin ("DS-3"), two hydroxypropyl substituted β-cyclodextrin ("DS-2"), and one hydroxypropyl substituted β-cyclodextrin ("DS-1"). In some embodiments, the composition comprises less than 1% of thirteen hydroxypropyl substituted β-cyclodextrin ("DS-13") and fourteen hydroxypropyl substituted β-cyclodextrin ("DS-14"). In some embodiments, the composition is free of DS-1, DS-2, DS-3, DS-4, and / or DS-14. In some embodiments, DS-9 has the highest concentration in the composition compared to DS-6, DS-7, DS-8, DS-10, DS-11, and DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 0% to about 6% DS-6. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 8% to about 14% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 19% to about 25% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 23% to about 29% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 17% to about 23% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 9% to about 15% DS-11. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 2% to about 8% DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules has an average degree of substitution of about 7 to about 8.In some embodiments, about 36% to about 42% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecules are located at the 3-O-position. In some embodiments, about 58% to about 64% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecules are located at the 2-O-position. In an exemplary embodiment, the composition has. Figure 13 In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules has an HPLC-CAD average retention time of about 11.9 minutes. In some embodiments, the composition has an -ESI-MS spectrum with peaks at about 682 m / z, about 712 m / z, about 740 m / z, about 770 m / z, about 798 m / z, about 828 m / z, about 856 m / z, and about 886 m / z, and a +ESI-MS spectrum with peaks at about 744 m / z, about 773 m / z, about 803 m / z, about 832 m / z, about 860 m / z, about 889 m / z, and about 919 m / z. In some embodiments, the composition has a MALDI-TOF-MS spectrum with peaks at about 1497 m / z, about 1557 m / z, about 1616 m / z, about 1675 m / z, about 1734 m / z, about 1794 m / z, and about 1914 m / z. In an exemplary embodiment, the composition has Figure 15 In one exemplary embodiment, the composition has Figure 11 of 1 H-NMR spectrum. In one exemplary embodiment, the composition has Figure 12 In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules has Figure 14 In some embodiments, the composition has an osmotic pressure of about 635-695 mOs / kg. In some embodiments, the composition has a true density of about 1.096-1.098 g / cm 3. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by HPLC. In some embodiments, the composition comprises no more than 1 ppm propylene oxide. In some embodiments, the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC. In some embodiments, the composition comprises between 0 and 10 ppm chloride. In some embodiments, the conductivity of the composition is between 0 and 8 μS / cm. In some embodiments, the composition is nanofiltered. In some embodiments, no substantial difference is observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration for the nanofiltered composition. In some embodiments, no substantial difference is observed in the NMR after nanofiltration compared to before nanofiltration for the nanofiltered composition.
[0020] Fraction 3 mixture
[0021] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising less than 1% hydroxypropyl β-cyclodextrin having six hydroxypropyl groups ("DS-6") and less than 1% β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the weight percentage. In some embodiments, the composition comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"), β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"), β-cyclodextrin substituted with three hydroxypropyl groups ("DS-3"), β-cyclodextrin substituted with two hydroxypropyl groups ("DS-2"), and β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is free of DS-1, DS-2, DS-3, DS-4, and / or DS-5. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 7% heptahydroxypropyl-substituted β-cyclodextrin ("DS-7"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 2% to about 6% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 16% to about 22% octahydroxypropyl-substituted β-cyclodextrin ("DS-8"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 17% to about 21% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 22% to about 28% β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 23% to about 27% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 19% to about 25% β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 20% to about 24% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 14% to about 20% β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 15% to about 19% DS- 11. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 5% to about 11% β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12").In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 6% to about 10% DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 7% thirteen hydroxypropyl-substituted β-cyclodextrin ("DS-13"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 2% to about 6% DS-13. In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrins is from about 8 to about 9. In an exemplary embodiment, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrins is about 8.53. In some embodiments, from about 26% to about 32% of the hydroxypropyl substitutions in the hydroxypropyl β-cyclodextrin molecules are located at the 3-O-position. In some aspects, about 27% to about 31% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 3-O-position. In some embodiments, about 68% to about 74% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some aspects, about 69% to about 73% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. In some aspects, the duration of the nanofiltration composition is between 1.04 and 1.20 hours / diafiltration volume (kg soln / m. 2 -hr / L soln). In some embodiments, no substantial differences in the composition are observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration. In some embodiments, no substantial differences in the composition are observed in the NMR after nanofiltration compared to before nanofiltration. In some embodiments, the conductivity of the composition is between 0 and 8.0 μS / cm, between 0 and 4.5 μS / cm, between 0 and 3 μS / cm, or between 0 and 1.5 μS / cm. In some embodiments, the pH of the composition is from about 4.0 to about 8.0. In some embodiments, the viscosity of the composition at 20°C is from about 1.5 cP to about 10,000 cP.
[0022] Further provided herein are compositions comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"); β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"); β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"); β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"); β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"); β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"); and β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"), wherein the composition comprises less than 1% β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6") and less than 1% β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some embodiments, the composition comprises less than 1% of five hydroxypropyl-substituted β-cyclodextrin ("DS-5"), four hydroxypropyl-substituted β-cyclodextrin ("DS-4"), three hydroxypropyl-substituted β-cyclodextrin ("DS-3"), two hydroxypropyl-substituted β-cyclodextrin ("DS-2"), and one hydroxypropyl-substituted β-cyclodextrin ("DS-1"). In some embodiments, DS-9 has the highest concentration in the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules compared to DS-6, DS-7, DS-8, DS-10, DS-11, DS-12, and DS-13. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 7% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 16% to about 22% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 22% to about 28% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 19% to about 25% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 14% to about 20% DS-11. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 5% to about 11% DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 1% to about 7% DS-13. In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules is from about 8 to about 9. In an exemplary embodiment, the average degree of substitution of the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules is about 8.53. In some embodiments, about 26% to about 32% of the hydroxypropyl substitution in the β-cyclodextrin molecules is at the 3-O-position.In some embodiments, about 68% to about 74% of the hydroxypropyl substitution in the β-cyclodextrin molecules is at the 2-O-position. In an exemplary embodiment, the composition has. Figure 18 In one exemplary embodiment, the composition has an HPLC-CAD average retention time of about 13.5 minutes. In some embodiments, the composition has an -ESI-MS spectrum with peaks at about 741 m / z, about 769 m / z, about 799 m / z, about 828 m / z, about 856 m / z, about 886 m / z, and a +ESI-MS spectrum with peaks at about 773 m / z, about 803 m / z, about 833 m / z, about 860 m / z, about 889 m / z, and about 920 m / z. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules has Figure 19 In some embodiments, the composition has a MALDI-TOF spectrum with peaks at about 1557 m / z, about 1617 m / z, about 1676 m / z, about 1736 m / z, about 1795 m / z, about 1855 m / z, and about 1915 m / z. In an exemplary embodiment, the composition has Figure 20 In one exemplary embodiment, the composition has Figure 17 In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules has Figure 16 of 1 H NMR spectrum. In some embodiments, the composition has a weight molar osmotic concentration of about 635-695 mOs / kg. In some embodiments, the composition has a true density of about 1.096-1.098 g / cm 3. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by HPLC. In some embodiments, the composition comprises no more than 1 ppm propylene oxide. In some embodiments, the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC. In some embodiments, the composition comprises chlorides between 0 and 10 ppm. In some embodiments, the composition comprises chlorides between 0 and 1 ppm. In some embodiments, the conductivity of the composition is between 0 and 8 μS / cm. In some embodiments, the composition is nanofiltered. In some embodiments, no substantial difference is observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration for the nanofiltered composition. In some embodiments, no substantial difference is observed in the NMR after nanofiltration compared to before nanofiltration for the nanofiltered composition.
[0023] Fraction 4 mixture
[0024] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising less than 1% hydroxypropyl β-cyclodextrin having six hydroxypropyl groups ("DS-6"). In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the weight percentage. In some embodiments, the composition comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"), β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"), β-cyclodextrin substituted with three hydroxypropyl groups ("DS-3"), β-cyclodextrin substituted with two hydroxypropyl groups ("DS-2"), and β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is free of DS-1, DS-2, DS-3, DS-4, and / or DS-5. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 0% to about 6% heptahydroxypropyl-substituted β-cyclodextrin ("DS-7"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 5% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 13% to about 19% octahydroxypropyl-substituted β-cyclodextrin ("DS-8"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 14% to about 18% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 22% to about 28% β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 23% to about 27% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 23% to about 29% β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 24% to about 28% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 12% to about 18% β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 13% to about 17% DS- 11. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 7% to about 13% β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12").In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 8% to about 12% DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 2% to about 8% β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 3% to about 7% DS-13. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 0% to about 6% β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 5% DS-14. In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrin is from about 7.5 to about 8.5. In an exemplary embodiment, the average degree of substitution of the mixture of isomerically purified hydroxypropyl beta-cyclodextrins is about 8.08. In some embodiments, about 22% to about 28% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecules are located at the 3-O-position. In some aspects, about 23% to about 27% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecules are located at the 3-O-position. In some embodiments, about 72% to about 78% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecules are located at the 2-O-position. In some aspects, about 73% to about 77% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecules are located at the 2-O-position. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. In some aspects, the duration of the nanofiltration composition is between 1.04 and 1.20 hours / diafiltration volume (kg soln / m. 2 -hr / L soln). In some embodiments, no substantial difference is observed in the nanofiltered composition in the HPLC-ELSD after nanofiltration compared to before nanofiltration. In some embodiments, no substantial difference is observed in the nanofiltered composition in the NMR after nanofiltration compared to before nanofiltration. In some embodiments, the conductivity of the composition is between 0 and 8.0 μS / cm, between 0 and 4.5 μS / cm, between 0 and 3 μS / cm, or between 0 and 1.5 μS / cm. In some embodiments, the pH of the composition is from about 4.0 to about 8.0. In some embodiments, the viscosity of the composition at 20°C is from about 1.5 cP to about 10,000 cP.
[0025] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"); β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"); β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"); β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"); β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"); β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"); β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"); and β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"), wherein the composition comprises less than 1% β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"). In some embodiments, the composition comprises less than 1% of five hydroxypropyl-substituted β-cyclodextrin ("DS-5"), four hydroxypropyl-substituted β-cyclodextrin ("DS-4"), three hydroxypropyl-substituted β-cyclodextrin ("DS-3"), two hydroxypropyl-substituted β-cyclodextrin ("DS-2"), and one hydroxypropyl-substituted β-cyclodextrin ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is free of DS-1, DS-2, DS-3, DS-4, and / or DS-5. In some embodiments, DS-9 and DS-10 are each present at a higher concentration in the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules than DS-7, DS-8, DS-11, DS-12, DS-13, and DS-14. In some embodiments, DS-9 has the highest concentration in the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules compared to DS-7, DS-8, DS-10, DS-11, DS-12, DS-13, and DS-14. In some embodiments, DS-10 has the highest concentration in the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules compared to DS-7, DS-8, DS-10, DS-11, DS-12, DS-13, and DS-14. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 0% to about 6% DS-7. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 13% to about 19% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 22% to about 28% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises about 23% to about 29% DS- 10. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises about 12% to about 18% DS-11.In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 7% to about 13% DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 2% to about 8% DS-13. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 0% to about 6% DS-14. In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules is from about 7.5 to about 8.5. In some embodiments, from about 22% to about 28% of the hydroxypropyl substitution in the hydroxypropyl beta-cyclodextrin molecules is located at the 3-O-position. In some embodiments, from about 72% to about 78% of the hydroxypropyl substitution in the beta-cyclodextrin molecules is located at the 2-O-position. In an exemplary embodiment, the composition has. Figure 23 In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules has an HPLC-CAD average retention time of about 14.3 minutes. In some embodiments, the composition has an -ESI-MS spectrum with peaks at about 740 m / z, about 770 m / z, about 798 m / z, about 828 m / z, and about 857 m / z, and a +ESI-MS spectrum with peaks at about 803 m / z, about 831 m / z, about 861 m / z, about 889 m / z, and about 919 m / z. In some embodiments, the composition has Figure 24 In some embodiments, the composition has a MALDI-TOF spectrum with peaks at about 1559 m / z, about 1618 m / z, about 1678 m / z, about 1737 m / z, about 1796 m / z, about 1857 m / z, and about 1916 m / z. In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules has Figure 25 In one exemplary embodiment, the composition has Figure 22 In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules has Figure 21 of 1 H NMR spectrum. In some embodiments, the composition has a weight molar osmotic concentration of about 635-695 mOs / kg. In some embodiments, the composition has a true density of about 1.096-1.098 g / cm 3. In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by HPLC. In some embodiments, the composition comprises no more than 1 ppm propylene oxide. In some embodiments, the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC. In some embodiments, the composition comprises between 0 and 10 ppm chloride. In some embodiments, the conductivity of the composition is between 0 and 8 μS / cm. In some embodiments, the composition is nanofiltered. In some embodiments, no substantial difference is observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration for the nanofiltered composition. In some embodiments, no substantial difference is observed in the NMR after nanofiltration compared to before nanofiltration for the nanofiltered composition.
[0026] Fraction 5 mixture
[0027] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising less than 1% hydroxypropyl β-cyclodextrin having seven hydroxypropyl groups ("DS-7"). In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the hydroxypropyl β-cyclodextrin percentage is based on the weight percentage. In some embodiments, the composition comprises less than 1% β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"), β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"), β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"), β-cyclodextrin substituted with three hydroxypropyl groups ("DS-3"), β-cyclodextrin substituted with two hydroxypropyl groups ("DS-2"), and β-cyclodextrin substituted with one hydroxypropyl group ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is free of DS-1, DS-2, DS-3, DS-4, DS-5, DS-5 and / or DS-6. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 6% to about 12% eight hydroxypropyl-substituted β-cyclodextrin ("DS-8"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 7% to about 11% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 18% to about 24% nine hydroxypropyl-substituted β-cyclodextrin ("DS-9"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 19% to about 23% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 24% to about 30% β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 25% to about 29% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 18% to about 24% β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 19% to about 23% DS-11. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 10% to about 16% β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 11% to about 15% DS-12.In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 4% to about 10% β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 5% to about 9% DS-13. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 0% to about 6% β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some aspects, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 5% DS-14. In some embodiments, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrins is from about 9 to about 10. In an exemplary embodiment, the average degree of substitution of the mixture of isomerically purified hydroxypropyl β-cyclodextrins is about 9.65. In some embodiments, about 15% to about 21% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 3-O-position. In some aspects, about 16% to about 20% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 3-O-position. In some embodiments, about 79% to about 85% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some aspects, about 80% to about 84% hydroxypropyl substitutions in the hydroxypropyl beta-cyclodextrin molecule are located at the 2-O-position. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. In some embodiments, the duration of the nanofiltration composition is 1.04 to 1.20 hours / diafiltration volume (kg soln / m. 2 -hr / L soln). In some embodiments, no substantial differences in the composition are observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration. In some embodiments, no substantial differences in the composition are observed in the NMR after nanofiltration compared to before nanofiltration. In some embodiments, the conductivity of the composition is between 0 and 8.0 μS / cm, between 0 and 4.5 μS / cm, between 0 and 3 μS / cm, or between 0 and 1.5 μS / cm. In some embodiments, the pH of the composition is from about 4.0 to about 8.0. In some embodiments, the viscosity of the composition at 20°C is from about 1.5 cP to about 10,000 cP.
[0028] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"); β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"); β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"); β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"); β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"); β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"); and β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"), wherein the composition comprises less than 1% β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"). In some embodiments, the composition comprises less than 1% of six hydroxypropyl-substituted β-cyclodextrin ("DS-6"), 1% of five hydroxypropyl-substituted β-cyclodextrin ("DS-5"), four hydroxypropyl-substituted β-cyclodextrin ("DS-4"), three hydroxypropyl-substituted β-cyclodextrin ("DS-3"), two hydroxypropyl-substituted β-cyclodextrin ("DS-2"), and one hydroxypropyl-substituted β-cyclodextrin ("DS-1"). In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules is free of DS-1, DS-2, DS-3, DS-4, DS-5, and / or DS-6. In some embodiments, DS-10 has the highest concentration in the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules compared to DS-8, DS-9, DS-11, DS-12, DS-13, and DS-14. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 6% to about 12% DS-8. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 18% to about 24% DS-9. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 24% to about 30% DS-10. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 18% to about 24% DS-11. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 10% to about 16% DS-12. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 4% to about 10% DS-13. In some embodiments, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 0% to about 6% DS-14. In some embodiments, the mixture of isomerically purified hydroxypropyl β-cyclodextrins has an average degree of substitution of about 9 to about 10. In some embodiments, about 15% to about 21% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecules is at the 3-O-position.In some embodiments, about 79% to about 85% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecule is at the 2-O-position. In an exemplary embodiment, the composition has. Figure 28 In one exemplary embodiment, the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules has an HPLC-CAD average retention time of about 15.4 minutes. In some embodiments, the composition has an -ESI-MS spectrum with peaks at about 770 m / z, about 798 m / z, about 828 m / z, about 857 m / z, about 885 m / z, and a +ESI-MS spectrum with peaks at about 803 m / z, about 831 m / z, about 861 m / z, about 889 m / z, and about 919 m / z. In one exemplary embodiment, the composition has Figure 29 In some embodiments, the composition has a MALDI-TOF spectrum with peaks at about 1614 m / z, about 1673 m / z, about 1733 m / z, about 1792 m / z, about 1852 m / z, about 1912 m / z, and about 1971 m / z. In an exemplary embodiment, the composition has Figure 30 In one exemplary embodiment, the composition has Figure 26 of 1 H-NMR spectrum. In one exemplary embodiment, the composition has Figure 27 DEPT edited HSQC spectrum of . In some embodiments, the weight molar osmotic concentration of the composition is about 635-695 mOs / kg. In some embodiments, the true density of the composition is about 1.096-1.098 g / cm 3 . In some embodiments, the composition comprises no more than 10 ppb propylene glycol as measured by HPLC. In some embodiments, the composition comprises no more than 1 ppm propylene oxide. In some embodiments, the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC. In some embodiments, the composition comprises between 0 and 10 ppm chloride. In some embodiments, the conductivity of the composition is between 0 and 8 μS / cm. In some embodiments, the composition is nanofiltered. In some embodiments, no substantial difference is observed in the HPLC-ELSD after nanofiltration compared to before nanofiltration for the nanofiltered composition. In some embodiments, no substantial difference is observed in the NMR after nanofiltration compared to before nanofiltration for the nanofiltered composition.
[0029] Compositions and mixtures of the present invention
[0030] Further provided herein is an isomerically purified composition comprising a mixture of hydroxypropyl-β-cyclodextrin molecules having the following general subunit structure:
[0031]
[0032] wherein n=7=m+k+y+z; m=0-7; k=0-7; y=0-7; z=0-7; R1, R2 and R3 are each independently H, hydroxypropyl, or
[0033]
[0034] wherein m refers to the number of subunits in which R1 is not H, R2 is H, and R3 is H; wherein k refers to the number of subunits in which R1 is H, R2 is not H, and R3 is H; wherein y refers to the number of subunits in which R1 is H, R2 is H, and R3 is not H; wherein z refers to the number of subunits in which R1 is H, R2 is H, and R3 is H; and wherein in at least 80% of the subunits, R3 = H. It will be understood by those skilled in the art that R1 is located at the 3-O-position, R2 is located at the 2-O-position, and R3 is located at the 6-O-position of the subunit structure. In some embodiments, R3 = H in at least 80%, 90%, 95%, 99%, or 100% of the subunits. In some embodiments, y = 0. In some embodiments, z = 0. In some embodiments, R1 is not H in at least 35% of the subunits or at least 40% of the subunits. In some embodiments, R1 is not H in about 50% to about 70% of the subunits. In some embodiments, R1 is not H in about 60% to about 80% of the subunits. In some embodiments, R1 is not H in about 65% to about 85% of the subunits. In some embodiments, R1 is not H in about 70% to about 80% of the subunits. In some embodiments, R2 is not H in no more than 65% of the subunits. In some embodiments, R2 is not H in about 35% to about 55% of the subunits. In some embodiments, R2 is not H in about 10% to about 30% of the subunits. In some embodiments, the general subunit structure has the following stereochemistry:
[0035]
[0036] Further provided herein is an isomerically purified composition comprising a mixture of hydroxypropyl-β-cyclodextrin molecules wherein 0% to 5% of the hydroxypropyl-β-cyclodextrin subunits are substituted at the 6-O-position.
[0037] Further provided herein is an isomerically purified composition comprising a mixture of hydroxypropyl-β-cyclodextrin molecules, wherein 80% to 100% of the hydroxypropyl-β-cyclodextrin subunits are substituted at the 2-O-position, the 3-O-position, or a combination thereof.
[0038] Further provided herein is an isomerically purified composition comprising a mixture of hydroxypropyl-β-cyclodextrin molecules eluted from a Cholester HPLC column.
[0039] Further provided herein is an isomerically purified composition comprising a mixture of 5% (w / w) hydroxypropyl-β-cyclodextrin high degree of substitution (HDS) molecules in an aqueous medium, the composition producing an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.2500 and about 0.6000 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.2500 and 0.2700 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.4000 and 0.4200 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.5000 and 0.5200 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.5400 and 0.5600 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol between about 0.3600 and 0.3800 mg / ml at a temperature of 37°C.
[0040] Further provided herein is an isomerically purified composition comprising 5% (w / w) of a mixture of hydroxypropyl-β-cyclodextrin HDS molecules in an aqueous medium, wherein the mixture of hydroxypropyl-β-cyclodextrin HDS molecules is insoluble in water (e.g., insoluble at room temperature (20-25° C.)).
[0041] Further provided herein is an isomerically purified composition comprising a mixture of 5% (w / w) hydroxypropyl-β-cyclodextrin low degree of substitution (LDS) molecules in an aqueous medium, the composition producing an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.1700 and about 0.3200 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.1800 and 0.2000 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.1700 and 0.1900 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.2000 and 0.2200 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol at a temperature of 37°C between about 0.2200 and 0.2400 mg / ml. In some embodiments, the composition produces an equilibrium solubility of cholesterol between about 0.3100 and 0.3300 mg / ml at a temperature of 37°C.
[0042] Further provided herein is an isomerically purified composition comprising a 20% (w / w) mixture of hydroxypropyl-β-cyclodextrin molecules in an aqueous medium, wherein the composition produces an equilibrium solubility of cholesterol between about 3.2500 and about 3.7500 mg / ml at a temperature of 37°C.
[0043] Nanofiltration
[0044] Further provided herein is a composition comprising a mixture of purified β-cyclodextrin molecules substituted with hydroxypropyl at one or more hydroxyl positions, wherein the unpurified mixture of β-cyclodextrin molecules comprises propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, as well as propylene glycol and sodium chloride, and wherein at least 90% of the propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, as well as the propylene glycol and sodium chloride content is removed after purification.
[0045] In some aspects, at least 95% of the propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, as well as the propylene glycol and sodium chloride content are removed after purification. In some additional aspects, at least 96% to at least 99% of the propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, as well as the propylene glycol and sodium chloride content are removed after purification.
[0046] In some aspects, at least 90% of the propylene oxide dimer and trimer content is removed after purification. In some additional aspects, at least 95% of the propylene oxide dimer and trimer content is removed after purification. In yet other aspects, at least 96% to at least 99% of the propylene oxide dimer and trimer content is removed after purification.
[0047] In some aspects, at least 90% to at least 95% of the propylene oxide tetramer content is removed.
[0048] In preferred embodiments, the purified composition does not contain detectable amounts of propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer. In other preferred embodiments, the purified composition does not contain detectable amounts of propylene glycol.
[0049] In some embodiments, the mixture of purified β-cyclodextrin molecules has a solution concentration of about 25.0 wt% solids to about 35.0 wt% solids. In some aspects, the mixture of purified β-cyclodextrin molecules has a solution concentration of about 27.5 wt% solids to about 32.5 wt% solids. In a preferred embodiment, the mixture of purified β-cyclodextrin molecules has a solution concentration of about 29.0 wt% solids to about 31.0 wt% solids.
[0050] Further provided herein is a method for purifying a mixture of β-cyclodextrin molecules substituted with hydroxypropyl at one or more hydroxyl positions, the method comprising: diluting the mixture of β-cyclodextrin molecules with water; and nanofiltering the mixture at least three times; wherein the removal efficiency (RE) of propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, and propylene glycol and sodium chloride content in the mixture of β-cyclodextrin molecules is at least 90%.
[0051] In some embodiments, the method further comprises isolating a mixture of purified β-cyclodextrin molecules having a solution concentration of about 25.0 wt% solids to about 35.0 wt% solids. In some aspects, the method further comprises isolating a mixture of purified β-cyclodextrin molecules having a solution concentration of about 27.5 wt% solids to about 32.5 wt% solids. In a preferred embodiment, the method further comprises isolating a mixture of purified β-cyclodextrin molecules having a solution concentration of about 29.0 wt% solids to about 31.0 wt% solids.
[0052] In some embodiments, the mixture is nanofiltered at least four times. In some preferred embodiments, the mixture is nanofiltered at least five times.
[0053] In some embodiments, the mixture is nanofiltered at least once at a temperature of at least about 40° C. to about 50° C. In some aspects, the mixture is nanofiltered at least once at a temperature of at least about 42.5° C. to about 47.5° C. In a preferred embodiment, the mixture is nanofiltered at least once at a temperature of about 45° C.
[0054] In some embodiments, the propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, as well as propylene glycol and sodium chloride content of the purified mixture of β-cyclodextrin molecules is removed with an efficiency of at least 95%. In preferred embodiments, the propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, as well as propylene glycol and sodium chloride content of the purified mixture of β-cyclodextrin molecules is removed with an efficiency of at least 96% to at least 99%.
[0055] In some embodiments, the propylene oxide dimer and trimer content of the mixture of β-cyclodextrin molecules is removed with an efficiency of at least 90%. In some aspects, the propylene oxide dimer and trimer content of the mixture of β-cyclodextrin molecules is removed with an efficiency of at least 95%. In preferred embodiments, the propylene oxide dimer and trimer content of the mixture of β-cyclodextrin molecules is removed with an efficiency of at least 96% to at least 99%. In some embodiments, the propylene oxide tetramer content of the mixture of β-cyclodextrin molecules is removed with an efficiency of at least 90% to at least 95%.
[0056] In some embodiments, the water is deionized water or 18.2 MΩ water.
[0057] In some embodiments, the nanofiltration is performed at a depth of at least 100 cm 2 The surface area of the membrane is measured.
[0058] In some embodiments, the nanofiltration is carried out at a pressure of about 500 psig to about 150 psig. In some aspects, the nanofiltration is carried out at a pressure of about 100 psig to about 300 psig. In some additional aspects, the nanofiltration is carried out at a pressure of about 200 psig to about 100 psig. In other aspects, the nanofiltration is carried out at a pressure of about 150 psig to about 200 psig. In other aspects, the nanofiltration is carried out at a pressure of about 200 psig to about 250 psig.
[0059] In some embodiments, the nanofiltration is effective to maintain about 200 g / (m 2min) to about 250g / (m 2 In some aspects, the nanofiltration is carried out at an operating pressure effective to maintain a flux of about 200 g / (m 2 min) to about 225g / (m 2 In one exemplary embodiment, the nanofiltration is carried out at an operating pressure effective to maintain a flux of about 217 g / (m 2 min) at an operating pressure of 1.5-2.5 % RH.
[0060] In some embodiments, the nanofiltration is performed at an operating pressure effective to maintain a mass flow rate of about 400 g / min to about 600 g / min. In some aspects, the nanofiltration is performed at an operating pressure effective to maintain a mass flow rate of about 450 g / min to about 550 g / min.
[0061] In some embodiments, the nanofiltration comprises a permeate production rate of about 600 kg / hour to about 1800 kg / hour. In some aspects, the nanofiltration comprises a permeate production rate of about 900 kg / hour to about 1500 kg / hour. In yet other aspects, the nanofiltration comprises a permeate production rate of about 1200 kg / hour to about 1500 kg / hour.
[0062] In some embodiments, nanofiltration is achieved using a Trisep XN45 membrane, a spiral wound membrane, a flat sheet membrane, or a combination thereof. In some aspects, the Trisep XN45 membrane is selected from the group consisting of #1812, #2540, #4040, #8040, and a combination thereof.
[0063] In some embodiments, the method further comprises recycling the permeate for nanofiltration.
[0064] In some embodiments, the method further comprises upconcentrating the mixture of β-cyclodextrin molecules after nanofiltration.
[0065] Further provided herein is a method for purifying a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising: diluting the mixture of hydroxypropyl β-cyclodextrin molecules with water and nanofiltering the mixture at least three times, wherein no detectable amount of β-cyclodextrin molecules are present in the permeate after nanofiltration, and the removal efficiency (RE) of the propylene oxide monomer, propylene oxide dimer, propylene oxide trimer and / or propylene oxide tetramer, and propylene glycol and sodium chloride content of the mixture of β-cyclodextrin molecules after nanofiltration of the mixture at least three times is at least 90%.
[0066] In some embodiments, the composition is nanofiltered at a temperature of about 40° C. to about 50° C. and a pressure of about 100 psig to about 300 psig. In some aspects, the composition is nanofiltered at a temperature of about 42.5° C. to about 47.5° C. and a pressure of about 150 psig to about 250 psig.
[0067] In some embodiments, the composition is at about 15 kg / (m 2 hr) to about 35kg / (m 2 In some aspects, the composition is filtered at a diafiltration flux of about 20 kg / (m 2 hr) to about 30kg / (m 2 In some additional aspects, the composition is filtered at a diafiltration flux of about 22.5 kg / (m 2 hr) to about 27.5kg / (m 2 hr) by nanofiltration. BRIEF DESCRIPTION OF THE DRAWINGS
[0068] This patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0069] Figure 1 is a MALDI-TOF-MS spectrum of an unfractionated mixture of hydroxypropyl-β-cyclodextrins of the present disclosure, showing the distribution of hydroxypropyl-β-cyclodextrin components with different degrees of substitution.
[0070] Figure 2 is an unfractionated mixture of hydroxypropyl-β-cyclodextrins of the present disclosure 1 H NMR spectrum (D2O, 298K, 600 MHz). The figure also includes an exemplary hydroxypropyl-β-cyclodextrin molecule with atoms labeled for structure elucidation.
[0071] Figure 3 is a DEPT-edited HSQC spectrum of an unfractionated mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0072] Figure 4 is an HPLC-CAD chromatogram of an unfractionated mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0073] Figure 5 Schematic representation of the isomeric purification of a mixture of hydroxypropyl-β-cyclodextrins using an HPLC Cholester column.
[0074] Figure 6 is the first HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein1 HNMR spectrum.
[0075] Figure 7 is a DEPT-edited HSQC spectrum of the first HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0076] Figure 8 is an HPLC-CAD chromatogram of the first HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0077] Figure 9 is the ESI-MS spectrum of the first HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0078] Figure 10 is a MALDI-TOF spectrum of the first HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein.
[0079] Figure 11 is the second HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein 1 H NMR spectroscopy.
[0080] Figure 12 is a DEPT-edited HSQC spectrum of the second HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0081] Figure 13 is an HPLC-CAD chromatogram of the second HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0082] Figure 14 is an ESI-MS spectrum of the second HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0083] Figure 15 is a MALDI-TOF spectrum of the second HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0084] Figure 16 is the third HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein 1 H NMR spectroscopy.
[0085] Figure 17 is a DEPT-edited HSQC spectrum of the third HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0086] Figure 18 is an HPLC-CAD chromatogram of the third HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0087] Figure 19 is the ESI-MS spectrum of the third HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0088] Figure 20 is a MALDI-TOF spectrum of the third HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein.
[0089] Figure 21 The fourth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein 1 H NMR spectroscopy.
[0090] Figure 22 is a DEPT-edited HSQC spectrum of the fourth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0091] Figure 23 is an HPLC-CAD chromatogram of the fourth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0092] Figure 24 is the ESI-MS spectrum of the fourth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0093] Figure 25 is a MALDI-TOF spectrum of the fourth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein.
[0094] Figure 26 is the fifth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein 1 H NMR spectroscopy.
[0095] Figure 27 is a DEPT-edited HSQC spectrum of the fifth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0096] Figure 28 is an HPLC-CAD chromatogram of the fifth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0097] Figure 29 is the ESI-MS spectrum of the fifth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins of the present disclosure.
[0098] Figure 30 is a MALDI-TOF spectrum of the fifth HDS fraction of the mixture of hydroxypropyl-β-cyclodextrins disclosed herein.
[0099] Figure 31is an HPLC chromatogram showing the HPLC chromatograms of HDS fractions 1-5 superimposed on the HPLC chromatogram of an unfractionated mixture of hydroxypropyl-β-cyclodextrin.
[0100] Figure 32 is a schematic representation of the switching scheme for collecting hydroxypropyl-β-cyclodextrin fractions.
[0101] Figure 33 is an HPLC chromatogram of a mixture of hydroxypropyl-β-cyclodextrins, in which no fractions were collected. The chromatogram shows each fraction as it elutes from the HPLC Cholester column.
[0102] Figures 34A to 34B Overlaid MALDI-TOF spectra of HDS fractions 1-5 are shown. Figure 34A Overlapping MALDI-TOF spectra of HDS fractions 1-3 are shown, and Figure 34B Overlaid MALDI-TOF spectra of HDS fractions 3-5 are shown.
[0103] Figure 35 Shows the overlap of HDS fractions 1-5 1 H NMR spectroscopy.
[0104] Figure 36 Shown are the trends for the average degrees of substitution in HDS fractions 1-5.
[0105] Figure 37 Shown are the trends of substitution patterns (%) in HDS fractions 1-5.
[0106] Figure 38 Shown are the differences between the DEPT-edited HSQC spectra of HDS fractions 1 and 5, which served to elucidate the substitution pattern.
[0107] Figure 39 The predicted structure of the most cholesterol-rich affine isomer of hydroxypropyl-β-cyclodextrin is shown.
[0108] Figure 40 Possible reaction schemes are shown to produce the most cholesterol affine isomer of hydroxypropyl-β-cyclodextrin.
[0109] Figure 41 are overlaid HPLC chromatograms showing the elution of a mixture of hydroxypropyl-β-cyclodextrin and the elution of cholesterol.
[0110] Figure 42 Shown is the equilibrium solubility of cholesterol in the presence of HDS hydroxypropyl-β-cyclodextrin and LDS hydroxypropyl-β-cyclodextrin.
[0111] Figure 43Shown is the equilibrium solubility of cholesterol in the presence of HDS fractions 1-5 of hydroxypropyl-β-cyclodextrin.
[0112] Figure 44 Shown is the equilibrium solubility of cholesterol in the presence of LDS fractions 1-5 of hydroxypropyl-β-cyclodextrin.
[0113] Figure 45 Shown are the conductivity of Cavitron HP7, AlcamiKleptose, and Cavitron HP5 before and after nanofiltration using the methods described herein.
[0114] Figure 46 Shown is the HPLC-ELSD spectrum of a Cavitron HP7 prior to nanofiltration using the methods described herein.
[0115] Figure 47 Shown is the HPLC-ELSD spectrum of a Cavitron HP7 after nanofiltration using the method described herein.
[0116] Figure 48 Shown are the Cavitron HP7 before and after nanofiltration using the methods described herein. 1 H-NMR spectrum.
[0117] Figure 49 HPLC-ELSD spectrum of the permeate of the first diafiltration volume of the Cavitron HP7 is shown.
[0118] Figure 50 HPLC-ELSD spectrum of the permeate of the second diafiltration volume of the Cavitron HP7 is shown.
[0119] Figure 51 HPLC-ELSD spectrum of the permeate of the fourth diafiltration volume of Cavitron HP7 is shown.
[0120] Figure 52 Shown is the HPLC-ELSD spectrum of the permeate of the fifth diafiltration volume of the Cavitron HP7.
[0121] Figure 53 HPLC-ELSD spectrum of the retentate of the first diafiltration volume of the Cavitron HP7 is shown.
[0122] Figure 54 HPLC-ELSD spectrum of the retentate of the second diafiltration volume of the Cavitron HP7 is shown.
[0123] Figure 55Shown is the HPLC-ELSD spectrum of the retentate of the third diafiltration volume of the Cavitron HP7.
[0124] Figure 56 Shown is the HPLC-ELSD spectrum of the retentate of the fourth diafiltration volume of the Cavitron HP7.
[0125] Figure 57 Shown is the HPLC-ELSD spectrum of the retentate of the fifth diafiltration volume of the Cavitron HP7.
[0126] Figure 58 Program data for nanofiltration from a Cavitron HP7 is displayed, including permeate mass, permeate mass flow rate, feed mass, combined permeate and feed mass, temperature, and pressure.
[0127] Figure 59 Shown are the conductivity of the permeate, permeate brix, retentate / feed / product, and retentate / feed / product brix for the purification of the Cavitron HP7.
[0128] Figure 60 Displays process data for nanofiltration from a Cavitron HP5, including permeate mass, permeate mass flow rate, feed mass, temperature, pressure, and pump.
[0129] Figure 61 Shown is the HPLC-ELSD spectrum of a Cavitron HP5 prior to nanofiltration using the methods described herein.
[0130] Figure 62 Shown is the HPLC-ELSD spectrum of a Cavitron HP5 after nanofiltration using the method described herein.
[0131] Figure 63 Shown are the Cavitron HP5 before and after nanofiltration using the methods described herein. 1 H-NMR spectrum.
[0132] Figure 64 Shown are the Cavitron HP5 before and after nanofiltration using the methods described herein. 1 H-NMR spectrum.
[0133] Figure 65 Shown is the HPLC-ELSD spectrum of Alcami Kleptose before nanofiltration using the method described herein.
[0134] Figure 66Shown is the HPLC-ELSD spectrum of Alcami Kleptose after nanofiltration using the method described herein.
[0135] Figure 67 Shown are the results of Alcami Kleptose before and after nanofiltration using the methods described herein. 1 H-NMR spectrum. DETAILED DESCRIPTION
[0136] Various embodiments of the present disclosure are discussed in detail below. Although specific implementations are discussed, it should be understood that this is done for illustrative purposes only. Those skilled in the relevant art will recognize that other components and configurations can be used without departing from the spirit and scope of the present disclosure. Therefore, the following description and accompanying drawings are illustrative and should not be construed as limiting. Many specific details are described to provide a thorough understanding of the present disclosure. However, in some cases, well-known or conventional details are not described to avoid confusing the description.
[0137] Reference to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are they all referring to mutually exclusive separate or alternative embodiments to other embodiments. In addition, various features are described that may be present in some embodiments but not in others. Thus, references to one or an embodiment of the present disclosure may be references to the same embodiment or any embodiment; and such references refer to at least one of the embodiments.
[0138] The terms used in this specification generally have their ordinary meaning in the art within the context of the present disclosure and in the specific context in which each term is used. Alternative wording and synonyms can be used for any one or more of the terms discussed herein, and no matter whether the terms are elaborated or discussed in detail in this article, there should be no special meaning. In some cases, synonyms for certain terms are provided. Narrating one or more synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification including examples of any term discussed herein is merely illustrative and is not intended to further limit the scope and meaning of the present disclosure or any exemplary term. Likewise, the present disclosure is not limited to the various embodiments provided in this specification.
[0139] Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It should be understood that this range format is used for convenience and brevity only and should be interpreted in a flexible manner to include not only the values explicitly recited as limits of the range, but also all individual values or subranges encompassed within the range, as if each value and subrange were explicitly recited. As an illustration, a numerical range of "about 2 to about 50" should be interpreted to include not only the explicitly recited values of 2 to 50, but also all individual values and subranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 2.4, 3, 3.7, 4, 5.5, 10, 10.1, 14, 15, 15.98, 20, 20.13, 23, 25.06, 30, 35.1, 38.0, 40, 44, 44.6, 45, 48, and subranges such as 1-3, 2-4, 5-10, 5-20, 5-25, 5-30, 5-35, 5-40, 5-50, 2-10, 2-20, 2-30, 2-40, 2-50, and the like. This same principle applies to ranges that recite only one numerical value as a minimum or maximum value. Furthermore, such interpretation should apply regardless of the breadth of the range or the characteristics described.
[0140] As used herein, the terms "a", "an" and "the" are to be understood to encompass the plural as well as the singular. Thus, the term "a mixture thereof" also refers to "mixtures thereof", and the term "a component" also refers to "components".
[0141] As used herein, the term "about" is used to provide flexibility to numerical range endpoints by providing that a given value can be "slightly above" or "slightly below" the endpoint. For example, the endpoint can be within 10%, 8%, 5%, 3%, 2%, or 1% of the listed value. In addition, for convenience and brevity, a numerical range of "about 50 mg / mL to about 80 mg / mL" should also be understood to support a range of "50 mg / mL to 80 mg / mL." Endpoints can also be based on variability allowed by appropriate regulatory agencies, such as the FDA, USP, etc.
[0142] In the present disclosure, “comprises,” “comprising,” “containing,” and “having,” etc. may have the meaning ascribed to them in U.S. patent law and may mean “includes,” “including,” etc., and are generally interpreted as open-ended terms. The term “consisting of” or “consists of” is a closed term and includes only the components, structures, steps, etc. specifically listed in conjunction with such term, as well as matters consistent with U.S. patent law. “Consisting essentially of” or “consists essentially of” have the meanings generally ascribed to them under U.S. patent law. In particular, such terms are generally closed terms, but allow for the inclusion of additional items, substances, components, steps, or elements that do not substantially affect the basic and novel features or functions of the items in conjunction with them. For example, trace elements that are present in a composition but do not affect the properties or characteristics of the composition would be permitted if present in the phrase “consisting essentially of,” even if not explicitly listed in the list of items following such term. In this specification, when open-ended terms such as "comprising" or "including" are used, it should be understood that it should also directly support the phrase "consisting essentially of and the phrase "consisting of" as if explicitly stated and vice versa.
[0143] In this disclosure, reference to methods of treatment comprising administering a product is to be understood as also directly supporting the product for such methods of treatment and the use of the product in such methods of treatment, as if explicitly stated.
[0144] Additional features and advantages of the present disclosure will be set forth in the following description, and in part will be apparent from the description, or may be learned by practice of the principles disclosed herein. The features and advantages of the present disclosure may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features of the present disclosure will become more fully apparent from the following description and the appended claims, or may be learned by practice of the principles set forth herein.
[0145] In one aspect, the present invention provides a composition comprising a mixture of β-cyclodextrin molecules. The degree of substitution (DS) of the β-cyclodextrin molecules depends on the number of functional groups attached to the β-cyclodextrin molecules or the hydroxypropyl side chains of the β-cyclodextrin molecules. More specifically, a composition comprising a mixture of hydroxypropyl-β-cyclodextrin molecules is described herein. The hydroxypropyl-β-cyclodextrin molecules may be substituted with one or more hydroxypropyl groups. As used herein, the term "β-cyclodextrin molecule" necessarily explicitly supports "hydroxypropyl-β-cyclodextrin molecule" and, therefore, may optionally be substituted with the term "hydroxypropyl-β-cyclodextrin molecule" anywhere "β-cyclodextrin molecule" is described. As used herein, the notation "DS-N" is used to refer to β-cyclodextrin molecules having a degree of substitution of N. Thus, as a non-limiting example, DS-1 refers to a β-cyclodextrin molecule having a degree of substitution of 1, e.g., a hydroxypropyl-β-cyclodextrin molecule substituted with one hydroxypropyl group.
[0146] The degree of substitution (e.g., average degree of substitution) of a mixture of β-cyclodextrin molecules can be measured via matrix-assisted laser desorption / ionization-time of flight mass spectrometry (MALDI-TOF-MS). The average degree of substitution can be calculated by measuring the average number of substituents bound to the cyclodextrin molecules in the compositions described herein. Systems and methods for performing MALDI-TOF-MS and interpreting the resulting spectrum are generally known to those of ordinary skill in the art. In some embodiments, the hydroxypropyl-β-cyclodextrin percentage is measured by the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the area percentage of the MALDI-TOF-MS spectrum is related to the concentration percentage (e.g., molar percentage). In some embodiments, the hydroxypropyl-β-cyclodextrin concentration percentage can be expressed as molar percentage, weight percentage (w / w), or volume percentage. In an exemplary embodiment, the hydroxypropyl-β-cyclodextrin percentage is a weight percentage.
[0147] General Description of the Compositions Provided Herein
[0148] Unless otherwise stated, any of the compositions described herein can have the physical and chemical properties, characteristics, or ingredients provided below. For example, unless otherwise stated, any of the compositions described herein comprising any of Fractions 1 to 5 can have the physical and chemical properties, characteristics, or ingredients provided below.
[0149] In some embodiments, the composition may have a true density of about 1.095 g / cm 3 to about 1.100g / cm3 In some aspects, the composition may have a true density of about 1.095 g / cm 3 to about 1.096 g / cm 3 , about 1.096g / cm 3 to about 1.097 g / cm 3 , about 1.097g / cm 3 to about 1.098 g / cm 3 , about 1.098g / cm 3 to about 1.099 g / cm 3 , about 1.099g / cm 3 to about 1.100g / cm 3 , about 1.095g / cm 3 to about 1.097 g / cm 3 , about 1.095g / cm 3 to about 1.098 g / cm 3 , about 1.095g / cm 3 to about 1.099 g / cm 3 , about 1.096g / cm 3 to about 1.100g / cm 3 , about 1.097g / cm 3 to about 1.100g / cm 3 , about 1.098g / cm 3 to about 1.100g / cm 3 , about 1.096g / cm 3 to about 1.098g / cm 3 or about 1.096 g / cm 3 to about 1.099 g / cm 3 In some additional aspects, the composition may have a true density of about 1.095 g / cm 3 , 1.096g / cm 3 , 1.097g / cm 3 , 1.098g / cm 3 , 1.099g / cm 3 or about 1.100g / cm 3 In one exemplary embodiment, the composition has a true density of about 1.096 g / cm 3 to about 1.098 g / cm 3 .
[0150] In some embodiments, the osmolality of the composition can be from about 600 mOs / kg to about 750 mOs / kg. In some aspects, the osmolality of the composition can be from about 600 mOs / kg to about 625 mOs / kg, from about 625 mOs / kg to about 650 mOs / kg, from about 650 mOs / kg to about 675 mOs / kg, from about 675 mOs / kg to about 700 mOs / kg, from about 700 mOs / kg to about 725 mOs / kg, or from about 725 mOs / kg to about 750 mOs / kg. In some additional aspects, the composition may have an osmolality of about 600 mOs / kg to about 650 mOs / kg, about 600 mOs / kg to about 675 mOs / kg, about 600 mOs / kg to about 700 mOs / kg, about 600 mOs / kg to about 725 mOs / kg, about 625 mOs / kg to about 750 mOs / kg, about 650 mOs / kg to about 750 mOs / kg, about 675 mOs / kg to about 750 mOs / kg, about 700 mOs / kg to about 750 mOs / kg, about 625 mOs / kg to about 725 mOs / kg, or about 650 mOs / kg to about 700 mOs / kg. In yet other embodiments, the composition can have an osmolality of about 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, or about 750 mOs / kg. In an exemplary embodiment, the composition has an osmolality of about 635 to about 695 mOs / kg.
[0151] In some embodiments, the composition may have a conductivity between about 0 and about 8 μS / cm. In some aspects, the composition may have a conductivity between about 0 and about 1 μS / cm, about 1 and about 2 μS / cm, about 3 and about 4 μS / cm, about 4 and about 5 μS / cm, about 5 and about 6 μS / cm, about 6 and about 7 μS / cm, or about 7 and about 8 μS / cm. In some additional embodiments, the electrical conductivity of the composition may be between about 0 μS / cm and about 1.5 μS / cm, about 0 μS / cm and about 2 μS / cm, about 0 μS / cm and about 2.5 μS / cm, about 0 μS / cm and about 3 μS / cm, about 0 and about 3.5 μS / cm, about 0 μS / cm and about 4 μS / cm, about 0 and about 4.5 μS / cm, about 0 μS / cm and about 5 μS / cm, about 0 and about 5.5 μS / cm, about 0 μS / cm and about 6 μS / cm, about 0 and about 6.5, about 0 μS / cm and about 7 μS / cm, about 0 and about 7.5, about 1 μS / cm and about 8 μS / cm, about 1.5 μS / cm and about 10 μS / cm. / cm and about 8 μS / cm, about 2 μS / cm and about 8 μS / cm, about 2.5 μS / cm and about 8 μS / cm, about 3 μS / cm and about 8 μS / cm, about 3.5 μS / cm and about 8 μS / cm, about 4 μS / cm and about 8 μS / cm, about 4.5 μS / cm and about 8 μS / cm, about 5 μS / cm and about 8 μS / cm, about 5.5 μS / cm and about 8 μS / cm, about 6 μS / cm and about 8 μS / cm, about 6.5 μS / cm and about 8 μS / cm, about 1 μS / cm and about 7 μS / cm, about 2 μS / cm and about 6 μS / cm, or about 3 μS / cm and about 5 μS / cm. In still other aspects, the composition can have a conductivity of about 0.5 μS / cm, 1.0 μS / cm, 1.5 μS / cm, 2.0 μS / cm, 2.5 μS / cm, 3.0 μS / cm, 3.5 μS / cm, 4.0 μS / cm, 4.5 μS / cm, 5.0 μS / cm, 5.5 μS / cm, 6.0 μS / cm, 6.5 μS / cm, 7.0 μS / cm, 7.5 μS / cm, or about 8.0 μS / cm.
[0152] In some embodiments, the pH of the composition can be from about 4.0 to about 8.0; for example, the pH of the composition can be about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or about 8.0. The pH of the composition can be within a range or sub-range comprising any of the above numbers, including but not limited to the following pH: about 4.0 to about 4.5, about 4.5 to about 5.0, about 5.0 to about 5.5, about 5.5 to about 6.0, about 6.0 to about 6.5, about 6.5 to about 7.0, about 7.0 to about 7.5, or about 7.5 to about 8.0. In some embodiments, the composition may also include a pH adjusting agent, such as hydrochloric acid or sodium hydroxide, to adjust the pH to the desired level. In some embodiments, the composition may also include a buffer. In some embodiments, the buffer may include sodium dihydrogen phosphate and disodium hydrogen phosphate.
[0153] In some embodiments, the composition can have a viscosity measured in centipoise (cP) at 20° C. For example, the composition can have a viscosity of about 1.5 cP to about 3.0 cP at 20° C. In some embodiments, the composition can have a viscosity of about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, , 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9 or about 10.0 cP. In other embodiments, the viscosity of the composition at 20°C may be from about 3.0 cP to about 5.0 cP, from about 5.0 cP to about 10.0 cP, from about 10 to about 15 cP, from about 15 to about 20 cP, from about 20 cP to about 25 cP, from about 25 cP to about 50 cP, from about 50 cP to about 80 cP, from about 80 cP to about 150 cP, from about 150 cP to about 250 cP, from about 250 cP to about 500 cP, from about 500 cP to about 1,000 cP, from about 1,000 cP to about 2,000 cP, from about 2,000 cP to about 3,000 cP, from about 3,000 cP to about 5,000 cP, or from about 5,000 cP to about 10,000 cP.
[0154] The composition can be substantially free of impurities. Impurities include particles having a diameter greater than or equal to 25 microns, particles having a diameter greater than or equal to 10 microns, chlorides, propylene glycol, propylene oxide, and other unspecified impurities. In some embodiments, the composition can include less than or equal to about 0.05% impurities; for example, the composition can include less than or equal to about 0.05%, 0.04%, 0.03%, 0.02%, or less than or equal to about 0.01% impurities.
[0155] In some embodiments, the composition may further comprise a container and non-visible particulate matter. In some embodiments, the composition may be provided in a container. In some embodiments, the composition may further comprise non-visible particulate matter.
[0156] In some embodiments, the composition can include less than 600 particles / container having a diameter greater than or equal to 25 microns. In some aspects, the composition can include less than 500, less than 400, less than 300, less than 200, or less than 100 particles / container having a diameter greater than or equal to 25 microns.
[0157] In some embodiments, the composition may include less than 6,000 particles having a diameter greater than or equal to 10 microns per container. In some aspects, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, or less than 100 particles having a diameter greater than or equal to 10 microns per container. In another aspect, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, or less than 100 particles having a diameter greater than or equal to 10 microns per container, wherein the container is ≤ 100 mL. In another aspect, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, less than 100, less than 50, less than 25, less than 10, less than 5, or less than 3 particles having a diameter greater than or equal to 10 microns per container, wherein the container is ≤ 100 mL.
[0158] In some embodiments, the composition may include no more than 10ppb propylene glycol. In some aspects, the composition may include no more than 9ppb, 8ppb, 7ppb, 6ppb, 5ppb, 4ppb, 3ppb, 2ppb or no more than 1ppb propylene glycol. In some aspects, the amount of the propylene glycol in the composition can be measured by HPLC. In some additional aspects, the amount of the propylene glycol in the composition can be measured by gas chromatography. In other aspects, the amount of the propylene glycol in the composition can be measured by measuring the PG / EG ratio of propylene glycol and ethylene glycol.
[0159] In some embodiments, the composition may include no more than 1ppm propylene oxide. In some aspects, the composition may include no more than 0.9ppm, 0.8ppm, 0.7ppm, 0.6ppm, 0.5ppm, 0.4ppm, 0.3ppm, 0.2ppm or 0.1ppm propylene oxide. In some aspects, the amount of propylene oxide in the composition can be measured by HPLC. In some additional aspects, the amount of propylene oxide in the composition can be measured by gas chromatography.
[0160] In some embodiments, the composition may include between about 0 ppm and about 10 ppm of chloride (e.g., Cl -ions). In some aspects, the composition may include about 0ppm chloride to about 2ppm chloride, about 2ppm chloride to about 4ppm chloride, about 4ppm chloride to about 6ppm chloride, about 6ppm chloride to about 8ppm chloride or about 8 to about 10ppm chloride. In some additional aspects, the composition may include about 0ppm chloride to about 4ppm chloride, about 0ppm chloride to about 6ppm chloride, about 0ppm chloride to about 8ppm chloride, about 2ppm chloride to about 1ppm chloride, about 4ppm chloride to about 1ppm chloride or about 6ppm chloride to about 1ppm chloride. In other aspects, the composition may include about 0ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm or about 10ppm chloride. In an exemplary embodiment, the composition may include the chloride between about 0ppm to about 1ppm.
[0161] In some embodiments, the composition may include between about 0 ppm and about 10 ppm of sodium (e.g., Na + ions). In some aspects, the composition can include about 0ppm sodium to about 2ppm sodium, about 2ppm sodium to about 4ppm sodium, about 4ppm sodium to about 6ppm sodium, about 6ppm sodium to about 8ppm sodium or about 8 to about 10ppm sodium. In some additional aspects, the composition can include about 0ppm sodium to about 4ppm sodium, about 0ppm sodium to about 6ppm sodium, about 0ppm sodium to about 8ppm sodium, about 2ppm sodium to about 1ppm sodium, about 4ppm sodium to about 1ppm sodium or about 6ppm sodium to about 1ppm sodium. In other aspects, the composition can include about 0ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm or about 10ppm sodium. In an exemplary embodiment, the composition can include the sodium between about 0ppm to about 1ppm.
[0162] In some embodiments, the composition can include less than or equal to 0.05% other unspecified impurities; for example, the composition can include less than or equal to 0.05%, 0.04%, 0.03%, 0.02%, or less than or equal to 0.01% other unspecified impurities.
[0163] In some embodiments, the composition can be stable for at least 6 months. For example, the composition can be stable for at least 3 months, 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 24 months, or at least 36 months.
[0164] The composition can be nanofiltered. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. Thus, the time required for nanofiltration does not increase or decrease as the concentration of the mixture of β-cyclodextrin molecules in the composition increases or decreases. In some aspects, the time required for nanofiltration of the composition is between about 1.04 and about 1.20 hours per diafiltration volume (kg soln / m 2 In some embodiments, no substantial differences are observed in the composition after nanofiltration by HPLC-ELSD compared to before nanofiltration. In some embodiments, no substantial differences are observed in the composition after nanofiltration by NMR compared to before nanofiltration.
[0165] In some embodiments, the composition can be terminally sterilized. Terminal sterilization methods are generally well known in the art. In some embodiments, the pH of the composition can be adjusted after terminal sterilization.
[0166] In some embodiments, the composition can include less than or equal to 10.0% w / w water. For example, the composition can include less than or equal to 10.0% w / w, 9.5% w / w, 9.0% w / w, 8.5% w / w, 8.0% w / w, 7.5% w / w, 7.0% w / w, 6.5% w / w, 6.0% w / w, 5.5% w / w, 5.0% w / w, 4.5% w / w, 4.0% w / w, 3.5% w / w, 3.0% w / w, 2.5% w / w, 2.0% w / w, 1.5% w / w, 1.0% w / w, 0.5% w / w, or less than or equal to 0.1% w / w water.
[0167] In some embodiments, the composition can be packaged in a vial suitable for injection into a human subject in need. The vial can be made of glass, plastic, or any other material known in the pharmaceutical art. The vial can be coated with a material such as silicon dioxide to prevent infiltration from the vial into the composition.
[0168] In some embodiments, the composition may be suitable for administration to a patient in need thereof. In some embodiments, the composition may be suitable for intrathecal administration, intravenous administration, oral administration, intracerebroventricular administration, or a combination thereof (e.g., intravenous and intrathecal administration) to a patient in need thereof. In some aspects, the patient may be a human, such as an adult patient or a pediatric patient. In some instances, the human patient may be an infant (e.g., less than 6 months old) or a newborn (e.g., less than 4 weeks old).
[0169] In some embodiments, the composition may be effective in treating Niemann-Pick disease. In some embodiments, the composition may be effective in treating Niemann-Pick disease type C. In some embodiments, the composition may be effective in treating liver disease. In some embodiments, the composition may be effective in treating cardiovascular disease. In some embodiments, the composition may be effective in treating familial hypercholesterolemia. In some embodiments, the composition may be effective in treating cholesterol deposition.
[0170] In some embodiments, the composition may further comprise a pharmaceutical excipient or carrier. In some embodiments, the composition may further comprise a pharmaceutically acceptable diluent. Examples of pharmaceutical excipients, carriers, and diluents are well known to those skilled in the art.
[0171] In some embodiments, the composition may exhibit Cyclo or In some embodiments, the composition may exhibit a lower toxicity than Cyclo or Substantially Low Ototoxicity. In some embodiments, the composition may exhibit substantially no ototoxicity.
[0172] Unpurified composition
[0173] Provided herein is a composition comprising a mixture of β-cyclodextrins, wherein the composition has not been isomerically purified. In some embodiments, the composition comprises a mixture of β-cyclodextrin molecules, wherein the mixture of β-cyclodextrin molecules may include β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"), β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"), β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"), β-cyclodextrin substituted with seven hydroxypropyl groups ("DS-7"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-8"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-9"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-10"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-11"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-12"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-13"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-14"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-15"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-16"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-17"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-18"), β-cyclodextrin substituted with eight hydroxypropyl groups ("DS-19"), β-cyclodextrin substituted with four hydroxypropyl groups ("DS-20"), β-cyclodextrin substituted with substituted β-cyclodextrin ("DS-8"), β-cyclodextrin substituted with nine hydroxypropyl groups ("DS-9"), β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"), β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"), β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"), β-cyclodextrin substituted with thirteen hydroxypropyl groups ("DS-13"), and β-cyclodextrin substituted with fourteen hydroxypropyl groups ("DS-14"). In some embodiments, the composition is a clear and colorless solution.
[0174] The degree of substitution of a mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. An exemplary MALDI-TOF-MS spectrum of a composition of the present disclosure is shown in Figure 1 In some embodiments, the MALDI-TOF-MS spectrum may include peaks at approximately 1389 m / z, 1447 m / z, 1505 m / z, 1564 m / z, 1622 m / z, 1680 m / z, 1738 m / z, 1796 m / z, 1855 m / z, and 1914 m / z. In an exemplary embodiment, the composition has a MALDI-TOF-MS spectrum wherein DS-4 has an area of 0.73%, DS-5 has an area of 3.49%, DS-6 has an area of 10.66%, DS-7 has an area of 24.10%, DS-8 has an area of 26.43%, DS-9 has an area of 18.09%, DS-10 has an area of 9.39%, DS-11 has an area of 4.58%, DS-12 has an area of 1.84%, and DS-13 has an area of 0.70%.
[0175] In some embodiments, the composition can have an average degree of substitution of between about 7 and about 9; for example, the average degree of substitution can be about 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or about 9.0. In an exemplary embodiment, the mixture of β-cyclodextrin molecules has an average degree of substitution of about 7.7.
[0176] In some embodiments, the mixture of β-cyclodextrin molecules may include less than 1% DS-4; for example, the mixture of β-cyclodextrin molecules may include about 0.9% DS-4, about 0.8% DS-4, about 0.7% DS-4, about 0.6% DS-4, about 0.5% DS-4, about 0.4% DS-4, about 0.3% DS-4, about 0.2% DS-4, or about 0.1% DS-4. In some aspects, the mixture of β-cyclodextrin molecules can include less than 1% to about 0.9% DS-4, about 0.9% to about 0.8% DS-4, about 0.8% to about 0.7% DS-4, about 0.7% to about 0.6% DS-4, about 0.7% to about 0.6% DS-4, about 0.6% to about 0.5% DS-4, about 0.5% to about 0.4% DS-4, about 0.4% to about 0.3% DS-4, about 0.3% to about 0.2% DS-4, about 0.2% to about 0.1% DS-4, or less than 0.1% DS-4. In some additional aspects, the mixture of β-cyclodextrin molecules may include less than 1% to about 0.8% DS-4, less than 1% to about 0.7% DS-4, less than 1% to about 0.6% DS-4, less than 1% to about 0.5% DS-4, less than 1% to about 0.4% DS-4, less than 1% to about 0.3% DS-4, less than 1% to about 0.2% DS-4, less than 1% to about 0.1% DS-4, about 0.9% to about 0.1% DS-4, about 0.8% to about 0.1% DS-4, about 0.7% to about 0.1% DS-4, about 0.6% to about 0.1% DS-4, about 0.5% to about 0.1% DS-4, about 0.4% to about 0.1% DS-4, or about 0.3% to about 0.1% DS-4. In yet other aspects, the mixture of β-cyclodextrin molecules can include less than 1% DS-4, less than 0.9% DS-4, less than 0.8% DS-4, less than 0.7% DS-4, less than 0.6% DS-4, less than 0.5% DS-4, less than 0.4% DS-4, less than 0.3% DS-4, less than 0.2% DS-4, or less than 0.1% DS-4. In yet other aspects, the mixture of β-cyclodextrin molecules can include about 0.001%, 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or about 1% DS-4. In some embodiments, the amount of DS-4 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-4 in the MALDI-TOF-MS spectrum is 0.73%.
[0177] In some embodiments, the mixture of β-cyclodextrin molecules may include about 2% to about 5% DS-5. In some aspects, the mixture of β-cyclodextrin molecules may include about 2% to about 2.5% DS-5, about 2.5% to about 3% DS-5, about 3% to about 3.5% DS-5, about 3.5% to about 4% DS-5, about 4% to about 4.5% DS-5, or about 4.5% to about 5% DS-5. In some additional aspects, the mixture of β-cyclodextrin molecules may include about 2% to about 3% DS-5, about 2% to about 3.5% DS-5, about 2% to about 4% DS-5, about 2% to about 4.5% DS-5, about 2.5% to about 5% DS-5, about 3% to about 5% DS-5, about 3.5% to about 5% DS-5, about 4% DS-5 to about 5% DS-5, or about 3% to about 4% DS-5. In yet other aspects, the mixture of β-cyclodextrin molecules can include about 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, or about 5.0% DS-5. In some embodiments, the amount of DS-5 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In an exemplary embodiment, the area of DS-5 in the MALDI-TOF-MS spectrum is 3.49%.
[0178] In some embodiments, the mixture of β-cyclodextrin molecules can include about 7% to about 13% DS-6. In some aspects, the mixture of β-cyclodextrin molecules can include about 7% to about 7.5% DS-6, about 7.5% to about 8% DS-6, about 8% to about 8.5% DS-6, about 8.5% to about 9% DS-6, about 9% to about 9.5% DS-6, about 9.5% to about 10% DS-6, about 10% DS-6 to about 10.5% DS-6, about 10.5% to about 11% DS-6, about 11% DS-6 to about 11.5% DS-6, about 11.5% to about 12% DS-6, about 12% to about 12.5% DS-6, or about 12.5% to about 13% DS-6. In some additional aspects, the mixture of beta-cyclodextrin molecules can include about 7% to about 8% DS-6, about 7% to about 8.5% DS-6, about 7% to about 9% DS-6, about 7% to about 9.5% DS-6, about 7% to about 10% DS-6, about 7% to about 10.5% DS-6, about 7% to about 11% DS-6, about 7% to about 11.5% DS-6, about 7% to about 12% DS-6, about 7% to about 12.5% DS-6, about 7.5% to about 10% DS-6. About 13% DS-6, about 8% to about 13% DS-6, about 8.5% to about 13% DS-6, about 9% to about 13% DS-6, about 9.5% to about 13% DS-6, about 10% to about 13% DS-6, about 10.5% to about 13% DS-6, about 11% to about 13% DS-6, about 11.5% to about 13% DS-6, about 12% to about 13% DS-6, about 8% to about 12% DS-6, or about 9% to about 11% DS-6. In still other aspects, the mixture of beta-cyclodextrin molecules can include about 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 10.0%, 10.1%, 10. .1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9% or about 13.0% DS-6.In some embodiments, the amount of DS-6 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-6 in the MALDI-TOF-MS spectrum is 10.66%.
[0179] In some embodiments, the mixture of β-cyclodextrin molecules can include about 21% to about 27% DS-7. In some aspects, the mixture of β-cyclodextrin molecules can include about 21% to about 21.5% DS-7, about 21.5% to about 22% DS-7, about 22% to about 22.5% DS-7, about 22.5% to about 23% DS-7, about 23% to about 23.5% DS-7, about 23.5% DS-7 to about 24% DS-7, about 24% to about 24.5% DS-7, about 24.5% to about 25% DS-7, about 25% to about 25.5% DS-7, about 25.5% to about 26% DS-7, about 26% to about 26.5% DS-7, or about 26.5% to about 27% DS-7. In some additional aspects, the mixture of beta-cyclodextrin molecules may include about 21% to about 22% DS-7, about 21% to about 22.5% DS-7, about 21% to about 23% DS-7, about 21% to about 23.5% DS-7, about 21% to about 24% DS-7, about 21% to about 24.5% DS-7, about 21% to about 25% DS-7, about 21% to about 25.5% DS-7, about 21% to about 26% DS-7, about 21% to about 26.5% DS-7, about 21% to about 27% DS-7, about 21% to about 28% DS-7, about 21% to about 29% DS-7, about 21% to about 29.5% DS-7, about 21% to about 29. 1.5% to about 27% DS-7, about 22% to about 27% DS-7, 22.5% to about 27% DS-7, about 23% to about 27% DS-7, about 23.5% to about 27% DS-7, about 24% to about 27% DS-7, about 24.5% to about 27% DS-7, about 25% to about 27% DS-7, about 25.5% to about 27% DS-7, about 26% to about 27% DS-7, about 22% to about 26% DS-7, or about 23% to about 25% DS-7.In yet other aspects, the mixture of beta-cyclodextrin molecules may include about 21.0%, 21.1%, 21.2%, 21.3%, 21.4%, 21.5%, 21.6%, 21.7%, 21.8%, 21.9%, 22.0%, 22.1%, 22.2%, 22.3%, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8% %, 23.9%, 24.0%, 24.1%, 24.2%, 24.3%, 24.4%, 24.5%, 24.6%, 24.7%, 24.8%, 24.9%, 25.0%, 25.1%, 25.2%, 25.3%, 25.4%, 25.5%, 25.6%, 25.7%, 25.8%, 25.9%, 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9% or about 27.0% DS-7. In some embodiments, the amount of DS-7 can be determined by MALDI-TOF-MS. In an exemplary embodiment, the area of DS-7 in the MALDI-TOF-MS spectrum is 24.10%.
[0180] In some embodiments, the mixture of β-cyclodextrin molecules can include about 23% to about 29% DS-8. In some aspects, the mixture of β-cyclodextrin molecules can include about 23% to about 23.5% DS-8, about 23.5% to about 24% DS-8, about 24% to about 24.5% DS-8, about 24.5% to about 25% DS-8, about 25% to about 25.5% DS-8, about 25.5% to about 26% DS-8, about 26% to about 26.5% DS-8, about 26.5% to about 27% DS-8, about 27% to about 27.5% DS-8, about 27.5% to about 28% DS-8, about 28% to about 28.5% DS-8, or about 28.5% to about 29% DS-8. In some additional aspects, the mixture of beta-cyclodextrin molecules may include about 23% to about 24% DS-8, about 23% to about 24.5% DS-8, about 23% to about 25% DS-8, about 23% to about 25.5% DS-8, about 23% to about 26% DS-8, about 23% to about 26.5% DS-8, about 23% to about 27% DS-8, about 23% to about 27.5% DS-8, about 23% to about 28% DS-8, about 23% to about 28.5% DS-8, and about 23.5% to about 29. 9% DS-8, about 24% to about 29% DS-8, about 24.5% to about 29% DS-8, about 25% to about 29% DS-8, about 25.5% to about 29% DS-8, about 26% to about 29% DS-8, about 26.5% to about 29% DS-8, about 27% to about 29% DS-8, about 27.5% to about 29% DS-8, about 28% to about 29% DS-8, about 24% to about 28% DS-8 or about 25% to about 27% DS-8.In yet other aspects, the mixture of beta-cyclodextrin molecules can include about 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23.9%, 24.0%, 24.1%, 24.2%, 24.3%, 24.4%, 24.5%, 24.6%, 24.7%, 24.8%, 24.9%, 25.0%, 25.1%, 25.2%, 25.3%, 25.4%, 25.5%, 25.6%, 25.7%, 25.8%, 25.9%, 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, 28.0%, 28.1%, 28.2%, 28.3%, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28 ... %, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, or about 29.0%. In some embodiments, the amount of DS-8 in the composition can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-8 in the MALDI-TOF-MS spectrum is 26.43%.
[0181] In some embodiments, the mixture of β-cyclodextrin molecules can include about 15% to about 21% DS-9. In some aspects, the mixture of β-cyclodextrin molecules can include about 15% to about 15.5% DS-9, about 15.5% to about 16% DS-9, about 16% to about 16.5% DS-9, about 16.5% to about 17% DS-9, about 17% to about 17.5% DS-9, about 17.5% to about 18% DS-9, about 18% to about 18.5% DS-9, about 18.5% to about 19% DS-9, about 19% to about 19.5% DS-9, about 19.5% to about 20% DS-9, about 20% to about 20.5% DS-9, or about 20.5% to about 21% DS-9. In some additional aspects, the mixture of beta-cyclodextrin molecules can include about 15% to about 16% DS-9, about 15% to about 16.5% DS-9, about 15% to about 17% DS-9, about 15% to about 17.5% DS-9, about 15% to about 18% DS-9, about 15% to about 18.5% DS-9, about 15% to about 19% DS-9, about 15% to about 19.5% DS-9, about 15% to about 20% DS-9, about 15% to about 20.5% DS-9, about 15% to about 25% DS-9, about 15% to about 26% DS-9, about 15% to about 27% DS-9, about 15% to about 28% DS-9, about 15% to about 29% DS-9, about 15% to about 29.5% DS-9, about 15% to about 20% DS-9, about 15% to about 21% DS-9, about 15% to about 15.5% DS-9, about 15% to about 16% DS-9, about 15% to about 16.5% DS-9, about 15% to about 16.5% DS-9, about 15% to about 17% DS-9, about 15% to about 18% DS-9, about 15% to about 18.5% DS-9, about .5% to about 21% DS-9, about 16% to about 21% DS-9, about 16.5% to about 21% DS-9, about 17% to about 21% DS-9, about 17.5% to about 21% DS-9, about 18% to about 21% DS-9, about 18.5% to about 21% DS-9, about 19% to about 21% DS-9, about 19.5% to about 21% DS-9, about 20% to about 21% DS-9, about 16% to about 20% DS-9, or about 17% to about 19% DS-9.In yet other aspects, the mixture of beta-cyclodextrin molecules may include about 15.0%, 15.1%, 15.2%, 15.3%, 15.4%, 15.5%, 15.6%, 15.7%, 15.8%, 15.9%, 16.0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, %, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0%, 20.1%, 20.2%, 20.3%, 20.4%, 20.5%, 20.6%, 20.7%, 20.8%, 20.9% or about 21.0% DS-9. In some embodiments, the amount of DS-9 in the composition can be determined by MALDI-TOF-MS. In an exemplary embodiment, the area of DS-9 in the MALDI-TOF-MS spectrum is 18.09%.
[0182] In some embodiments, the mixture of β-cyclodextrin molecules can include about 6% to about 12% DS- 10. In some aspects, the mixture of β-cyclodextrin molecules can include about 6% to about 6.5% DS-10, about 6.5% to about 7% DS-10, about 7% to about 7.5% DS-10, about 7.5% to about 8% DS-10, about 8% to about 8.5% DS-10, about 8.5% to about 9% DS-10, about 9% to about 9.5% DS-10, about 9.5% to about 10% DS-10, about 10% to about 10.5% DS-10, about 10.5% to about 11% DS-10, about 11% to about 11.5% DS-10, or about 11.5% to about 12% DS-10. In some additional aspects, the mixture of beta-cyclodextrin molecules can include about 6% to about 7% DS-10, about 6% to about 7.5% DS-10, about 6% to about 8% DS-10, about 6% to about 8.5% DS-10, about 6% to about 9% DS-10, about 6% to about 9.5% DS-10, about 6% to about 10% DS-10, about 6% to about 10.5% DS-10, about 6% to about 11% DS-10, about 6% to about 11.5% DS-10, about 6.5% to about 10. 12% DS-10, about 7% to about 12% DS-10, about 7.5% to about 12% DS-10, about 8% to about 12% DS-10, about 8.5% to about 12% DS-10, about 9% to about 12% DS-10, about 9.5% to about 12% DS-10, about 10% to about 12% DS-10, about 10.5% to about 12% DS-10, about 11% to about 12% DS-10, about 7% to about 11% DS-10, or about 8% to about 10% DS-10. In yet other aspects, the mixture of beta-cyclodextrin molecules can include about 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, , 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9% or about 12.0% DS-10.In some embodiments, the amount of DS-10 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-10 in the MALDI-TOF-MS spectrum is 9.39%.
[0183] In some embodiments, the mixture of β-cyclodextrin molecules can include about 2% to about 6% DS- 11. In some aspects, the mixture of β-cyclodextrin molecules can include about 2% to about 2.5% DS- 11, about 2.5% to about 3% DS- 11, about 3% to about 3.5% DS- 11, about 3.5% to about 4% DS- 11, about 4% to about 4.5% DS- 11, about 4.5% to about 5% DS- 11, about 5% to about 5.5% DS- 11, or about 5.5% to about 6% DS- 11. In some additional aspects, the mixture of β-cyclodextrin molecules can include about 2% to about 3% DS-11, about 2% to about 3.5% DS-11, about 2% to about 4% DS-11, about 2% to about 4.5% DS-11, about 2% to about 5% DS-11, about 2% to about 5.5% DS-11, about 2.5% to about 6% DS-11, about 3% to about 6% DS-11, about 3.5% to about 6% DS-11, about 4% to about 6% DS-11, about 4.5% to about 6% DS-11, about 5% to about 6% DS-11, or about 3% to about 5% DS-11. In still additional aspects, the mixture of beta-cyclodextrin molecules can include about 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, or about 6.0% DS-11. In some embodiments, the amount of DS-11 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-11 in the MALDI-TOF-MS spectrum is 4.58%.
[0184] In some embodiments, the mixture of β-cyclodextrin molecules can include about 0.5% to about 4% DS- 12. In some aspects, the mixture of β-cyclodextrin molecules can include about 0.5% to about 1% DS-12, about 1% to about 1.5% DS-12, about 1.5% DS-12 to about 2% DS-12, about 2% to about 2.5% DS-12, about 2.5% DS-12 to about 3% DS-12, about 3% to about 3.5% DS-12, or about 3.5% DS-12 to about 4% DS-12. In some additional aspects, the mixture of β-cyclodextrin molecules can include about 0.5% to about 1.5% DS-12, about 0.5% to about 2% DS-12, about 0.5% to about 2.5% DS-12, about 0.5% to about 3% DS-12, about 0.5% to about 3.5% DS-12, about 1% to about 4% DS-12, about 1.5% to about 4% DS-12, about 2% to about 4% DS-12, about 2.5% to about 4% DS-12, about 3% to about 4% DS-12, or about 1% to about 3% DS-12. In yet other aspects, the mixture of beta-cyclodextrin molecules can include about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, or about 4.0%. In some embodiments, the amount of DS-12 in the mixture of beta-cyclodextrin molecules can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-12 in the MALDI-TOF-MS spectrum is 1.84%.
[0185] In some embodiments, the mixture of β-cyclodextrin molecules may include less than 1% DS-13; for example, the mixture of β-cyclodextrin molecules may include about 0.9% DS-13, about 0.8% DS-13, about 0.7% DS-13, about 0.6% DS-13, about 0.5% DS-13, about 0.4% DS-13, about 0.3% DS-13, about 0.2% DS-13, or about 0.1% DS-13. In some aspects, the mixture of β-cyclodextrin molecules can include less than 1% to about 0.9% DS-13, about 0.9% to about 0.8% DS-13, about 0.8% to about 0.7% DS-13, about 0.7% to about 0.6% DS-13, about 0.7% to about 0.6% DS-13, about 0.6% to about 0.5% DS-13, about 0.5% to about 0.4% DS-13, about 0.4% to about 0.3% DS-13, about 0.3% to about 0.2% DS-13, about 0.2% to about 0.1% DS-13, or less than 0.1% DS-13. In some additional aspects, the mixture of β-cyclodextrin molecules may include less than 1% to about 0.8% DS-13, less than 1% to about 0.7% DS-13, less than 1% to about 0.6% DS-13, less than 1% to about 0.5% DS-13, less than 1% to about 0.4% DS-13, less than 1% to about 0.3% DS-13, less than 1% to about 0.2% DS-13, less than 1% to about 0.1% DS-13, about 0.9% to about 0.1% DS-13, about 0.8% to about 0.1% DS-13, about 0.7% to about 0.1% DS-13, about 0.6% to about 0.1% DS-13, about 0.5% to about 0.1% DS-13, about 0.4% to about 0.1% DS-13, or about 0.3% to about 0.1% DS-13. In yet other aspects, the mixture of β-cyclodextrin molecules can include less than 1% DS-13, less than 0.9% DS-13, less than 0.8% DS-13, less than 0.7% DS-13, less than 0.6% DS-13, less than 0.5% DS-13, less than 0.4% DS-13, less than 0.3% DS-13, less than 0.2% DS-13, or less than 0.1% DS-13. In some embodiments, the amount of DS-13 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In one exemplary embodiment, the area of DS-13 in the MALDI-TOF-MS spectrum is 0.70%.
[0186] In some embodiments, the composition may include less than 1% DS-14; for example, a mixture of β-cyclodextrin molecules may include about 0.9% DS-14, about 0.8% DS-14, about 0.7% DS-14, about 0.6% DS-14, about 0.5% DS-14, about 0.4% DS-14, about 0.3% DS-14, about 0.2% DS-14, or about 0.1% DS-14. In some aspects, the mixture of β-cyclodextrin molecules can include less than 1% to about 0.9% DS-14, about 0.9% to about 0.8% DS-14, about 0.8% to about 0.7% DS-14, about 0.7% to about 0.6% DS-14, about 0.7% to about 0.6% DS-14, about 0.6% to about 0.5% DS-14, about 0.5% to about 0.4% DS-14, about 0.4% to about 0.3% DS-14, about 0.3% to about 0.2% DS-14, about 0.2% to about 0.1% DS-14, or less than 0.1% DS-14. In some additional aspects, the mixture of β-cyclodextrin molecules may include less than 1% to about 0.8% DS-14, less than 1% to about 0.7% DS-14, less than 1% to about 0.6% DS-14, less than 1% to about 0.5% DS-14, less than 1% to about 0.4% DS-14, less than 1% to about 0.3% DS-14, less than 1% to about 0.2% DS-14, less than 1% to about 0.1% DS-14, about 0.9% to about 0.1% DS-14, about 0.8% to about 0.1% DS-14, about 0.7% to about 0.1% DS-14, about 0.6% to about 0.1% DS-14, about 0.5% to about 0.1% DS-14, about 0.4% to about 0.1% DS-14, or about 0.3% to about 0.1% DS-14. In yet other aspects, the mixture of β-cyclodextrin molecules may optionally include less than 1% DS-14, less than 0.9% DS-14, less than 0.8% DS-14, less than 0.7% DS-14, less than 0.6% DS-14, less than 0.5% DS-14, less than 0.4% DS-14, less than 0.3% DS-14, less than 0.2% DS-14, or less than 0.1% DS-4. In yet other aspects, the mixture of β-cyclodextrin molecules may optionally include about 0.001%, 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or about 1% DS-14. In some embodiments, the amount of DS-14 in the mixture of β-cyclodextrin molecules can be determined by MALDI-TOF-MS. In some embodiments, DS-14 is not present in the composition.
[0187] In an exemplary embodiment, the composition includes a mixture of β-cyclodextrin molecules, wherein the mixture of β-cyclodextrin molecules includes DS-4, DS-5, DS-6, DS-7, DS-8, DS-9, DS-10, DS-11, DS-12, DS-13, and DS-14, wherein the mixture of β-cyclodextrin molecules includes less than 1% of DS-1, DS-2, DS-3, and DS-4.
[0188] Proton nuclear magnetic resonance spectroscopy ( 1 H-NMR) characterization of the mixture of β-cyclodextrin molecules. 1 H-NMR and methods of interpreting the resulting spectra are generally well known to those of ordinary skill in the art. In some embodiments, the composition may have 1 H-NMR spectrum, which includes at least one peak at about 5.0-5.4 ppm corresponding to the anomeric protons of the β-cyclodextrin molecule; at least one peak at about 3.2-4.2 ppm corresponding to the protons in the core region of the β-cyclodextrin molecule; and at least one peak at about 1.0-1.2 ppm corresponding to the methyl protons of the side chains of the β-cyclodextrin molecule. 1 H-NMR spectra are provided in Figure 2 middle.
[0189] The mixture of β-cyclodextrin molecules may be substituted at one or more of the 2-O-position, 3-O-position, or 6-O-position on each of the cyclodextrin subunits. Additionally, the mixture of β-cyclodextrin molecules may be substituted on one side chain derived from one or more of the above positions. This substitution pattern can be qualitatively determined using DEPT-ed heteronuclear single quantum coherence (DEPT-ed HSQC). Methods for performing DEPT-edited HSQC and interpreting the resulting spectra are generally well known to those of ordinary skill in the art. Exemplary DEPT-edited HSQC spectra of the mixture of β-cyclodextrins disclosed herein are provided at Figure 3 middle.
[0190] In some embodiments, the mixture of β-cyclodextrin molecules may be substituted at the 2-O-position at a rate of substitution ranging from about 35% to about 55%; that is, about 35% to about 55% of the 2-O-positions of the β-cyclodextrin molecules are substituted. In some aspects, the mixture of β-cyclodextrin molecules may be substituted at the 2-O-position at a rate of substitution ranging from about 35% to about 40%, from about 40% to about 45%, from about 45% to about 50%, or from about 50% to about 55%. In some additional aspects, the mixture of β-cyclodextrin molecules may be substituted at the 2-O-position at a rate of substitution ranging from about 35% to about 45%, from about 35% to about 50%, from about 40% to about 55%, from about 45% to about 55%, or from about 40% to about 50%. In yet other aspects, the mixture of β-cyclodextrin molecules can be substituted at the 2-O-position at a rate of about 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, or about 55%. In some embodiments, the mixture of β-cyclodextrin molecules can be substituted at the 2-O-position at a rate of about 46%.
[0191] In some embodiments, the mixture of β-cyclodextrin molecules may be substituted at the 3-O-position at a rate of substitution of about 45% to about 65%. In some aspects, the mixture of β-cyclodextrin molecules may be substituted at the 3-O-position at a rate of substitution of about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, or about 60% to about 65%. In some additional aspects, the mixture of β-cyclodextrin molecules may be substituted at the 3-O-position at a rate of substitution of about 45% to about 55%, about 45% to about 60%, about 50% to about 65%, about 55% to about 65%, or about 50% to about 60%. In yet other embodiments, the mixture of β-cyclodextrin molecules may be substituted at the 3-O-position at a rate of about 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, or about 65%. In some embodiments, the mixture of β-cyclodextrin molecules may be substituted at the 3-O-position at a rate of about 54%.
[0192] In some embodiments, the mixture of β-cyclodextrin molecules may be substituted at the 6-O-position at a rate of about 0% to about 20%. In some aspects, the mixture of β-cyclodextrin molecules may be substituted at the 6-O-position at a rate of about 0% to about 5%, about 5% to about 10%, about 10% to about 15%, or about 15% to about 20%. In some additional aspects, the β-cyclodextrin molecules may be substituted at the 6-O-position at a rate of about 0% to about 10%, about 0% to about 15%, about 5% to about 20%, about 10% to about 20%, or about 5% to about 15%. In yet other aspects, the β-cyclodextrin molecules can be substituted at the 6-O-position at a rate of about 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or about 20%. In some embodiments, the β-cyclodextrin molecules can be substituted at the 6-O-position at a rate of about 10%.
[0193] In some embodiments, about 4-10% of the hydroxypropyl substituents are in an oligomeric state. For example, the hydroxypropyl substituents in an oligomeric state may have the formula:
[0194]
[0195] In some aspects, the percentage of hydroxypropyl substituents in oligomeric state can be from about 4% to about 5%, from about 5% to about 6%, from about 6% to about 7%, from about 7% to about 8%, from about 8% to about 9%, or from about 9% to about 10%. In some additional aspects, the percentage of hydroxypropyl substituents in oligomeric state can be from about 4% to about 6%, from about 4% to about 7%, from about 4% to about 8%, from about 4% to about 9%, from about 5% to about 10%, from about 6% to about 10%, from about 7% to about 10%, from about 8% to about 10%, from about 5% to about 9%, or from about 6% to about 8%. In an exemplary embodiment, about 7% of the hydroxypropyl substituents are in oligomeric state.
[0196] The composition can be characterized by HPLC-CAD using methods known in the art. An exemplary HPLC-CAD chromatogram is shown in Figure 4 In some embodiments, the average retention time of the composition can be from about 11 minutes to about 13 minutes; for example, the average retention time can be about 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, or about 13.0 minutes. In an exemplary embodiment, the average retention time is about 12 minutes.
[0197] Further provided herein is a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. In some embodiments, the composition has an average degree of substitution of from about 6.02 to about 7.98. The average degree of substitution can be determined by 1 H-NMR determination. In some embodiments, the amount of DS-0 and DS-1 is determined by peak height in electrospray MS spectroscopy.
[0198] In some embodiments, the pH of the composition may be between about 6.0 and about 7.9. In some aspects, the pH of the composition may be about 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or about 7.9. Preferably, the pH of the composition is between about 7.1 and 7.7, more preferably between about 7.3 and 7.5.
[0199] In some embodiments, the composition can be purified by alumina adsorption chromatography, solvent precipitation, or a combination thereof, or by other methods known to those of ordinary skill in the art.
[0200] Further provided herein is a method for preparing a mixture of purified β-cyclodextrins suitable for intrathecal, intravenous, oral or intraventricular administration to a patient in need thereof. The method comprises nanofiltration of the β-cyclodextrin to obtain a mixture of purified β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, and then adjusting the pH of the nanofiltered purified β-cyclodextrin mixture to obtain a pH of about 6.0 to about 7.8. The mixture may include less than 0.05% DS-0 and less than 0.05% DS-1. The average degree of substitution of the mixture may be about 6.02-7.98. The pH can be adjusted with sodium hydroxide, such as 0.1M sodium hydroxide.
[0201] Further provided herein is a method of treating Niemann-Pick disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. Further provided herein is a composition for use in a method of treating Niemann-Pick disease, the composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1.
[0202] Further provided herein is a method of treating Niemann-Pick disease type C, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. Further provided herein is a composition for use in a method of treating Niemann-Pick disease type C, the composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1.
[0203] Further provided herein is a method of treating a liver disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. Further provided herein is a composition for use in a method of treating a liver disease, the composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1.
[0204] Further provided herein is a method of treating cardiovascular disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. Further provided herein is a composition for use in a method of treating cardiovascular disease, the composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1.
[0205] Further provided herein is a method for treating familial hypercholesterolemia, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. Further provided herein is a composition for use in a method for treating familial hypercholesterolemia, the composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1.
[0206] Further provided herein is a method for treating cholesterol deposition, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, wherein: the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1. Further provided herein is a composition for use in a method for treating cholesterol deposition, the composition comprising a mixture of β-cyclodextrin molecules substituted with hydroxypropyl groups at one or more hydroxyl positions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a composition, wherein the mixture comprises less than 0.05% unsubstituted β-cyclodextrin ("DS-0") and less than 0.05% DS-1.
[0207] In some embodiments, the method may comprise administering to a patient about 50 mg to about 2000 mg of β-cyclodextrin. In some aspects, the method may comprise administering to a patient about 50 mg to about 100 mg, about 100 mg to about 250 mg, about 250 mg to about 500 mg, about 500 mg to about 750 mg, about 750 mg to about 1000 mg, about 1000 mg to about 1250 mg, about 1250 mg to about 1500 mg, about 1500 mg to about 1750 mg, or about 1750 mg to about 2000 mg of β-cyclodextrin. In some additional aspects, the method may comprise administering to the patient about 50 mg to about 250 mg, about 50 mg to about 500 mg, about 50 mg to about 750 mg, about 50 mg to about 1000 mg, about 50 mg to about 1250 mg, about 50 mg to about 1500 mg, about 50 mg to about 1750 mg, about 100 mg to about 2000 mg, about 250 mg to about 2000 mg, about 500 mg to about 2000 mg, about 750 mg to about 2000 mg, about 1000 mg to about 2000 mg, about 1250 mg to about 2000 mg, or about 1500 mg to about 2000 mg of β-cyclodextrin. In an exemplary embodiment, the method comprises administering to the patient about 50 mg to about 300 mg of β-cyclodextrin.
[0208] In some embodiments, the method may include administering the composition at 1 day, 2 day, or 3 day intervals. In other embodiments, the method may include administering the composition at least once a week. In yet other embodiments, the method may include administering the composition once every two weeks.
[0209] In some embodiments, the method comprises administering to the patient intravenously about 200 mg / kg to about 4100 mg / kg of β-cyclodextrin. In some aspects, the method comprises administering intravenously about 200 mg / kg to about 500 mg / kg, about 500 mg / kg to about 1000 mg / kg, about 1000 mg / kg to about 1500 mg / kg, about 1500 mg / kg to about 2000 mg / kg, about 2000 mg / kg to about 2500 mg / kg, about 2500 mg / kg to about 3000 mg / kg, about 3000 mg / kg to about 3500 mg / kg, or about 3500 mg / kg to about 4100 mg / kg. In some additional aspects, the methods comprise intravenously administering about 200 mg / kg to about 1000 mg / kg, about 200 mg / kg to about 1500 mg / kg, about 200 mg / kg to about 2000 mg / kg, about 200 mg / kg to about 2500 mg / kg, about 200 mg / kg to about 3000 mg / kg, about 200 mg / kg to about 3500 mg / kg, about 500 mg / kg to about 4100 mg / kg, about 1000 mg / kg to about 4100 mg / kg, about 1500 mg / kg to about 4100 mg / kg, about 2000 mg / kg to about 4100 mg / kg, about 2500 mg / kg to about 4100 mg / kg, or about 3000 mg / kg to about 4100 mg / kg.
[0210] In some embodiments, the administration can be carried out within about 4 hours. For example, the administration can be carried out within 4 hours, within 3 hours, within 2 hours, within 1 hour, or within 30 minutes. In some embodiments, the duration of administration (preferably intravenous administration) can be about 4 hours or shorter. For example, the duration of administration is about 4 hours or shorter, about 3 hours or shorter, about 2 hours or shorter, about 1 hour or shorter, or about 30 minutes or shorter.
[0211] In some embodiments, the administration can result in a decrease in one or more lipids by 75% ± 5%, 80% ± 5%, 85% ± 5%, 90% ± 5%, or 95% ± 5%. In some embodiments, the administration can be sufficient to regulate the level of one or more of 7-keto-cholesterol, 7β-hydroxy-cholesterol, 24S-hydroxy-cholesterol, 25-hydroxy-cholesterol, 27-hydroxy-cholesterol, and cholestane-3β,5α,6β-triol in plasma.
[0212] In some embodiments, the administration can be sufficient to maintain or reduce one or more domain scores of the NPC severity scale, wherein the one or more domain scores are selected from the group consisting of: walking, fine motor skills, cognition, speech, swallowing, eye movement, memory, hearing, and seizures. The NPC severity scale and methods of using it are known to those of ordinary skill in the art.
[0213] In some embodiments, the administration prevents NPC progression compared to no administration or administration of a placebo.
[0214] Grading
[0215] The unfractionated composition described above can be isomerically purified by the purification methods described below.
[0216] Without being bound by theory, the isomers of hydroxypropyl-β-cyclodextrin differ from each other, from their starting material (β-cyclodextrin), and from their byproducts (propylene glycol) in their ability to form non-covalent inclusion complexes with hydrophobic compounds. Therefore, the present inventors developed an inclusion compound-assisted HPLC method for separating the isomers of hydroxypropyl-β-cyclodextrin from a composition and separating other components. Inclusion compound-assisted HPLC methods are generally known and described in the art. In the inclusion compound-assisted HPLC method of the present invention, a hydrophobic substance can be grafted onto the silica surface in the stationary phase of the HPLC. Components that are unable to form inclusion complexes (e.g., propylene glycol and hydroxypropyl-β-cyclodextrin degradation products) or components that are only able to form weak inclusion complexes with the silica-grafted substance (e.g., unsubstituted β-cyclodextrin or DS-1) have no retention time or a short retention time when eluted. Components that form stronger inclusion complexes elute with higher retention times (DS-2, DS-3, DS-4, etc.).
[0217] This article provides a method for a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, wherein the method includes separating hydroxypropyl-β-cyclodextrin molecules via high performance liquid chromatography (HPLC). The column for the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules is a chromatographic column (also referred to herein as "Cholester HPLC" column) with a cholesteryl portion fixed on a silica gel surface. This allows the inclusion-type interaction between the fixed cholesteryl portion and the cyclodextrin cavity to cause β-cyclodextrin and propylene glycol to be separated into secondary fractions from the hydroxypropyl-β-cyclodextrin isomers. The cholesteryl portion (stationary phase of "Cholester HPLC" column) fixed on the silica gel surface may include the following:
[0218]
[0219] A schematic diagram of the separation mechanism will be provided in Figure 5 middle.
[0220] Further provided herein is an isomerically purified composition comprising a mixture of hydroxypropyl-β-cyclodextrin molecules eluted from a Cholester HPLC column. The mixture of hydroxypropyl-β-cyclodextrin molecules can have a low degree of substitution (LDS) or a high degree of substitution (HDS). In some embodiments, a mixture of about five LDS hydroxypropyl-β-cyclodextrins and a mixture of about five HDS hydroxypropyl-β-cyclodextrins can be eluted from a Cholester HPLC column. Each of the mixtures is referred to herein as a "fraction."
[0221] Further provided herein is an isomerically purified composition comprising a 5% (w / w) mixture of hydroxypropyl-β-cyclodextrin HDS molecules in an aqueous medium, the composition producing an equilibrium solubility of cholesterol between about 0.2500 and about 0.6000 mg / mL at a temperature of 37° C. In some aspects, the composition can produce an equilibrium solubility of about 0.2500 mg / mL to about 0.3000 mg / mL, about 0.3000 mg / mL to about 0.3500 mg / mL, about 0.3500 mg / mL to about 0.4000 mg / mL, about 0.4000 mg / mL to about 0.4500 mg / mL, about 0.4500 mg / mL to about 0.5000 mg / mL, about 0.5000 mg / mL to about 0.5500 mg / mL, or about 0.6000 mg / mL at a temperature of 37° C. In some additional aspects, the composition can produce an equilibrium solubility at a temperature of 37° C. of about 0.2500 mg / mL to about 0.3500 mg / mL, about 0.2500 mg / mL to about 0.4000 mg / mL, about 0.2500 mg / mL to about 0.4500 mg / mL, about 0.2500 mg / mL to about 0.5000 mg / mL, about 0.2500 mg / mL to about 0.5500 mg / mL, about 0.3000 mg / mL, or about 0.4500 mg / mL. mL to about 0.6000 mg / mL, about 0.3500 mg / mL to about 0.6000 mg / mL, about 0.4000 mg / mL to about 0.6000 mg / mL, about 0.4500 mg / mL to about 0.6000 mg / mL, about 0.5000 mg / mL to about 0.6000 mg / mL, about 0.3000 mg / mL to about 0.5500 mg / mL, or about 0.3500 mg / mL to about 0.5000 mg / mL.
[0222] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.4000 and 0.4200 mg / ml at a temperature of 37°C.
[0223] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.5000 and 0.5200 mg / ml at a temperature of 37°C.
[0224] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.5400 and 0.5600 mg / ml at a temperature of 37°C.
[0225] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.3600 and 0.3800 mg / ml at a temperature of 37°C.
[0226] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.2400 and about 0.2600 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is HDS Fraction 1 and produces an equilibrium solubility of cholesterol between about 0.2400 and about 0.2600 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.2400 and about 0.2450 mg / ml, about 0.2400 and about 0.2500 mg / ml, about 0.2400 and about 0.2550 mg / ml, about 0.2400 and about 0.2600 mg / ml, about 0.2450 and about 0.2600 mg / ml, about 0.2500 and about 0.2600 mg / ml, about 0.2550 and about 0.2600 mg / ml. In additional embodiments, the HDS fraction 1 can produce an equilibrium solubility of cholesterol between about 0.2400 to about 0.2450 mg / ml, about 0.2400 to about 0.2500 mg / ml, about 0.2400 to about 0.2550 mg / ml, about 0.2400 to about 0.2600 mg / ml, about 0.2450 to about 0.2600 mg / ml, about 0.2500 to about 0.2600 mg / ml, about 0.2550 to about 0.2600 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.2400, 0.2410, 0.2420, 0.2430, 0.2440, 0.2450, 0.2460, 0.2470, 0.2480, 0.2490, 0.2500, 0.2510, 0.2520, 0.2530, 0.2540, 0.2550, 0.2560, 0.2570, 0.2580, 0.2590, or about 0.2600 mg / ml. In yet additional embodiments, HDS Fraction 1 may produce an equilibrium solubility of cholesterol of about 0.2400, 0.2410, 0.2420, 0.2430, 0.2440, 0.2450, 0.2460, 0.2470, 0.2480, 0.2490, 0.2500, 0.2510, 0.2520, 0.2530, 0.2540, 0.2550, 0.2560, 0.2570, 0.2580, 0.2590 or about 0.2600 mg / ml.
[0227] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.4000 and about 0.4200 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is HDS Fraction 2 and produces an equilibrium solubility of cholesterol between about 0.4000 and about 0.4200 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.4000 and about 0.4050 mg / ml, about 0.4000 and about 0.4100 mg / ml, about 0.4000 and about 0.4150 mg / ml, about 0.4000 and about 0.4200 mg / ml, about 0.4050 and about 0.4200 mg / ml, about 0.4100 and about 0.4200 mg / ml, about 0.4150 and about 0.4200 mg / ml. In additional embodiments, the HDS fraction 2 can produce an equilibrium solubility of cholesterol between about 0.4000 to about 0.4050 mg / ml, about 0.4000 to about 0.4100 mg / ml, about 0.4000 to about 0.4150 mg / ml, about 0.4000 to about 0.4200 mg / ml, about 0.4050 to about 0.4200 mg / ml, about 0.4100 to about 0.4200 mg / ml, about 0.4150 to about 0.4200 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.4000, 0.4010, 0.4020, 0.4030, 0.4040, 0.4050, 0.4060, 0.4070, 0.4080, 0.4090, 0.4100, 0.4110, 0.4120, 0.4130, 0.4140, 0.4150, 0.4160, 0.4170, 0.4180, 0.4190, or about 0.4200 mg / ml. In yet additional embodiments, HDS Fraction 2 may produce an equilibrium solubility of cholesterol of about 0.4000, 0.4010, 0.4020, 0.4030, 0.4040, 0.4050, 0.4060, 0.4070, 0.4080, 0.4090, 0.4100, 0.4110, 0.4120, 0.4130, 0.4140, 0.4150, 0.4160, 0.4170, 0.4180, 0.4190 or about 0.4200 mg / ml.
[0228] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.5000 and about 0.5200 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is HDS Fraction 3 and produces an equilibrium solubility of cholesterol between about 0.5000 and about 0.5200 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.5000 and about 0.5050 mg / ml, about 0.5000 and about 0.5100 mg / ml, about 0.5000 and about 0.5150 mg / ml, about 0.5000 and about 0.5200 mg / ml, about 0.5050 and about 0.5200 mg / ml, about 0.5100 and about 0.5200 mg / ml, about 0.5150 and about 0.5200 mg / ml. In additional embodiments, the HDS fraction 3 can produce an equilibrium solubility of cholesterol between about 0.5000 to about 0.5050 mg / ml, about 0.5000 to about 0.5100 mg / ml, about 0.5000 to about 0.5150 mg / ml, about 0.5000 to about 0.5200 mg / ml, about 0.5050 to about 0.5200 mg / ml, about 0.5100 to about 0.5200 mg / ml, about 0.5150 to about 0.5200 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.5000, 0.5010, 0.5020, 0.5030, 0.5040, 0.5050, 0.5060, 0.5070, 0.5080, 0.5090, 0.5100, 0.5110, 0.5120, 0.5130, 0.5140, 0.5150, 0.5160, 0.5170, 0.5180, 0.5190, or about 0.5200 mg / ml. In yet additional embodiments, the HDS Fraction 3 may produce an equilibrium solubility of cholesterol of about 0.5000, 0.5010, 0.5020, 0.5030, 0.5040, 0.5050, 0.5060, 0.5070, 0.5080, 0.5090, 0.5100, 0.5110, 0.5120, 0.5130, 0.5140, 0.5150, 0.5160, 0.5170, 0.5180, 0.5190 or about 0.5200 mg / ml.
[0229] In some embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.5400 to about 0.5600 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is HDS Fraction 4 and produces an equilibrium solubility of cholesterol of between about 0.5400 to about 0.5600 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol of between about 0.5400 to about 0.5450 mg / ml, about 0.5400 to about 0.5500 mg / ml, about 0.5400 to about 0.5550 mg / ml, about 0.5400 to about 0.5600 mg / ml, about 0.5450 to about 0.5600 mg / ml, about 0.5500 to about 0.5600 mg / ml, about 0.5550 to about 0.5600 mg / ml. In some additional embodiments, the HDS fraction 4 can produce an equilibrium solubility of cholesterol between about 0.5400 to about 0.5450 mg / ml, about 0.5400 to about 0.5500 mg / ml, about 0.5400 to about 0.5550 mg / ml, about 0.5400 to about 0.5600 mg / ml, about 0.5450 to about 0.5600 mg / ml, about 0.5500 to about 0.5600 mg / ml, about 0.5550 to about 0.5600 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.5400, 0.5410, 0.5420, 0.5430, 0.5440, 0.5450, 0.5460, 0.5470, 0.5480, 0.5490, 0.5500, 0.5510, 0.5520, 0.5530, 0.5540, 0.5550, 0.5560, 0.5570, 0.5580, 0.5590, or about 0.5600 mg / ml. In yet additional embodiments, the HDS Fraction 4 may produce an equilibrium solubility of cholesterol of about 0.5400, 0.5410, 0.5420, 0.5430, 0.5440, 0.5450, 0.5460, 0.5470, 0.5480, 0.5490, 0.5500, 0.5510, 0.5520, 0.5530, 0.5540, 0.5550, 0.5560, 0.5570, 0.5580, 0.5590 or about 0.5600 mg / ml.
[0230] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.3600 and about 0.3800 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is HDS Fraction 5 and produces an equilibrium solubility of cholesterol between about 0.3600 and about 0.3800 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.3600 and about 0.3650 mg / ml, about 0.3600 and about 0.3700 mg / ml, about 0.3600 and about 0.3750 mg / ml, about 0.3600 and about 0.3800 mg / ml, about 0.3650 and about 0.3800 mg / ml, about 0.3700 and about 0.3800 mg / ml, about 0.3750 and about 0.3800 mg / ml. In some additional embodiments, the HDS fraction 5 can produce an equilibrium solubility of cholesterol between about 0.3600 to about 0.3650 mg / ml, about 0.3600 to about 0.3700 mg / ml, about 0.3600 to about 0.3750 mg / ml, about 0.3600 to about 0.3800 mg / ml, about 0.3650 to about 0.3800 mg / ml, about 0.3700 to about 0.3800 mg / ml, about 0.3750 to about 0.3800 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.3600, 0.3610, 0.3620, 0.3630, 0.3640, 0.3650, 0.3660, 0.3670, 0.3680, 0.3690, 0.3700, 0.3710, 0.3720, 0.3730, 0.3740, 0.3750, 0.3760, 0.3770, 0.3780, 0.3790, or about 0.3800 mg / ml. In yet additional embodiments, the HDS Fraction 5 may produce an equilibrium solubility of cholesterol of about 0.3600, 0.3610, 0.3620, 0.3630, 0.3640, 0.3650, 0.3660, 0.3670, 0.3680, 0.3690, 0.3700, 0.3710, 0.3720, 0.3730, 0.3740, 0.3750, 0.3760, 0.3770, 0.3780, 0.3790 or about 0.3800 mg / ml.
[0231] Further provided herein is an isomerically purified composition comprising 5% (w / w) of a mixture of hydroxypropyl-β-cyclodextrin HDS molecules in an aqueous medium, wherein the mixture of hydroxypropyl-β-cyclodextrin HDS molecules is insoluble in water. In some aspects, the mixture of hydroxypropyl-β-cyclodextrin HDS molecules can become soluble in water (e.g., soluble at room temperature (20-25° C.)) in the presence of cholesterol.
[0232] Further provided herein is an isomerically purified composition comprising a mixture of 5% (w / w) hydroxypropyl-β-cyclodextrin LDS molecules in an aqueous medium, the composition producing an equilibrium solubility of cholesterol at a temperature of 37° C. between about 0.1700 and about 0.3200 mg / mL. In some aspects, the composition can produce an equilibrium solubility of cholesterol at a temperature of 37° C. between about 0.1700 mg / mL and about 0.2200 mg / mL, between about 0.2200 mg / mL and about 0.2700 mg / mL, or between about 0.2700 and about 0.3200 mg / mL. In some additional aspects, the composition can produce an equilibrium solubility of cholesterol at a temperature of 37° C. between about 0.1700 mg / mL and about 0.2700 mg / mL or between about 0.2200 mg / mL and about 0.3200 mg / mL.
[0233] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.1800 and about 0.2000 mg / ml at a temperature of 37°C.
[0234] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.1700 and about 0.1900 mg / ml at a temperature of 37°C.
[0235] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.2000 and about 0.2200 mg / ml at a temperature of 37°C.
[0236] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.2200 and about 0.2400 mg / ml at a temperature of 37°C.
[0237] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.3100 and about 0.3300 mg / ml at a temperature of 37°C.
[0238] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.1800 and about 0.2000 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is LDS Fraction 1, which produces an equilibrium solubility of cholesterol between about 0.1800 and about 0.2000 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.1800 and about 0.1850 mg / ml, about 0.1800 and about 0.1900 mg / ml, about 0.1800 and about 0.1950 mg / ml, about 0.1800 and about 0.2000 mg / ml, about 0.1850 and about 0.2000 mg / ml, about 0.1900 and about 0.2000 mg / ml, about 0.1950 and about 0.2000 mg / ml. In additional embodiments, the LDS fraction 1 can produce an equilibrium solubility of cholesterol between about 0.1800 to about 0.1850 mg / ml, about 0.1800 to about 0.1900 mg / ml, about 0.1800 to about 0.1950 mg / ml, about 0.1800 to about 0.2000 mg / ml, about 0.1850 to about 0.2000 mg / ml, about 0.1900 to about 0.2000 mg / ml, about 0.1950 to about 0.2000 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.1800, 0.1810, 0.1820, 0.1830, 0.1840, 0.1850, 0.1860, 0.1870, 0.1880, 0.1890, 0.1900, 0.1910, 0.1920, 0.1930, 0.1940, 0.1950, 0.1960, 0.1970, 0.1980, 0.1990, or about 0.2000 mg / ml. In yet additional embodiments, the LDS Fraction 1 may produce an equilibrium solubility of cholesterol of about 0.1800, 0.1810, 0.1820, 0.1830, 0.1840, 0.1850, 0.1860, 0.1870, 0.1880, 0.1890, 0.1900, 0.1910, 0.1920, 0.1930, 0.1940, 0.1950, 0.1960, 0.1970, 0.1980, 0.1990 or about 0.2000 mg / ml.
[0239] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.1700 and about 0.1900 mg / ml, for example, between about 0.1700 and about 0.1790 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is LDS Fraction 2 and produces an equilibrium solubility of cholesterol between about 0.1700 and about 0.1900 mg / ml, for example, between about 0.1700 and about 0.1790 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.1700 to about 0.1750 mg / ml, about 0.1700 to about 0.1800 mg / ml, about 0.1700 to about 0.1850 mg / ml, about 0.1700 to about 0.1900 mg / ml, about 0.1750 to about 0.1900 mg / ml, about 0.1800 to about 0.1900 mg / ml, about 0.1850 to about 0.1900 mg / ml. In additional embodiments, the LDS fraction 2 can produce an equilibrium solubility of cholesterol between about 0.1700 to about 0.1750 mg / ml, about 0.1700 to about 0.1800 mg / ml, about 0.1700 to about 0.1850 mg / ml, about 0.1700 to about 0.1900 mg / ml, about 0.1750 to about 0.1900 mg / ml, about 0.1800 to about 0.1900 mg / ml, about 0.1850 to about 0.1900 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.1700, 0.1710, 0.1720, 0.1730, 0.1740, 0.1750, 0.1760, 0.1770, 0.1780, 0.1790, 0.1800, 0.1810, 0.1820, 0.1830, 0.1840, 0.1850, 0.1860, 0.1870, 0.1880, 0.1890, or about 0.1900 mg / ml. In yet additional embodiments, the LDS Fraction 2 may produce an equilibrium solubility of cholesterol of about 0.1700, 0.1710, 0.1720, 0.1730, 0.1740, 0.1750, 0.1760, 0.1770, 0.1780, 0.1790, 0.1800, 0.1810, 0.1820, 0.1830, 0.1840, 0.1850, 0.1860, 0.1870, 0.1880, 0.1890 or about 0.1900 mg / ml.
[0240] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.2000 and about 0.2200 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is LDS Fraction 3 and produces an equilibrium solubility of cholesterol between about 0.2000 and about 0.2200 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.2000 and about 0.2050 mg / ml, about 0.2000 and about 0.2100 mg / ml, about 0.2000 and about 0.2150 mg / ml, about 0.2000 and about 0.2200 mg / ml, about 0.2050 and about 0.2200 mg / ml, about 0.2100 and about 0.2200 mg / ml, about 0.2150 and about 0.2200 mg / ml. In additional embodiments, the LDS fraction 3 can produce an equilibrium solubility of cholesterol between about 0.2000 to about 0.2050 mg / ml, about 0.2000 to about 0.2100 mg / ml, about 0.2000 to about 0.2150 mg / ml, about 0.2000 to about 0.2200 mg / ml, about 0.2050 to about 0.2200 mg / ml, about 0.2100 to about 0.2200 mg / ml, about 0.2150 to about 0.2200 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.2000, 0.2010, 0.2020, 0.2030, 0.2040, 0.2050, 0.2060, 0.2070, 0.2080, 0.2090, 0.2100, 0.2110, 0.2120, 0.2130, 0.2140, 0.2150, 0.2160, 0.2170, 0.2180, 0.2190, or about 0.2200 mg / ml. In yet additional embodiments, the LDS Fraction 3 may produce an equilibrium solubility of cholesterol of about 0.2000, 0.2010, 0.2020, 0.2030, 0.2040, 0.2050, 0.2060, 0.2070, 0.2080, 0.2090, 0.2100, 0.2110, 0.2120, 0.2130, 0.2140, 0.2150, 0.2160, 0.2170, 0.2180, 0.2190 or about 0.2200 mg / ml.
[0241] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.2200 and about 0.2400 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is LDS Fraction 4 and produces an equilibrium solubility of cholesterol between about 0.2200 and about 0.2400 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.2200 and about 0.2250 mg / ml, about 0.2200 and about 0.2300 mg / ml, about 0.2200 and about 0.2350 mg / ml, about 0.2200 and about 0.2400 mg / ml, about 0.2250 and about 0.2400 mg / ml, about 0.2300 and about 0.2400 mg / ml, about 0.2350 and about 0.2400 mg / ml. In additional embodiments, the LDS fraction 4 can produce an equilibrium solubility of cholesterol between about 0.2200 to about 0.2250 mg / ml, about 0.2200 to about 0.2300 mg / ml, about 0.2200 to about 0.2350 mg / ml, about 0.2200 to about 0.2400 mg / ml, about 0.2250 to about 0.2400 mg / ml, about 0.2300 to about 0.2400 mg / ml, about 0.2350 to about 0.2400 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.2200, 0.2210, 0.2220, 0.2230, 0.2240, 0.2250, 0.2260, 0.2270, 0.2280, 0.2290, 0.2300, 0.2310, 0.2320, 0.2330, 0.2340, 0.2350, 0.2360, 0.2370, 0.2380, 0.2390, or about 0.2400 mg / ml. In yet additional embodiments, the LDS fraction 4 may produce an equilibrium solubility of cholesterol of about 0.2200, 0.2210, 0.2220, 0.2230, 0.2240, 0.2250, 0.2260, 0.2270, 0.2280, 0.2290, 0.2300, 0.2310, 0.2320, 0.2330, 0.2340, 0.2350, 0.2360, 0.2370, 0.2380, 0.2390 or about 0.2400 mg / ml.
[0242] In some embodiments, the composition can produce an equilibrium solubility of cholesterol between about 0.3100 and about 0.3300 mg / ml at a temperature of 37° C. In an exemplary embodiment, the composition is LDS Fraction 5 and produces an equilibrium solubility of cholesterol between about 0.3100 and about 0.3300 mg / ml at a temperature of 37° C. For example, the composition can produce an equilibrium solubility of cholesterol between about 0.3100 and about 0.3150 mg / ml, about 0.3100 and about 0.3200 mg / ml, about 0.3100 and about 0.3250 mg / ml, about 0.3100 and about 0.3300 mg / ml, about 0.3150 and about 0.3300 mg / ml, about 0.3200 and about 0.3300 mg / ml, about 0.3250 and about 0.3300 mg / ml. In some additional embodiments, the LDS fraction 5 can produce an equilibrium solubility of cholesterol between about 0.3100 to about 0.3150 mg / ml, about 0.3100 to about 0.3200 mg / ml, about 0.3100 to about 0.3250 mg / ml, about 0.3100 to about 0.3300 mg / ml, about 0.3150 to about 0.3300 mg / ml, about 0.3200 to about 0.3300 mg / ml, about 0.3250 to about 0.3300 mg / ml. In yet additional embodiments, the composition can produce an equilibrium solubility of cholesterol of about 0.3100, 0.3110, 0.3120, 0.3130, 0.3140, 0.3150, 0.3160, 0.3170, 0.3180, 0.3190, 0.3200, 0.3210, 0.3220, 0.3230, 0.3240, 0.3250, 0.3260, 0.3270, 0.3280, 0.3290 or about 0.3300 mg / ml. In yet additional embodiments, the LDS fraction 5 may produce an equilibrium solubility of cholesterol of about 0.3100, 0.3110, 0.3120, 0.3130, 0.3140, 0.3150, 0.3160, 0.3170, 0.3180, 0.3190, 0.3200, 0.3210, 0.3220, 0.3230, 0.3240, 0.3250, 0.3260, 0.3270, 0.3280, 0.3290 or about 0.3300 mg / ml.
[0243] Further provided herein is an isomerically purified composition comprising a mixture of 20% (w / w) hydroxypropyl-β-cyclodextrin molecules in an aqueous medium, the composition producing an equilibrium solubility of cholesterol between about 3.2500 mg / mL and about 3.7500 mg / mL at a temperature of 37° C. In some aspects, the composition can produce an equilibrium solubility of cholesterol between about 3.2500 mg / mL and about 3.3500 mg / mL, about 3.3500 mg / mL and about 3.4500 mg / mL, about 3.4500 mg / mL and about 3.5500 mg / mL, about 3.5500 mg / mL and about 3.6500 mg / mL, or about 3.6500 mg / mL and about 3.7500 mg / mL. In some additional aspects, the compositions can produce an equilibrium solubility of cholesterol between about 3.2500 mg / mL to about 3.4500 mg / mL, about 3.2500 mg / mL to about 3.5500 mg / mL, about 3.2500 mg / mL to about 3.6500 mg / mL, about 3.3500 mg / mL to about 3.7500 mg / mL, about 3.4500 mg / mL to about 3.7500 mg / mL, or about 3.5500 mg / mL to about 3.7500 mg / mL.
[0244] Further provided herein is a method of increasing the solubility of a mixture of hydroxypropyl β-cyclodextrin molecules in water (e.g., at 37° C.) by increasing the substitution at the 2-O-position of the hydroxypropyl β-cyclodextrin molecules. Also provided herein is a method of increasing the solubility of a mixture of hydroxypropyl β-cyclodextrin molecules in water (e.g., at 37° C.) by increasing the substitution at the 2-O-position of the hydroxypropyl β-cyclodextrin molecules without increasing the hydroxypropyl substitution at other positions of the hydroxypropyl β-cyclodextrin molecules. Further provided herein is a method for increasing the solubility of a mixture of hydroxypropyl β-cyclodextrin molecules in water (e.g., at 37° C.) by increasing the substitution at the 2-O-position of the hydroxypropyl β-cyclodextrin molecules while maintaining the hydroxypropyl substitution at other positions of the hydroxypropyl β-cyclodextrin molecules (e.g., 3-O and / or 6-O) at less than or equal to 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% by weight. In yet another embodiment, provided herein is a method for increasing the solubility of a mixture of hydroxypropyl β-cyclodextrin molecules in water (e.g., at 37° C.) by increasing the substitution at the 2-O-position of the hydroxypropyl β-cyclodextrin molecules without substantially increasing the hydroxypropyl substitution at the 3-O position. Without wishing to be bound by theory, the solubility of hydroxypropyl β-cyclodextrin may be largely affected by the interaction between the hydroxyl groups of the molecule and the hydroxyl groups in water. When the hydroxypropyl group is substituted at the 3-O-position, the hydroxyl group of water may be sterically hindered from interacting with the hydroxyl group of the hydroxypropyl moiety; therefore, water solubility may be reduced. When the hydroxypropyl group is substituted at the 2-O-position, the hydroxyl group of water is no longer sterically hindered and can interact with the hydroxyl group of the hydroxypropyl moiety; therefore, water solubility may be increased.
[0245] Without wishing to be bound by theory, it is believed that the increase in the solubility of fraction 5 in water caused by the addition of cholesterol is due to a conformational change in the hydroxypropyl β-cyclodextrin molecules that form inclusion complexes with the cholesterol molecules. When the hydroxypropyl β-cyclodextrin molecules have oligomeric side chains at the 2-O-position, the hydroxyl groups in the oligomeric side chains can form self-inclusion complexes and are therefore unable to interact with the hydroxyl groups of water molecules. When cholesterol is added to the solution, the cholesterol molecules interact with the hydroxypropyl β-cyclodextrin molecules, causing the hydroxypropyl β-cyclodextrin molecules to undergo a conformational change. This frees the hydroxyl groups of the side chains to interact with the hydroxyl groups of water molecules; thus, the solubility of fraction 5 is increased.
[0246] Further provided herein is a composition comprising a mixture of hydroxypropyl beta-cyclodextrin molecules and cholesterol, wherein the mixture of hydroxypropyl beta-cyclodextrin molecules is present in molar equivalent or molar excess compared to cholesterol. The composition may include a solvent, such as water. The concentration of the mixture of the hydroxypropyl beta-cyclodextrin molecules in the composition may be from about 5 weight % to about 20 weight %. In some embodiments, the concentration of the mixture of the hydroxypropyl beta-cyclodextrin molecules may be from about 5 weight % to about 10 weight %, from about 10 weight % to about 15 weight %, from about 10 weight % to about 20 weight % or from about 15 weight % to about 20 weight % (wherein weight % may be the weight % of the composition in some embodiments). In some embodiments, the presence of cholesterol substantially increases the solubility of the mixture of hydroxypropyl beta-cyclodextrin molecules. In some embodiments, the presence of cholesterol substantially increases the solubility of the mixture of hydroxypropyl beta-cyclodextrin molecules in water. Surprisingly, in some embodiments, the water solubility of hydroxypropyl β-cyclodextrin (e.g., at 37° C.) increases by about 2.5% to about 200%, for example, about 10% to about 100%, in the presence of cholesterol. Thus, one aspect of the present invention is a composition comprising a mixture of hydroxypropyl β-cyclodextrin molecules and cholesterol, wherein the solubility of the hydroxypropyl β-cyclodextrin molecules (e.g., at 37° C.) increases by about 2.5% to about 200%, for example, about 10% to about 100%, in the presence of cholesterol. Another aspect of the present disclosure is a composition comprising a mixture of hydroxypropyl β-cyclodextrin molecules and cholesterol, wherein the water solubility of hydroxypropyl β-cyclodextrin (e.g., at 37° C.) increases by about 2.5% to about 200%, for example, about 10% to about 100%, in the presence of cholesterol, due to a conformational change in the hydroxypropyl β-cyclodextrin molecules bound and / or complexed with cholesterol. In some embodiments, the presence of cholesterol substantially increases the water solubility (e.g., at 37° C.) of a mixture of hydroxypropyl β-cyclodextrin molecules by about 2.5% to about 5%, 5% to about 10%, about 10% to about 15%, about 15% to about 25%, about 25% to about 50%, about 50% to about 75%, about 75% to about 100%, about 100% to about 150%, about 150% to about 200%.
[0247] In some embodiments, the hydroxypropyl β-cyclodextrin can be present in the composition at a molar ratio to cholesterol of about 100:1 to about 1:1. In some aspects, the hydroxypropyl β-cyclodextrin can be present in the composition at a molar ratio to cholesterol of about 1:1 to about 25:1, about 25:1 to about 50:1, about 50:1 to about 75:1, or about 75:1 to about 100:1. In some embodiments, the solubility of the hydroxypropyl β-cyclodextrin is increased by about 10% to about 100% in the presence of a mixture of cholesterol and a molar excess of hydroxypropyl β-cyclodextrin molecules (e.g., Fraction 5).
[0248] In other embodiments, the hydroxypropyl β-cyclodextrin can be present in the composition at a molar ratio to cholesterol of about 1:1 to about 1:100 (i.e., a molar excess). In some aspects, the hydroxypropyl β-cyclodextrin can be present in the composition at a molar ratio to cholesterol of about 1:1 to about 1:25, about 1:25 to about 1:50, about 1:50 to about 1:75, or about 1:75 to about 1:100.
[0249] Further provided herein are compositions comprising a mixture of hydroxypropyl β-cyclodextrin molecules in which the substitution at the 3-O-position dimerizes. Without wishing to be bound by theory, in hydroxypropyl β-cyclodextrin molecules having two or more substitutions at the 3-O-position, the hydroxyl groups of the hydroxypropyl moieties may react to form hydroxypropyl dimers. In these molecules, the hydroxyl group at the 3-O-position becomes insoluble in water and, therefore, has low water solubility.
[0250] Further provided herein are compositions comprising a mixture of hydroxypropyl β-cyclodextrin molecules wherein the substitution at the 3-O-position forms a self-inclusion complex. Without wishing to be bound by theory, in hydroxypropyl β-cyclodextrin molecules having two or more substitutions at the 3-O-position, the hydroxyl groups of the hydroxypropyl moieties may interact to form a self-inclusion complex. In these molecules, the hydroxyl group at the 3-O-position becomes insoluble in water and, therefore, has low water solubility.
[0251] Further provided herein is a method of increasing the surface polarity of a hydroxypropyl β-cyclodextrin molecule, the method comprising increasing the number of substitutions at the 2-O-position. In some embodiments, the method may further comprise increasing the number of substitutions at the 3-O-position of the hydroxypropyl β-cyclodextrin molecule.
[0252] Fraction 1 HDS
[0253] Provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, the mixture comprising less than 1% DS-4. In some embodiments, the hydroxypropyl-β-cyclodextrin percentage is an area percentage based on a MALDI-TOF-MS spectrum. In some embodiments, the hydroxypropyl-β-cyclodextrin percentage can be a weight percentage, a mole percentage, or a volume percentage. In an exemplary embodiment, the hydroxypropyl-β-cyclodextrin percentage is a weight percentage.
[0254] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1% DS-3, DS-2, and DS-1. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-3, DS-2, and DS-1. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-4, DS-3, DS-2, and / or DS-1. In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules is free of DS-3, DS-2, and / or DS-1.
[0255] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules may include less than 1% DS-12, DS-13, and DS-14. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-12, DS-13, and DS-14. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-12, DS-13, and / or DS-14. In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules is free of DS-12, DS-13, and / or DS-14.
[0256] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 1% to about 5% DS-5. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 1% to about 1.5% DS-5, from about 1.5% to about 2% DS-5, from about 2% to about 2.5% DS-5, from about 2.5% to about 3% DS-5, from about 3% DS-5 to about 3.5% DS-5, from about 3.5% to about 4% DS-5, from about 4% to about 4.5% DS-5, or from about 4.5% to about 5% DS-5. In some additional aspects, the mixture of isomerically purified β-cyclodextrin molecules comprises about 1% to about 2% DS-5, about 1% to about 2.5% DS-5, about 1% to about 3% DS-5, about 1% to about 3.5% DS-5, about 1% to about 4% DS-5, about 1% to about 4.5% DS-5, about 1.5% to about 5% DS-5, about 2% to about 5% DS-5, about 2.5% to about 5% DS-5, about 3% to about 5% DS-5, about 3.5% to about 5% DS-5, about 4% to about 5% DS-5, about 1.5% to about 4.5% DS-5, about 2% to about 4% DS-5, or about 2.5% to about 3.5% DS-5. In yet other embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, or about 5.0% DS-5. In an exemplary embodiment, the area of DS-5 in the MALDI-TOF-MS spectrum is 2.83%.
[0257] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 7% to about 13% DS-6. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can comprise from about 7% to about 7.5% DS-6, from about 7.5% to about 8% DS-6, from about 8% to about 8.5% DS-6, from about 8.5% to about 9% DS-6, from about 9% to about 9.5% DS-6, from about 9.5% to about 10% DS-6, from about 10% to about 10.5% DS-6, from about 10.5% to about 11% DS-6, from about 11% to about 11.5% DS-6, from about 11.5% to about 12% DS-6, from about 12% to about 12.5% DS-6, or from about 12.5% to about 13% DS-6. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 7% to about 8% DS-6, about 7% to about 8.5% DS-6, about 7% to about 9% DS-6, about 7% to about 9.5% DS-6, about 7% to about 10% DS-6, about 7% to about 10.5% DS-6, about 7% to about 11% DS-6, about 7% to about 11.5% DS-6, about 7% to about 12% DS-6, about 7% to about 12.5% DS-6, about 7.5% to about 13% DS-6, about 8% to about 8.5 .... 6, about 8.5% to about 13% DS-6, about 9% to about 13% DS-6, about 9.5% to about 13% DS-6, about 10% to about 13% DS-6, about 10.5% to about 13% DS-6, about 11% to about 13% DS-6, about 11.5% to about 13% DS-6, about 12% to about 13% DS-6, about 7.5% to about 12.5% DS-6, about 8% to about 12% DS-6, about 8.5% to about 11.5% DS-6, about 9% to about 11% DS-6, or about 9.5% to about 10.5% DS-6.In yet additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can comprise about 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10. %, 12.8%, 12.9%, or about 13.0% DS-6. In one exemplary embodiment, the area of DS-6 in the MALDI-TOF-MS spectrum is 10.64%.
[0258] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16% to about 22% DS-7. In some aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16% to about 16.5% DS-7, about 16.5% to about 17% DS-7, about 17% to about 17.5% DS-7, about 17.5% to about 18% DS-7, about 18% to about 18.5% DS-7, about 18.5% to about 19% DS-7, about 19% to about 19.5% DS-7, about 19.5% to about 20% DS-7, about 20% to about 20.5% DS-7, about 20.5% to about 21% DS-7, about 21% to about 21.5% DS-7, or about 21.5% to about 22% DS-7. In some additional aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16% to about 17% DS-7, about 16% to about 17.5% DS-7, about 16% to about 18% DS-7, about 16% to about 18.5% DS-7, about 16% to about 19% DS-7, about 16% to about 19.5% DS-7, about 16% to about 20% DS-7, about 16% to about 20.5% DS-7, about 16% to about 21% DS-7, about 16% to about 21.5% DS-7, about 16.5% to about 22% DS-7, about 17% to about 22.5% DS-7. -7, about 17.5% to about 22% DS-7, about 18% to about 22% DS-7, about 18.5% to about 22% DS-7, about 19% to about 22% DS-7, about 19.5% to about 22% DS-7, about 20% to about 22% DS-7, about 20.5% to about 22% DS-7, about 21% to about 22% DS-7, about 16.5% to about 21.5% DS-7, about 17% to about 21% DS-7, about 17.5% to about 20.5% DS-7, about 18% to about 20% DS-7 or about 18.5% to about 19.5% DS-7.In still other aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16.0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%. %, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0%, 20.1%, 20.2%, 20.3%, 20.4%, 20.5%, 20.6%, 20.7%, 20.8%, 20.9%, 21.0%, 21.1%, 21.2%, 21.3%, 21.4%, 21.5%, 21.6%, 21.7%, 21.8%, 21.9%, or about 22.0% DS-7. In an exemplary embodiment, the area of DS-7 in the MALDI-TOF-MS spectrum is 19.30%.
[0259] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 26% to about 32% DS-8. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 26% to about 26.5% DS-8, about 26.5% to about 27% DS-8, about 27% to about 27.5% DS-8, about 27.5% to about 28% DS-8, about 28% to about 28.5% DS-8, about 28.5% to about 29% DS-8, about 29% to about 29.5% DS-8, about 29.5% to about 30% DS-8, about 30% to about 30.5% DS-8, about 30.5% to about 31% DS-8, about 31% to about 31.5% DS-8, or about 31.5% to about 32% DS-8. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 26% to about 27% DS-8, about 26% to about 27.5% DS-8, about 26% to about 28% DS-8, about 26% to about 28.5% DS-8, about 26% to about 29% DS-8, about 26% to about 29.5% DS-8, about 26% to about 30% DS-8, about 26% to about 30.5% DS-8, about 26% to about 31% DS-8, about 26% to about 31.5% DS-8, about 26.5% to about 32% DS-8, about 27% to about 32% DS-8, or about 28.5% DS-8. -8, about 27.5% to about 32% DS-8, about 28% to about 32% DS-8, about 28.5% to about 32% DS-8, about 29% to about 32% DS-8, about 29.5% to about 32% DS-8, about 30% to about 32% DS-8, about 30.5% to about 32% DS-8, about 31% to about 32% DS-8, about 26.5% to about 31.5% DS-8, about 27% to about 31% DS-8, about 27.5% to about 30.5% DS-8, about 28% to about 30% DS-8, or about 28.5% to about 29.5% DS-8.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, 28.0%, 28.1%, 28.2%, 28.3%, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, 29.0%, 29.1%, 29.2%, 29.3%, 29.4%, 29.5%, 29.6%, 29.7%, 29.8%, 29 ... %. In one exemplary embodiment, the area of DS-8 in the MALDI-TOF-MS spectrum is 29.30%.
[0260] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 22% to about 28% DS-9. In some aspects, the mixture of isomerically purified β-cyclodextrin molecules includes about 22% to about 22.5% DS-9, about 22.5% to about 23% DS-9, about 23% to about 23.5% DS-9, about 23.5% to about 24% DS-9, about 24% to about 24.5% to about 25% DS-9, about 25% to about 25.5% DS-9, about 25.5% to about 26% DS-9, about 26% to about 26.5% DS-9, about 26.5% to about 27% DS-9, about 27% to about 27.5% DS-9, or about 27.5% to about 28% DS-9. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 22% to about 23% DS-9, about 22% to about 23.5% DS-9, about 22% to about 24% DS-9, about 22% to about 24.5% DS-9, about 22% to about 25% DS-9, about 22% to about 25.5% DS-9, about 22% to about 26% DS-9, about 22% to about 26.5% DS-9, about 22% to about 27% DS-9, about 22% to about 27.5% DS-9, about 22.5% to about 28% DS-9, about 23% to about 28% DS-9. -9, about 23.5% to about 28% DS-9, about 24% to about 28% DS-9, about 24.5% to about 28% DS-9, about 25% to about 28% DS-9, about 25.5% to about 28% DS-9, about 26% to about 28% DS-9, about 26.5% to about 28% DS-9, about 27% to about 28% DS-9, about 22.5% to about 27.5% DS-9, about 23% to about 27% DS-9, about 23.5% to about 26.5% DS-9, about 24% to about 26% DS-9, or about 24.5% to about 25.5% DS-9.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 22.0%, 22.1%, 22.2%, 22.3%, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23.9%, 24.0%, 24.1%, 24.2%, 24.3%, 24.4%, 24.5%, 24.6%, 24.7%, 24.8%, 24.9%, 25.0%, 25.1%, 25.2%, 25.3%, 25.4%, 25.5%, 25.6%, 25.7%, 25.8%, 25.9%, 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, %. In one exemplary embodiment, the area of DS-9 in the MALDI-TOF-MS spectrum is 25.30%.
[0261] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11% to about 17% DS-10. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11% to about 11.5% DS-10, about 11.5% to about 12% DS-10, about 12% to about 12.5% DS-10, about 12.5% to about 13% DS-10, about 13% to about 13.5% DS-10, about 13.5% to about 14% DS-10, about 14% to about 14.5% DS-10, about 14.5% to about 15% DS-10, about 15% to about 15.5% DS-10, about 15.5% to about 16% DS-10, about 16% to about 16.5% DS-10, or about 16.5% to about 17% DS-10. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11% to about 12% DS-10, about 11% to about 12.5% DS-10, about 11% to about 13% DS-10, about 11% to about 13.5% DS-10, about 11% to about 14% DS-10, about 11% to about 14.5% DS-10, about 11% to about 15% DS-10, about 11% to about 15.5% DS-10, about 11% to about 16% DS-10, about 11% to about 16.5% DS-10, about 11.5% to about 17% DS-10, about 12% to about 17.5% DS-10. S-10, about 12.5% to about 17% DS-10, about 13% to about 17% DS-10, about 13.5% to about 17% DS-10, about 14% to about 17% DS-10, about 14.5% to about 17% DS-10, about 15% to about 17% DS-10, about 15.5% to about 17% DS-10, about 16% to about 17% DS-10, about 11.5% to about 16.5% DS-10, about 12% to about 16% DS-10, about 12.5% to about 15.5% DS-10, about 13% to about 15% DS-10, or about 13.5% to about 14.5% DS-10.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14.0%, 14.1%, 14.2%, 14.3%, 14.4%, 14.5%, 14.6%, 14.7%, 14.8%, 14.9%, 15.0%, 15.1%, 15.2%, 15.3%, 15.4%, 15.5%, 15.6%, 15.7%, 15.8%, 15.9%, 16.0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18. %, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, or about 17.0% DS- 10. In one exemplary embodiment, the area of DS-10 in the MALDI-TOF-MS spectrum is 14.30%.
[0262] In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 1% to about 5% DS-5, about 7% to about 13% DS-6, about 16% to about 22% DS-7, about 26% to about 32% DS-8, about 22% to about 28% DS-9, and about 11% to about 17% DS-10.
[0263] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, the mixture comprising DS-5, DS-6, DS-7, DS-8, DS-9, and DS-10. In some embodiments, the composition comprises less than 1% DS-4. In some additional embodiments, the composition comprises less than 1% DS-11. In some embodiments, DS-8 may have the highest concentration in the composition compared to DS-5, DS-6, DS-7, DS-9, and DS-10.
[0264] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 1% to about 5% DS-5. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 1% to about 1.5% DS-5, from about 1.5% to about 2% DS-5, from about 2% to about 2.5% DS-5, from about 2.5% to about 3% DS-5, from about 3% DS-5 to about 3.5% DS-5, from about 3.5% to about 4% DS-5, from about 4% to about 4.5% DS-5, or from about 4.5% to about 5% DS-5. In some additional aspects, the mixture of isomerically purified β-cyclodextrin molecules comprises about 1% to about 2% DS-5, about 1% to about 2.5% DS-5, about 1% to about 3% DS-5, about 1% to about 3.5% DS-5, about 1% to about 4% DS-5, about 1% to about 4.5% DS-5, about 1.5% to about 5% DS-5, about 2% to about 5% DS-5, about 2.5% to about 5% DS-5, about 3% to about 5% DS-5, about 3.5% to about 5% DS-5, about 4% to about 5% DS-5, about 1.5% to about 4.5% DS-5, about 2% to about 4% DS-5, or about 2.5% to about 3.5% DS-5. In yet other embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, or about 5.0% DS-5. In an exemplary embodiment, the area of DS-5 in the MALDI-TOF-MS spectrum is 2.83%.
[0265] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 7% to about 13% DS-6. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can comprise from about 7% to about 7.5% DS-6, from about 7.5% to about 8% DS-6, from about 8% to about 8.5% DS-6, from about 8.5% to about 9% DS-6, from about 9% to about 9.5% DS-6, from about 9.5% to about 10% DS-6, from about 10% to about 10.5% DS-6, from about 10.5% to about 11% DS-6, from about 11% to about 11.5% DS-6, from about 11.5% to about 12% DS-6, from about 12% to about 12.5% DS-6, or from about 12.5% to about 13% DS-6. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 7% to about 8% DS-6, about 7% to about 8.5% DS-6, about 7% to about 9% DS-6, about 7% to about 9.5% DS-6, about 7% to about 10% DS-6, about 7% to about 10.5% DS-6, about 7% to about 11% DS-6, about 7% to about 11.5% DS-6, about 7% to about 12% DS-6, about 7% to about 12.5% DS-6, about 7.5% to about 13% DS-6, about 8% to about 8.5 .... 6, about 8.5% to about 13% DS-6, about 9% to about 13% DS-6, about 9.5% to about 13% DS-6, about 10% to about 13% DS-6, about 10.5% to about 13% DS-6, about 11% to about 13% DS-6, about 11.5% to about 13% DS-6, about 12% to about 13% DS-6, about 7.5% to about 12.5% DS-6, about 8% to about 12% DS-6, about 8.5% to about 11.5% DS-6, about 9% to about 11% DS-6, or about 9.5% to about 10.5% DS-6.In yet additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can comprise about 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10. %, 12.8%, 12.9%, or about 13.0% DS-6. In one exemplary embodiment, the area of DS-6 in the MALDI-TOF-MS spectrum is 10.64%.
[0266] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16% to about 22% DS-7. In some aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16% to about 16.5% DS-7, about 16.5% to about 17% DS-7, about 17% to about 17.5% DS-7, about 17.5% to about 18% DS-7, about 18% to about 18.5% DS-7, about 18.5% to about 19% DS-7, about 19% to about 19.5% DS-7, about 19.5% to about 20% DS-7, about 20% to about 20.5% DS-7, about 20.5% to about 21% DS-7, about 21% to about 21.5% DS-7, or about 21.5% to about 22% DS-7. In some additional aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16% to about 17% DS-7, about 16% to about 17.5% DS-7, about 16% to about 18% DS-7, about 16% to about 18.5% DS-7, about 16% to about 19% DS-7, about 16% to about 19.5% DS-7, about 16% to about 20% DS-7, about 16% to about 20.5% DS-7, about 16% to about 21% DS-7, about 16% to about 21.5% DS-7, about 16.5% to about 22% DS-7, about 17% to about 22.5% DS-7. -7, about 17.5% to about 22% DS-7, about 18% to about 22% DS-7, about 18.5% to about 22% DS-7, about 19% to about 22% DS-7, about 19.5% to about 22% DS-7, about 20% to about 22% DS-7, about 20.5% to about 22% DS-7, about 21% to about 22% DS-7, about 16.5% to about 21.5% DS-7, about 17% to about 21% DS-7, about 17.5% to about 20.5% DS-7, about 18% to about 20% DS-7 or about 18.5% to about 19.5% DS-7.In still other aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 16.0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%. %, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0%, 20.1%, 20.2%, 20.3%, 20.4%, 20.5%, 20.6%, 20.7%, 20.8%, 20.9%, 21.0%, 21.1%, 21.2%, 21.3%, 21.4%, 21.5%, 21.6%, 21.7%, 21.8%, 21.9%, or about 22.0% DS-7. In an exemplary embodiment, the area of DS-7 in the MALDI-TOF-MS spectrum is 19.30%.
[0267] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 26% to about 32% DS-8. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 26% to about 26.5% DS-8, about 26.5% to about 27% DS-8, about 27% to about 27.5% DS-8, about 27.5% to about 28% DS-8, about 28% to about 28.5% DS-8, about 28.5% to about 29% DS-8, about 29% to about 29.5% DS-8, about 29.5% to about 30% DS-8, about 30% to about 30.5% DS-8, about 30.5% to about 31% DS-8, about 31% to about 31.5% DS-8, or about 31.5% to about 32% DS-8. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 26% to about 27% DS-8, about 26% to about 27.5% DS-8, about 26% to about 28% DS-8, about 26% to about 28.5% DS-8, about 26% to about 29% DS-8, about 26% to about 29.5% DS-8, about 26% to about 30% DS-8, about 26% to about 30.5% DS-8, about 26% to about 31% DS-8, about 26% to about 31.5% DS-8, about 26.5% to about 32% DS-8, about 27% to about 32% DS-8, or about 28.5% DS-8. -8, about 27.5% to about 32% DS-8, about 28% to about 32% DS-8, about 28.5% to about 32% DS-8, about 29% to about 32% DS-8, about 29.5% to about 32% DS-8, about 30% to about 32% DS-8, about 30.5% to about 32% DS-8, about 31% to about 32% DS-8, about 26.5% to about 31.5% DS-8, about 27% to about 31% DS-8, about 27.5% to about 30.5% DS-8, about 28% to about 30% DS-8, or about 28.5% to about 29.5% DS-8.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, 28.0%, 28.1%, 28.2%, 28.3%, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, 29.0%, 29.1%, 29.2%, 29.3%, 29.4%, 29.5%, 29.6%, 29.7%, 29.8%, 29 ... %. In one exemplary embodiment, the area of DS-8 in the MALDI-TOF-MS spectrum is 29.30%.
[0268] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 22% to about 28% DS-9. In some aspects, the mixture of isomerically purified β-cyclodextrin molecules includes about 22% to about 22.5% DS-9, about 22.5% to about 23% DS-9, about 23% to about 23.5% DS-9, about 23.5% to about 24% DS-9, about 24% to about 24.5% to about 25% DS-9, about 25% to about 25.5% DS-9, about 25.5% to about 26% DS-9, about 26% to about 26.5% DS-9, about 26.5% to about 27% DS-9, about 27% to about 27.5% DS-9, or about 27.5% to about 28% DS-9. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 22% to about 23% DS-9, about 22% to about 23.5% DS-9, about 22% to about 24% DS-9, about 22% to about 24.5% DS-9, about 22% to about 25% DS-9, about 22% to about 25.5% DS-9, about 22% to about 26% DS-9, about 22% to about 26.5% DS-9, about 22% to about 27% DS-9, about 22% to about 27.5% DS-9, about 22.5% to about 28% DS-9, about 23% to about 28% DS-9. -9, about 23.5% to about 28% DS-9, about 24% to about 28% DS-9, about 24.5% to about 28% DS-9, about 25% to about 28% DS-9, about 25.5% to about 28% DS-9, about 26% to about 28% DS-9, about 26.5% to about 28% DS-9, about 27% to about 28% DS-9, about 22.5% to about 27.5% DS-9, about 23% to about 27% DS-9, about 23.5% to about 26.5% DS-9, about 24% to about 26% DS-9, or about 24.5% to about 25.5% DS-9.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 22.0%, 22.1%, 22.2%, 22.3%, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23.9%, 24.0%, 24.1%, 24.2%, 24.3%, 24.4%, 24.5%, 24.6%, 24.7%, 24.8%, 24.9%, 25.0%, 25.1%, 25.2%, 25.3%, 25.4%, 25.5%, 25.6%, 25.7%, 25.8%, 25.9%, 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, %. In one exemplary embodiment, the area of DS-9 in the MALDI-TOF-MS spectrum is 25.30%.
[0269] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11% to about 17% DS-10. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11% to about 11.5% DS-10, about 11.5% to about 12% DS-10, about 12% to about 12.5% DS-10, about 12.5% to about 13% DS-10, about 13% to about 13.5% DS-10, about 13.5% to about 14% DS-10, about 14% to about 14.5% DS-10, about 14.5% to about 15% DS-10, about 15% to about 15.5% DS-10, about 15.5% to about 16% DS-10, about 16% to about 16.5% DS-10, or about 16.5% to about 17% DS-10. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11% to about 12% DS-10, about 11% to about 12.5% DS-10, about 11% to about 13% DS-10, about 11% to about 13.5% DS-10, about 11% to about 14% DS-10, about 11% to about 14.5% DS-10, about 11% to about 15% DS-10, about 11% to about 15.5% DS-10, about 11% to about 16% DS-10, about 11% to about 16.5% DS-10, about 11.5% to about 17% DS-10, about 12% to about 17.5% DS-10. S-10, about 12.5% to about 17% DS-10, about 13% to about 17% DS-10, about 13.5% to about 17% DS-10, about 14% to about 17% DS-10, about 14.5% to about 17% DS-10, about 15% to about 17% DS-10, about 15.5% to about 17% DS-10, about 16% to about 17% DS-10, about 11.5% to about 16.5% DS-10, about 12% to about 16% DS-10, about 12.5% to about 15.5% DS-10, about 13% to about 15% DS-10, or about 13.5% to about 14.5% DS-10.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14.0%, 14.1%, 14.2%, 14.3%, 14.4%, 14.5%, 14.6%, 14.7%, 14.8%, 14.9%, 15.0%, 15.1%, 15.2%, 15.3%, 15.4%, 15.5%, 15.6%, 15.7%, 15.8%, 15.9%, 16.0%, 16.1%, 16.2%, 16.3%, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%, %, 16.4%, 16.5%, 16.6%, 16.7%, 16.8%, 16.9%, or about 17.0% DS- 10. In one exemplary embodiment, the area of DS-10 in the MALDI-TOF-MS spectrum is 14.30%.
[0270] In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 1% to about 5% DS-5, about 7% to about 13% DS-6, about 16% to about 22% DS-7, about 26% to about 32% DS-8, about 22% to about 28% DS-9, and about 11% to about 17% DS-10.
[0271] In another exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules includes DS-5, DS-6, DS-7, DS-8, DS-9, and DS-10; the composition includes less than 1% of DS-4, DS-3, DS-2, and DS-1; and the composition includes less than 1% of DS-11, DS-12, DS-13, and DS-14. In another exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules includes DS-5, DS-6, DS-7, DS-8, DS-9, and DS-10 and the composition is free of DS-11, DS-12, DS-13, and / or DS-14. In another exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules includes DS-5, DS-6, DS-7, DS-8, DS-9, and DS-10 and the composition is free of DS-4, DS-3, DS-2, and / or DS-1.
[0272] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may have an average degree of substitution of about 6.4 to about 7.0. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may have an average degree of substitution of about 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or about 7.0. In an exemplary embodiment, the mixture of hydroxypropyl-β-cyclodextrin molecules may have an average degree of substitution of about 6.69.
[0273] The positions of substitution in the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can be determined using methods known to those skilled in the art. In some embodiments, the composition can be composed of 1 H-NMR characterization. In some aspects, 1 H-NMR can be used to determine the degree of substitution of the composition. 1 H-NMR spectra are provided in Figure 6 In some embodiments, the composition can be characterized by DEPT-edited HSQC. Exemplary DEPT-edited HSQC spectra are provided in Figure 7 middle.
[0274] In some embodiments, about 52% to about 58% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecules may be located at the 3-O-position. In some aspects, the percent substitution at the 3-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules may be about 52% to about 53%, about 53% to about 54%, about 54% to about 55%, about 55% to about 56%, about 56% to about 57%, or about 57% to about 58%. In some additional aspects, the percent substitution at the 3-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules may be about 52% to about 54%, about 52% to about 55%, about 52% to about 56%, about 52% to about 57%, about 53% to about 58%, about 54% to about 58%, about 55% to about 58%, about 56% to about 58%, about 53% to about 57%, or about 54% to about 56%. In an exemplary embodiment, the percent substitution at the 3-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 55.43%.
[0275] In some embodiments, about 41% to about 47% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecules are located at the 2-O-position. In some aspects, the percentage of substitution at the 2-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 41% to about 42%, about 42% to about 43%, about 43% to about 44%, about 44% to about 45%, about 45% to about 46%, or about 46% to about 47%. In some additional aspects, the percentage of substitution at the 2-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 41% to about 43%, about 41% to about 44%, about 41% to about 45%, about 41% to about 46%, about 42% to about 47%, about 43% to about 47%, about 44% to about 47%, about 45% to about 47%, about 42% to about 46%, or about 43% to about 45%. In an exemplary embodiment, the percent substitution at the 2-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 44.57%.
[0276] In some embodiments, the percent substitution at the 6-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 0%.
[0277] In some embodiments, the composition may have Figure 8 HPLC-CAD chromatogram. In some aspects, the average retention time of the composition, as measured by HPLC-CAD, can be from about 9 minutes to about 11 minutes. In some additional aspects, the average retention time of the composition can be from about 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 or about 11 minutes. In an exemplary embodiment, the average retention time is about 10.1 minutes.
[0278] In some embodiments, the composition may have a -ESI-MS spectrum with peaks at about 653 m / z, about 682 m / z, about 711 m / z, about 741 m / z, about 769 m / z, about 799 m / z, about 828 m / z, and about 857 m / z. In some embodiments, the composition may have a +ESI-MS spectrum with peaks at about 686 m / z, about 715 m / z, about 744 m / z, about 773 m / z, about 802 m / z, about 832 m / z, about 861 m / z, and about 890 m / z. In an exemplary embodiment, the composition has Figure 9 ESI-MS spectra shown in .
[0279] The percentage of hydroxypropyl-β-cyclodextrin can be based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the composition can have a MALDI-TOF-MS spectrum with peaks at about 1436 m / z, about 1495 m / z, about 1555 m / z, about 1614 m / z, about 1674 m / z, and about 1733 m / z. In an exemplary embodiment, the composition has Figure 10 In one exemplary embodiment, the composition has a MALDI-TOF-MS spectrum in which DS-5 has an area of 2.83%, DS-6 has an area of 10.64%, DS-7 has an area of 19.30%, DS-8 has an area of 29.30%, DS-9 has an area of 25.30%, and DS-10 has an area of 14.30%.
[0280] In some embodiments, the composition may have a true density of about 1.095 g / cm 3 to about 1.100g / cm 3 In some aspects, the composition may have a true density of about 1.095 g / cm 3 to about 1.096 g / cm 3 , about 1.096g / cm 3 to about 1.097 g / cm 3 , about 1.097g / cm 3 to about 1.098 g / cm 3 , about 1.098g / cm 3 to about 1.099 g / cm 3 , about 1.099g / cm 3 to about 1.100g / cm 3 , about 1.095g / cm 3 to about 1.097 g / cm 3 , about 1.095g / cm 3 to about 1.098 g / cm 3 , about 1.095g / cm 3 to about 1.099 g / cm 3 , about 1.096g / cm 3 to about 1.100g / cm 3 , about 1.097g / cm 3 to about 1.100g / cm 3 , about 1.098g / cm 3 to about 1.100g / cm 3 , about 1.096g / cm 3 to about 1.098 g / cm 3or about 1.096 g / cm 3 to about 1.099 g / cm 3 In some additional aspects, the composition may have a true density of about 1.095 g / cm 3 , 1.096g / cm 3 , 1.097g / cm 3 , 1.098g / cm 3 , 1.099g / cm 3 or about 1.100g / cm 3 In one exemplary embodiment, the composition has a true density of about 1.096 g / cm 3 to about 1.098 g / cm 3 .
[0281] In some embodiments, the osmolality of the composition can be from about 600 mOs / kg to about 750 mOs / kg. In some aspects, the osmolality of the composition can be from about 600 mOs / kg to about 625 mOs / kg, from about 625 mOs / kg to about 650 mOs / kg, from about 650 mOs / kg to about 675 mOs / kg, from about 675 mOs / kg to about 700 mOs / kg, from about 700 mOs / kg to about 725 mOs / kg, or from about 725 mOs / kg to about 750 mOs / kg. In some additional aspects, the composition may have an osmolality of about 600 mOs / kg to about 650 mOs / kg, about 600 mOs / kg to about 675 mOs / kg, about 600 mOs / kg to about 700 mOs / kg, about 600 mOs / kg to about 725 mOs / kg, about 625 mOs / kg to about 750 mOs / kg, about 650 mOs / kg to about 750 mOs / kg, about 675 mOs / kg to about 750 mOs / kg, about 700 mOs / kg to about 750 mOs / kg, about 625 mOs / kg to about 725 mOs / kg, or about 650 mOs / kg to about 700 mOs / kg. In yet other embodiments, the composition can have an osmolality of about 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, or about 750 mOs / kg. In an exemplary embodiment, the composition has an osmolality of about 635 to about 695 mOs / kg.
[0282] In some embodiments, the composition may have a conductivity between about 0 and about 8 μS / cm. In some aspects, the composition may have a conductivity between about 0 and about 1 μS / cm, about 1 and about 2 μS / cm, about 3 and about 4 μS / cm, about 4 and about 5 μS / cm, about 5 and about 6 μS / cm, about 6 and about 7 μS / cm, or about 7 and about 8 μS / cm. In some additional embodiments, the electrical conductivity of the composition may be between about 0 μS / cm and about 1.5 μS / cm, about 0 μS / cm and about 2 μS / cm, about 0 μS / cm and about 2.5 μS / cm, about 0 μS / cm and about 3 μS / cm, about 0 and about 3.5 μS / cm, about 0 μS / cm and about 4 μS / cm, about 0 and about 4.5 μS / cm, about 0 μS / cm and about 5 μS / cm, about 0 and about 5.5 μS / cm, about 0 μS / cm and about 6 μS / cm, about 0 and about 6.5, about 0 μS / cm and about 7 μS / cm, about 0 and about 7.5, about 1 μS / cm and about 8 μS / cm, about 1.5 μS / cm and about 10 μS / cm. / cm and about 8 μS / cm, about 2 μS / cm and about 8 μS / cm, about 2.5 μS / cm and about 8 μS / cm, about 3 μS / cm and about 8 μS / cm, about 3.5 μS / cm and about 8 μS / cm, about 4 μS / cm and about 8 μS / cm, about 4.5 μS / cm and about 8 μS / cm, about 5 μS / cm and about 8 μS / cm, about 5.5 μS / cm and about 8 μS / cm, about 6 μS / cm and about 8 μS / cm, about 6.5 μS / cm and about 8 μS / cm, about 1 μS / cm and about 7 μS / cm, about 2 μS / cm and about 6 μS / cm, or about 3 μS / cm and about 5 μS / cm. In still other aspects, the composition can have a conductivity of about 0.5 μS / cm, 1.0 μS / cm, 1.5 μS / cm, 2.0 μS / cm, 2.5 μS / cm, 3.0 μS / cm, 3.5 μS / cm, 4.0 μS / cm, 4.5 μS / cm, 5.0 μS / cm, 5.5 μS / cm, 6.0 μS / cm, 6.5 μS / cm, 7.0 μS / cm, 7.5 μS / cm, or about 8.0 μS / cm.
[0283] In some embodiments, the pH of the composition can be from about 4.0 to about 8.0; for example, the pH of the composition can be about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or about 8.0. The pH of the composition can be within a range or sub-range comprising any of the above numbers, including but not limited to the following pH: about 4.0 to about 4.5, about 4.5 to about 5.0, about 5.0 to about 5.5, about 5.5 to about 6.0, about 6.0 to about 6.5, about 6.5 to about 7.0, about 7.0 to about 7.5, or about 7.5 to about 8.0. In some embodiments, the composition may also include a pH adjusting agent, such as hydrochloric acid or sodium hydroxide, to adjust the pH to the desired level. In some embodiments, the composition may also include a buffer. In some embodiments, the buffer may include sodium dihydrogen phosphate and disodium hydrogen phosphate.
[0284] In some embodiments, the composition can have a viscosity measured in centipoise (cP) at 20° C. For example, the composition can have a viscosity of about 1.5 cP to about 3.0 cP at 20° C. In some embodiments, the composition can have a viscosity of about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, , 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9 or about 10.0 cP. In other embodiments, the viscosity of the composition at 20°C may be from about 3.0 cP to about 5.0 cP, from about 5.0 cP to about 10.0 cP, from about 10 to about 15 cP, from about 15 to about 20 cP, from about 20 cP to about 25 cP, from about 25 cP to about 50 cP, from about 50 cP to about 80 cP, from about 80 cP to about 150 cP, from about 150 cP to about 250 cP, from about 250 cP to about 500 cP, from about 500 cP to about 1,000 cP, from about 1,000 cP to about 2,000 cP, from about 2,000 cP to about 3,000 cP, from about 3,000 cP to about 5,000 cP, or from about 5,000 cP to about 10,000 cP.
[0285] The composition can be substantially free of impurities. Impurities include particles having a diameter greater than or equal to 25 microns, particles having a diameter greater than or equal to 10 microns, chlorides, propylene glycol, propylene oxide, and other unspecified impurities. In some embodiments, the composition can include less than or equal to about 0.05% impurities; for example, the composition can include less than or equal to about 0.05%, 0.04%, 0.03%, 0.02%, or less than or equal to about 0.01% impurities.
[0286] In some embodiments, the composition may further comprise a container and non-visible particulate matter. In some embodiments, the composition may be provided in a container. In some embodiments, the composition may further comprise non-visible particulate matter.
[0287] In some embodiments, the composition can include less than 600 particles / container having a diameter greater than or equal to 25 microns. In some aspects, the composition can include less than 500, less than 400, less than 300, less than 200, or less than 100 particles / container having a diameter greater than or equal to 25 microns.
[0288] In some embodiments, the composition may include less than 6,000 particles having a diameter greater than or equal to 10 microns per container. In some aspects, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, or less than 100 particles having a diameter greater than or equal to 10 microns per container. In another aspect, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, or less than 100 particles having a diameter greater than or equal to 10 microns per container, wherein the container is ≤ 100 mL. In another aspect, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, less than 100, less than 50, less than 25, less than 10, less than 5, or less than 3 particles having a diameter greater than or equal to 10 microns per container, wherein the container is > 100 mL.
[0289] In some embodiments, the composition may include no more than 10ppb propylene glycol. In some aspects, the composition may include no more than 9ppb, 8ppb, 7ppb, 6ppb, 5ppb, 4ppb, 3ppb, 2ppb or no more than 1ppb propylene glycol. In some aspects, the amount of the propylene glycol in the composition can be measured by HPLC. In some additional aspects, the amount of the propylene glycol in the composition can be measured by gas chromatography. In other aspects, the amount of the propylene glycol in the composition can be measured by measuring the PG / EG ratio of propylene glycol and ethylene glycol.
[0290] In some embodiments, the composition may include no more than 1ppm propylene oxide. In some aspects, the composition may include no more than 0.9ppm, 0.8ppm, 0.7ppm, 0.6ppm, 0.5ppm, 0.4ppm, 0.3ppm, 0.2ppm or 0.1ppm propylene oxide. In some aspects, the amount of propylene oxide in the composition can be measured by HPLC. In some additional aspects, the amount of propylene oxide in the composition can be measured by gas chromatography.
[0291] In some embodiments, the composition may include between about 0 ppm and about 10 ppm of chloride (e.g., Cl -ions). In some aspects, the composition may include about 0ppm chloride to about 2ppm chloride, about 2ppm chloride to about 4ppm chloride, about 4ppm chloride to about 6ppm chloride, about 6ppm chloride to about 8ppm chloride or about 8 to about 10ppm chloride. In some additional aspects, the composition may include about 0ppm chloride to about 4ppm chloride, about 0ppm chloride to about 6ppm chloride, about 0ppm chloride to about 8ppm chloride, about 2ppm chloride to about 1ppm chloride, about 4ppm chloride to about 1ppm chloride or about 6ppm chloride to about 1ppm chloride. In other aspects, the composition may include about 0ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm or about 10ppm chloride. In an exemplary embodiment, the composition may include the chloride between about 0ppm to about 1ppm.
[0292] In some embodiments, the composition may include between about 0 ppm and about 10 ppm of sodium (e.g., Na + ions). In some aspects, the composition can include about 0ppm sodium to about 2ppm sodium, about 2ppm sodium to about 4ppm sodium, about 4ppm sodium to about 6ppm sodium, about 6ppm sodium to about 8ppm sodium or about 8 to about 10ppm sodium. In some additional aspects, the composition can include about 0ppm sodium to about 4ppm sodium, about 0ppm sodium to about 6ppm sodium, about 0ppm sodium to about 8ppm sodium, about 2ppm sodium to about 1ppm sodium, about 4ppm sodium to about 1ppm sodium or about 6ppm sodium to about 1ppm sodium. In other aspects, the composition can include about 0ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm or about 10ppm sodium. In an exemplary embodiment, the composition can include the sodium between about 0ppm to about 1ppm.
[0293] In some embodiments, the composition can include less than or equal to 0.05% other unspecified impurities; for example, the composition can include less than or equal to 0.05%, 0.04%, 0.03%, 0.02%, or less than or equal to 0.01% other unspecified impurities.
[0294] In some embodiments, the composition can be stable for at least 6 months. For example, the composition can be stable for at least 3 months, 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 24 months, or at least 36 months.
[0295] The composition can be nanofiltered. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. Thus, the time required for nanofiltration does not increase or decrease as the concentration of the mixture of β-cyclodextrin molecules in the composition increases or decreases. In some aspects, the time required for nanofiltration of the composition is between about 1.04 and about 1.20 hours per diafiltration volume (kg soln / m 2 In some embodiments, no substantial differences are observed in the composition after nanofiltration by HPLC-ELSD compared to before nanofiltration. In some embodiments, no substantial differences are observed in the composition after nanofiltration by NMR compared to before nanofiltration.
[0296] In some embodiments, the composition can be terminally sterilized. Terminal sterilization methods are generally well known in the art. In some embodiments, the pH of the composition can be adjusted after terminal sterilization.
[0297] In some embodiments, the composition can include less than or equal to 10.0% w / w water. For example, the composition can include less than or equal to 10.0% w / w, 9.5% w / w, 9.0% w / w, 8.5% w / w, 8.0% w / w, 7.5% w / w, 7.0% w / w, 6.5% w / w, 6.0% w / w, 5.5% w / w, 5.0% w / w, 4.5% w / w, 4.0% w / w, 3.5% w / w, 3.0% w / w, 2.5% w / w, 2.0% w / w, 1.5% w / w, 1.0% w / w, 0.5% w / w, or less than or equal to 0.1% w / w water.
[0298] In some embodiments, the composition can be packaged in a vial suitable for injection into a human subject in need. The vial can be made of glass, plastic, or any other material known in the pharmaceutical art. The vial can be coated with a material such as silicon dioxide to prevent infiltration from the vial into the composition.
[0299] In some embodiments, the composition may be suitable for administration to a patient in need thereof. In some embodiments, the composition may be suitable for intrathecal administration, intravenous administration, oral administration, intracerebroventricular administration, or a combination thereof (e.g., intravenous and intrathecal administration) to a patient in need thereof. In some aspects, the patient may be a human, such as an adult patient or a pediatric patient. In some instances, the human patient may be an infant (e.g., less than 6 months of age) or a newborn (e.g., less than 4 weeks of age).
[0300] In some embodiments, the composition may be effective in treating Niemann-Pick disease. In some embodiments, the composition may be effective in treating Niemann-Pick disease type C. In some embodiments, the composition may be effective in treating liver disease. In some embodiments, the composition may be effective in treating cardiovascular disease. In some embodiments, the composition may be effective in treating familial hypercholesterolemia. In some embodiments, the composition may be effective in treating cholesterol deposition.
[0301] In some embodiments, the composition may further comprise a pharmaceutical excipient or carrier. In some embodiments, the composition may further comprise a pharmaceutically acceptable diluent. Examples of pharmaceutical excipients, carriers, and diluents are well known to those skilled in the art.
[0302] In some embodiments, the composition may exhibit Cyclo or In some embodiments, the composition may exhibit a lower toxicity than Cyclo or Substantially Low Ototoxicity. In some embodiments, the composition may exhibit substantially no ototoxicity.
[0303] Fraction 2HDS
[0304] Provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, the mixture comprising less than 1% DS-5 and less than 1% DS-13. In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may comprise less than 1% DS-4, DS-3, DS-2, and DS-1. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may comprise less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-4, DS-3, DS-2, and DS-1. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules does not contain DS-4, DS-3, DS-2, and / or DS-1.
[0305] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules may include less than 1% DS-13 and DS- 14. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-13 and DS-14.
[0306] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules may optionally include less than 1% DS-13 and / or DS-14. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may optionally include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-13 and / or DS-14. In preferred embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules is free of DS-14.
[0307] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 0% to about 6% DS-6. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can comprise from about 0% to about 0.5% DS-6, from about 0.5% to about 1% DS-6, from about 1% to about 1.5% DS-6, from about 1.5% to about 2% DS-6, from about 2% to about 2.5% DS-6, from about 2.5% to about 3% DS-6, from about 3% to about 3.5% DS-6, from about 3.5% to about 4% DS-6, from about 4% to about 4.5% DS-6, from about 4.5% to about 5% DS-6, from about 5% to about 5.5% DS-6, or from about 5.5% to about 6% DS-6. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 0% to about 1% DS-6, about 0% to about 1.5% DS-6, about 0% to about 2% DS-6, about 0% to about 2.5% DS-6, about 0% to about 3% DS-6, about 0% to about 3.5% DS-6, about 0% to about 4% DS-6, about 0% to about 4.5% DS-6, about 0% to about 5% DS-6, about 0% to about 5.5% DS-6, about 0.5% to about 6% DS-6, about 1% to about 6% DS-6, and about 1% to about 6% DS-6. % DS-6, about 1.5% to about 6% DS-6, about 2% to about 6% DS-6, about 2.5% to about 6% DS-6, about 3% to about 6% DS-6, about 3.5% to about 6% DS-6, about 4% to about 6% DS-6, about 4.5% to about 6% DS-6, about 5% to about 6% DS-6, about 0.5% to about 5.5% DS-6, about 1% to about 5% DS-6, about 1.5% to about 4.5% DS-6, about 2% to about 4% DS-6, or about 2.5% to about 3.5% DS-6. In yet additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may comprise about 0.0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5. %, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9% or about 6.0% DS-6.In an exemplary embodiment, the area of DS-6 in the MALDI-TOF-MS spectrum is 2.91%.
[0308] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8% to about 14% DS-7. In some aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8% to about 8.5% DS-7, about 8.5% to about 9% DS-7, about 9% to about 9.5% DS-7, about 9.5% to about 10% DS-7, about 10% to about 10.5% DS-7, about 10.5% to about 11% DS-7, about 11% to about 11.5% DS-7, about 11.5% to about 12% DS-7, about 12% to about 12.5% DS-7, about 12.5% to about 13% DS-7, about 13% to about 13.5% DS-7, or about 13.5% to about 14% DS-7. In some additional aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8% to about 9% DS-7, about 8% to about 9.5% DS-7, about 8% to about 10% DS-7, about 8% to about 10.5% DS-7, about 8% to about 11% DS-7, about 8% to about 11.5% DS-7, about 8% to about 12% DS-7, about 8% to about 12.5% DS-7, about 8% to about 13% DS-7, about 8% to about 13.5% DS-7, about 8.5% to about 14% DS-7, about 9% to about 14.5% DS-7, about 9% to about 15% DS-7, about 9% to about 16% DS-7. .5% to about 14% DS-7, about 10% to about 14% DS-7, about 10.5% to about 14% DS-7, about 11% to about 14% DS-7, about 11.5% to about 14% DS-7, about 12% to about 14% DS-7, about 12.5% to about 14% DS-7, about 13% to about 14% DS-7, about 8.5% to about 13.5% DS-7, about 9% to about 13% DS-7, about 9.5% to about 12.5% DS-7, about 10% to about 12% DS-7, or about 10.5% to about 11.5% DS-7.In still other aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 1 ... %, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, or about 14.0% DS-7. In one exemplary embodiment, the area of DS-7 in the MALDI-TOF-MS spectrum is 10.93%.
[0309] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 19% to about 25% DS-8. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 19% to about 19.5% DS-8, about 19.5% to about 20% DS-8, about 20% to about 20.5% DS-8, about 20.5% to about 21% DS-8, about 21% to about 21.5% DS-8, about 21.5% to about 22% DS-8, about 22% to about 22.5% DS-8, about 22.5% to about 23% DS-8, about 23% to about 23.5% DS-8, about 23.5% to about 24% DS-8, about 24% to about 24.5% DS-8, or about 24.5% to about 25% DS-8. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 19% to about 20% DS-8, about 19% to about 20.5% DS-8, about 19% to about 21% DS-8, about 19% to about 21.5% DS-8, about 19% to about 22% DS-8, about 19% to about 22.5% DS-8, about 19% to about 23% DS-8, about 19% to about 23.5% DS-8, about 19% to about 24% DS-8, about 19% to about 24.5% DS-8, about 19.5% to about 25% DS-8, about 20% to about 25% DS-8. -8, about 20.5% to about 25% DS-8, about 21% to about 25% DS-8, about 21.5% to about 25% DS-8, about 22% to about 25% DS-8, about 22.5% to about 25% DS-8, about 23% to about 25% DS-8, about 23.5% to about 25% DS-8, about 24% to about 25% DS-8, about 19.5% to about 24.5% DS-8, about 20% to about 24% DS-8, about 20.5% to about 23.5% DS-8, about 21% to about 23% DS-8, or about 21.5% to about 22.5% DS-8.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0%, 20.1%, 20.2%, 20.3%, 20.4%, 20.5%, 20.6%, 20.7%, 20.8%, 20.9%, 21.0%, 21.1%, 21.2%, 21.3%, 21.4%, 21.5%, 21.6%, 21.7%, 21.8%, 21.9%, 22.0%, 22.1%, 22.2%, 22.3%, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23 ... %, 24.8%, 24.9%, or about 25.0% DS- 8. In an exemplary embodiment, the area of DS-8 in the MALDI-TOF-MS spectrum is 22.52%.
[0310] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 23% to about 29% DS-9. In some aspects, the mixture of isomerically purified β-cyclodextrin molecules includes about 23% to about 23.5% DS-9, about 23.5% to about 24% DS-9, about 24% to about 24.5% to about 25% DS-9, about 25% to about 25.5% DS-9, about 25.5% to about 26% DS-9, about 26% to about 26.5% DS-9, about 26.5% to about 27% DS-9, about 27% to about 27.5% DS-9, about 27.5% to about 28% DS-9, about 28% to about 28.5% DS-9, or about 28.5% to about 29% DS-9. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 23% to about 24% DS-9, about 23% to about 24.5% DS-9, about 23% to about 25% DS-9, about 23% to about 25.5% DS-9, about 23% to about 26% DS-9, about 23% to about 26.5% DS-9, about 23% to about 27% DS-9, about 23% to about 27.5% DS-9, about 23% to about 28% DS-9, about 23% to about 28.5% DS-9, about 23.5% to about 29% DS-9, about 24% to about 29% DS-9. -9, about 24.5% to about 29% DS-9, about 25% to about 29% DS-9, about 25.5% to about 29% DS-9, about 26% to about 29% DS-9, about 26.5% to about 29% DS-9, about 27% to about 29% DS-9, about 27.5% to about 29% DS-9, about 28% to about 29% DS-9, about 23.5% to about 28.5% DS-9, about 24% to about 28% DS-9, about 24.5% to about 27.5% DS-9, about 25% to about 27% DS-9, or about 25.5% to about 26.5% DS-9.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23.9%, 24.0%, 24.1%, 24.2%, 24.3%, 24.4%, 24.5%, 24.6%, 24.7%, 24.8%, 24.9%, 25.0%, 25.1%, 25.2%, 25.3%, 25.4%, 25.5%, 25.6%, 25.7%, 25.8%, 25.9%, 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, 28.0%, 28.1%, 28.2%, 28.3%, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, %, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, or about 29.0% DS- 9. In an exemplary embodiment, the area of DS-9 in the MALDI-TOF-MS spectrum is 26.42%.
[0311] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17% to about 23% DS-10. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17% to about 17.5% DS-10, about 17.5% to about 18% DS-10, about 18% to about 18.5% DS-10, about 18.5% to about 19% DS-10, about 19% to about 19.5% DS-10, about 19.5% to about 20% DS-10, about 20% to about 20.5% DS-10, about 20.5% to about 21% DS-10, about 21% to about 21.5% DS-10, about 21.5% to about 22% DS-10, about 22% to about 22.5% DS-10, or about 22.5% to about 23% DS-10. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17% to about 18% DS-10, about 17% to about 18.5% DS-10, about 17% to about 19% DS-10, about 17% to about 19.5% DS-10, about 17% to about 20% DS-10, about 17% to about 20.5% DS-10, about 17% to about 21% DS-10, about 17% to about 21.5% DS-10, about 17% to about 22% DS-10, about 17% to about 22.5% DS-10, about 17.5% to about 23% DS-10, about 18% to about 23% DS-10, about 19% to about 20.5% DS-10, about 19% to about 21.5% DS-10, about 19% to about 22.5% DS-10, about 19% to about 23 .... S-10, about 18.5% to about 23% DS-10, about 19% to about 23% DS-10, about 19.5% to about 23% DS-10, about 20% to about 23% DS-10, about 20.5% to about 23% DS-10, about 21% to about 23% DS-10, about 21.5% to about 23% DS-10, about 22% to about 23% DS-10, about 17.5% to about 22.5% DS-10, about 18% to about 22% DS-10, about 18.5% to about 21.5% DS-10, about 19% to about 21% DS-10, or about 19.5% to about 20.5% DS-10.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19 ... %, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, or about 23.0% DS- 10. In an exemplary embodiment, the area of DS-10 in the MALDI-TOF-MS spectrum is 20.35%.
[0312] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9% to about 15% DS-11. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9% to about 9.5% DS-11, about 9.5% to about 10% DS-11, about 10% to about 10.5% DS-11, about 10.5% to about 11% DS-11, about 11% to about 11.5% DS-11, about 11.5% to about 12% DS-11, about 12% to about 12.5% DS-11, about 12.5% to about 13% DS-11, about 13% to about 13.5% DS-11, about 13.5% to about 14% DS-11, about 14% to about 14.5% DS-11, or about 14.5% to about 15% DS-11. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9% to about 10% DS-11, about 9% to about 10.5% DS-11, about 9% to about 11% DS-11, about 9% to about 11.5% DS-11, about 9% to about 12% DS-11, about 9% to about 12.5% DS-11, about 9% to about 13% DS-11, about 9% to about 13.5% DS-11, about 9% to about 14% DS-11, about 9% to about 14.5% DS-11, about 9.5% to about 15% DS-11, about 10% to about 15% DS-11, About 10.5% to about 15% DS-11, about 11% to about 15% DS-11, about 11.5% to about 15% DS-11, about 12% to about 15% DS-11, about 12.5% to about 15% DS-11, about 13% to about 15% DS-11, about 13.5% to about 15% DS-11, about 14% to about 15% DS-11, about 9.5% to about 14.5% DS-11, about 10% to about 14% DS-11, about 10.5% to about 13.5% DS-11, about 11% to about 13% DS-11, or about 11.5% to about 12.5% DS-11.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 13.1% %, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14.0%, 14.1%, 14.2%, 14.3%, 14.4%, 14.5%, 14.6%, 14.7%, 14.8%, 14.9%, or about 15.0% DS- 11. In an exemplary embodiment, the area of DS- 11 in the MALDI-TOF-MS spectrum is 12.02%.
[0313] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2% to about 8% DS- 12. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2% to about 2.5% DS-12, about 2.5% to about 3% DS-12, about 3% to about 3.5% DS-12, about 3.5% to about 4% DS-12, about 4% to about 4.5% DS-12, about 4.5% to about 5% DS-12, about 5% to about 5.5% DS-12, about 5.5% to about 6% DS-12, about 6% to about 6.5% DS-12, about 6.5% to about 7% DS-12, about 7% to about 7.5% DS-12, or about 7.5% to about 8% DS-12. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2% to about 3% DS-12, about 2% to about 3.5% DS-12, about 2% to about 4% DS-12, about 2% to about 4.5% DS-12, about 2% to about 5% DS-12, about 2% to about 5.5% DS-12, about 2% to about 6% DS-12, about 2% to about 6.5% DS-12, about 2% to about 7% DS-12, about 2% to about 7.5% DS-12, about 2.5% to about 8% DS-12, about 3% to about 8% DS-12. DS-12, about 3.5% to about 8% DS-12, about 4% to about 8% DS-12, about 4.5% to about 8% DS-12, about 5% to about 8% DS-12, about 5.5% to about 8% DS-12, about 6% to about 8% DS-12, about 6.5% to about 8% DS-12, about 7% to about 8% DS-12, about 2.5% to about 7.5% DS-12, about 3% to about 7% DS-12, about 3.5% to about 6.5% DS-12, about 4% to about 6% DS-12, or about 4.5% to about 5.5% DS-12.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.8%, 7.9%, 8.0%, 8.1%, 8. %, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, or about 8.0% DS- 12. In an exemplary embodiment, the area of DS- 12 in the MALDI-TOF-MS spectrum is 4.85%.
[0314] Further provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, the mixture comprising DS-6, DS-7, DS-8, DS-9, DS-10, DS-11, and DS-12. In some embodiments, the composition comprises less than 1% DS-5. In some additional embodiments, the composition comprises less than 1% DS-13. In some embodiments, DS-9 may have the highest concentration in the composition compared to DS-6, DS-7, DS-8, DS-10, DS-11, and DS-12.
[0315] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules comprises from about 0% to about 6% DS-6. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can comprise from about 0% to about 0.5% DS-6, from about 0.5% to about 1% DS-6, from about 1% to about 1.5% DS-6, from about 1.5% to about 2% DS-6, from about 2% to about 2.5% DS-6, from about 2.5% to about 3% DS-6, from about 3% to about 3.5% DS-6, from about 3.5% to about 4% DS-6, from about 4% to about 4.5% DS-6, from about 4.5% to about 5% DS-6, from about 5% to about 5.5% DS-6, or from about 5.5% to about 6% DS-6. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 0% to about 1% DS-6, about 0% to about 1.5% DS-6, about 0% to about 2% DS-6, about 0% to about 2.5% DS-6, about 0% to about 3% DS-6, about 0% to about 3.5% DS-6, about 0% to about 4% DS-6, about 0% to about 4.5% DS-6, about 0% to about 5% DS-6, about 0% to about 5.5% DS-6, about 0.5% to about 6% DS-6, about 1% to about 6% DS-6, and about 1% to about 6% DS-6. % DS-6, about 1.5% to about 6% DS-6, about 2% to about 6% DS-6, about 2.5% to about 6% DS-6, about 3% to about 6% DS-6, about 3.5% to about 6% DS-6, about 4% to about 6% DS-6, about 4.5% to about 6% DS-6, about 5% to about 6% DS-6, about 0.5% to about 5.5% DS-6, about 1% to about 5% DS-6, about 1.5% to about 4.5% DS-6, about 2% to about 4% DS-6, or about 2.5% to about 3.5% DS-6. In yet additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may comprise about 0.0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5. %, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9% or about 6.0% DS-6.In an exemplary embodiment, the area of DS-6 in the MALDI-TOF-MS spectrum is 2.91%.
[0316] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8% to about 14% DS-7. In some aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8% to about 8.5% DS-7, about 8.5% to about 9% DS-7, about 9% to about 9.5% DS-7, about 9.5% to about 10% DS-7, about 10% to about 10.5% DS-7, about 10.5% to about 11% DS-7, about 11% to about 11.5% DS-7, about 11.5% to about 12% DS-7, about 12% to about 12.5% DS-7, about 12.5% to about 13% DS-7, about 13% to about 13.5% DS-7, or about 13.5% to about 14% DS-7. In some additional aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8% to about 9% DS-7, about 8% to about 9.5% DS-7, about 8% to about 10% DS-7, about 8% to about 10.5% DS-7, about 8% to about 11% DS-7, about 8% to about 11.5% DS-7, about 8% to about 12% DS-7, about 8% to about 12.5% DS-7, about 8% to about 13% DS-7, about 8% to about 13.5% DS-7, about 8.5% to about 14% DS-7, about 9% to about 14.5% DS-7, about 9% to about 15% DS-7, about 9% to about 16% DS-7. .5% to about 14% DS-7, about 10% to about 14% DS-7, about 10.5% to about 14% DS-7, about 11% to about 14% DS-7, about 11.5% to about 14% DS-7, about 12% to about 14% DS-7, about 12.5% to about 14% DS-7, about 13% to about 14% DS-7, about 8.5% to about 13.5% DS-7, about 9% to about 13% DS-7, about 9.5% to about 12.5% DS-7, about 10% to about 12% DS-7, or about 10.5% to about 11.5% DS-7.In still other aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 1 ... %, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, or about 14.0% DS-7. In one exemplary embodiment, the area of DS-7 in the MALDI-TOF-MS spectrum is 10.93%.
[0317] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 19% to about 25% DS-8. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 19% to about 19.5% DS-8, about 19.5% to about 20% DS-8, about 20% to about 20.5% DS-8, about 20.5% to about 21% DS-8, about 21% to about 21.5% DS-8, about 21.5% to about 22% DS-8, about 22% to about 22.5% DS-8, about 22.5% to about 23% DS-8, about 23% to about 23.5% DS-8, about 23.5% to about 24% DS-8, about 24% to about 24.5% DS-8, or about 24.5% to about 25% DS-8. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 19% to about 20% DS-8, about 19% to about 20.5% DS-8, about 19% to about 21% DS-8, about 19% to about 21.5% DS-8, about 19% to about 22% DS-8, about 19% to about 22.5% DS-8, about 19% to about 23% DS-8, about 19% to about 23.5% DS-8, about 19% to about 24% DS-8, about 19% to about 24.5% DS-8, about 19.5% to about 25% DS-8, about 20% to about 25% DS-8. -8, about 20.5% to about 25% DS-8, about 21% to about 25% DS-8, about 21.5% to about 25% DS-8, about 22% to about 25% DS-8, about 22.5% to about 25% DS-8, about 23% to about 25% DS-8, about 23.5% to about 25% DS-8, about 24% to about 25% DS-8, about 19.5% to about 24.5% DS-8, about 20% to about 24% DS-8, about 20.5% to about 23.5% DS-8, about 21% to about 23% DS-8, or about 21.5% to about 22.5% DS-8.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.0%, 20.1%, 20.2%, 20.3%, 20.4%, 20.5%, 20.6%, 20.7%, 20.8%, 20.9%, 21.0%, 21.1%, 21.2%, 21.3%, 21.4%, 21.5%, 21.6%, 21.7%, 21.8%, 21.9%, 22.0%, 22.1%, 22.2%, 22.3%, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23 ... %, 24.8%, 24.9%, or about 25.0% DS- 8. In an exemplary embodiment, the area of DS-8 in the MALDI-TOF-MS spectrum is 22.52%.
[0318] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 23% to about 29% DS-9. In some aspects, the mixture of isomerically purified β-cyclodextrin molecules includes about 23% to about 23.5% DS-9, about 23.5% to about 24% DS-9, about 24% to about 24.5% to about 25% DS-9, about 25% to about 25.5% DS-9, about 25.5% to about 26% DS-9, about 26% to about 26.5% DS-9, about 26.5% to about 27% DS-9, about 27% to about 27.5% DS-9, about 27.5% to about 28% DS-9, about 28% to about 28.5% DS-9, or about 28.5% to about 29% DS-9. In some additional aspects, the mixture of isomerically purified β-cyclodextrins can include about 23% to about 24% DS-9, about 23% to about 24.5% DS-9, about 23% to about 25% DS-9, about 23% to about 25.5% DS-9, about 23% to about 26% DS-9, about 23% to about 26.5% DS-9, about 23% to about 27% DS-9, about 23% to about 27.5% DS-9, about 23% to about 28% DS-9, about 23% to about 28.5% DS-9, about 23.5% to about 29% DS-9, about 24% to about 29% DS-9. -9, about 24.5% to about 29% DS-9, about 25% to about 29% DS-9, about 25.5% to about 29% DS-9, about 26% to about 29% DS-9, about 26.5% to about 29% DS-9, about 27% to about 29% DS-9, about 27.5% to about 29% DS-9, about 28% to about 29% DS-9, about 23.5% to about 28.5% DS-9, about 24% to about 28% DS-9, about 24.5% to about 27.5% DS-9, about 25% to about 27% DS-9, or about 25.5% to about 26.5% DS-9.In yet other aspects, the mixture of isomerically purified β-cyclodextrin molecules can include about 23.0%, 23.1%, 23.2%, 23.3%, 23.4%, 23.5%, 23.6%, 23.7%, 23.8%, 23.9%, 24.0%, 24.1%, 24.2%, 24.3%, 24.4%, 24.5%, 24.6%, 24.7%, 24.8%, 24.9%, 25.0%, 25.1%, 25.2%, 25.3%, 25.4%, 25.5%, 25.6%, 25.7%, 25.8%, 25.9%, 26.0%, 26.1%, 26.2%, 26.3%, 26.4%, 26.5%, 26.6%, 26.7%, 26.8%, 26.9%, 27.0%, 27.1%, 27.2%, 27.3%, 27.4%, 27.5%, 27.6%, 27.7%, 27.8%, 27.9%, 28.0%, 28.1%, 28.2%, 28.3%, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, %, 28.4%, 28.5%, 28.6%, 28.7%, 28.8%, 28.9%, or about 29.0% DS- 9. In an exemplary embodiment, the area of DS-9 in the MALDI-TOF-MS spectrum is 26.42%.
[0319] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17% to about 23% DS-10. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17% to about 17.5% DS-10, about 17.5% to about 18% DS-10, about 18% to about 18.5% DS-10, about 18.5% to about 19% DS-10, about 19% to about 19.5% DS-10, about 19.5% to about 20% DS-10, about 20% to about 20.5% DS-10, about 20.5% to about 21% DS-10, about 21% to about 21.5% DS-10, about 21.5% to about 22% DS-10, about 22% to about 22.5% DS-10, or about 22.5% to about 23% DS-10. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17% to about 18% DS-10, about 17% to about 18.5% DS-10, about 17% to about 19% DS-10, about 17% to about 19.5% DS-10, about 17% to about 20% DS-10, about 17% to about 20.5% DS-10, about 17% to about 21% DS-10, about 17% to about 21.5% DS-10, about 17% to about 22% DS-10, about 17% to about 22.5% DS-10, about 17.5% to about 23% DS-10, about 18% to about 23% DS-10, about 19% to about 20.5% DS-10, about 19% to about 21.5% DS-10, about 19% to about 22.5% DS-10, about 19% to about 23 .... S-10, about 18.5% to about 23% DS-10, about 19% to about 23% DS-10, about 19.5% to about 23% DS-10, about 20% to about 23% DS-10, about 20.5% to about 23% DS-10, about 21% to about 23% DS-10, about 21.5% to about 23% DS-10, about 22% to about 23% DS-10, about 17.5% to about 22.5% DS-10, about 18% to about 22% DS-10, about 18.5% to about 21.5% DS-10, about 19% to about 21% DS-10, or about 19.5% to about 20.5% DS-10.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 17.0%, 17.1%, 17.2%, 17.3%, 17.4%, 17.5%, 17.6%, 17.7%, 17.8%, 17.9%, 18.0%, 18.1%, 18.2%, 18.3%, 18.4%, 18.5%, 18.6%, 18.7%, 18.8%, 18.9%, 19.0%, 19.1%, 19.2%, 19.3%, 19.4%, 19.5%, 19.6%, 19.7%, 19.8%, 19 ... %, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, 22.9%, or about 23.0% DS- 10. In an exemplary embodiment, the area of DS-10 in the MALDI-TOF-MS spectrum is 20.35%.
[0320] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9% to about 15% DS-11. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9% to about 9.5% DS-11, about 9.5% to about 10% DS-11, about 10% to about 10.5% DS-11, about 10.5% to about 11% DS-11, about 11% to about 11.5% DS-11, about 11.5% to about 12% DS-11, about 12% to about 12.5% DS-11, about 12.5% to about 13% DS-11, about 13% to about 13.5% DS-11, about 13.5% to about 14% DS-11, about 14% to about 14.5% DS-11, or about 14.5% to about 15% DS-11. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9% to about 10% DS-11, about 9% to about 10.5% DS-11, about 9% to about 11% DS-11, about 9% to about 11.5% DS-11, about 9% to about 12% DS-11, about 9% to about 12.5% DS-11, about 9% to about 13% DS-11, about 9% to about 13.5% DS-11, about 9% to about 14% DS-11, about 9% to about 14.5% DS-11, about 9.5% to about 15% DS-11, about 10% to about 15% DS-11, About 10.5% to about 15% DS-11, about 11% to about 15% DS-11, about 11.5% to about 15% DS-11, about 12% to about 15% DS-11, about 12.5% to about 15% DS-11, about 13% to about 15% DS-11, about 13.5% to about 15% DS-11, about 14% to about 15% DS-11, about 9.5% to about 14.5% DS-11, about 10% to about 14% DS-11, about 10.5% to about 13.5% DS-11, about 11% to about 13% DS-11, or about 11.5% to about 12.5% DS-11.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10.0%, 10.1%, 10.2%, 10.3%, 10.4%, 10.5%, 10.6%, 10.7%, 10.8%, 10.9%, 11.0%, 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, 11.6%, 11.7%, 11.8%, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 13.1% %, 11.9%, 12.0%, 12.1%, 12.2%, 12.3%, 12.4%, 12.5%, 12.6%, 12.7%, 12.8%, 12.9%, 13.0%, 13.1%, 13.2%, 13.3%, 13.4%, 13.5%, 13.6%, 13.7%, 13.8%, 13.9%, 14.0%, 14.1%, 14.2%, 14.3%, 14.4%, 14.5%, 14.6%, 14.7%, 14.8%, 14.9%, or about 15.0% DS- 11. In an exemplary embodiment, the area of DS- 11 in the MALDI-TOF-MS spectrum is 12.02%.
[0321] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2% to about 8% DS- 12. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2% to about 2.5% DS-12, about 2.5% to about 3% DS-12, about 3% to about 3.5% DS-12, about 3.5% to about 4% DS-12, about 4% to about 4.5% DS-12, about 4.5% to about 5% DS-12, about 5% to about 5.5% DS-12, about 5.5% to about 6% DS-12, about 6% to about 6.5% DS-12, about 6.5% to about 7% DS-12, about 7% to about 7.5% DS-12, or about 7.5% to about 8% DS-12. In some additional aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2% to about 3% DS-12, about 2% to about 3.5% DS-12, about 2% to about 4% DS-12, about 2% to about 4.5% DS-12, about 2% to about 5% DS-12, about 2% to about 5.5% DS-12, about 2% to about 6% DS-12, about 2% to about 6.5% DS-12, about 2% to about 7% DS-12, about 2% to about 7.5% DS-12, about 2.5% to about 8% DS-12, about 3% to about 8% DS-12. DS-12, about 3.5% to about 8% DS-12, about 4% to about 8% DS-12, about 4.5% to about 8% DS-12, about 5% to about 8% DS-12, about 5.5% to about 8% DS-12, about 6% to about 8% DS-12, about 6.5% to about 8% DS-12, about 7% to about 8% DS-12, about 2.5% to about 7.5% DS-12, about 3% to about 7% DS-12, about 3.5% to about 6.5% DS-12, about 4% to about 6% DS-12, or about 4.5% to about 5.5% DS-12.In yet other aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.8%, 7.9%, 8.0%, 8.1%, 8. %, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, or about 8.0% DS- 12. In an exemplary embodiment, the area of DS- 12 in the MALDI-TOF-MS spectrum is 4.85%.
[0322] In an exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include about 0.5% to about 6% DS-6, about 8% to about 14% DS-7, about 19% to about 25% DS-8, about 23% to about 29% DS-9, about 17% to about 23% DS-10, about 9% to about 15% DS-11, and about 2% to about 8% DS-12.
[0323] In another exemplary embodiment, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include DS-6, DS-7, DS-8, DS-9, DS-10, DS-11, and DS-12; wherein the mixture includes less than 1% DS-5, DS-4, DS-3, DS-2, and DS-1; and wherein the mixture includes less than 1% DS-13 and DS-14.
[0324] In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can have an average degree of substitution of about 7 to about 8. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can have an average degree of substitution of about 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or about 8.0. In an exemplary embodiment, the mixture of hydroxypropyl-β-cyclodextrin molecules can have an average degree of substitution of about 7.42.
[0325] The positions of substitution in the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can be determined using methods known to those skilled in the art. In some embodiments, the composition can be composed of 1 H-NMR characterization. In some aspects, 1 H-NMR can be used to determine the degree of substitution of a composition. 1 H-NMR spectra are provided in Figure 11 In some embodiments, the composition can be characterized by DEPT-edited HSQC. Exemplary DEPT-edited HSQC spectra are provided in Figure 12 middle.
[0326] In some embodiments, about 36% to about 42% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecules may be located at the 3-O-position. In some aspects, the percent substitution at the 3-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules may be about 36% to about 37%, about 37% to about 38%, about 38% to about 39%, about 39% to about 40%, about 40% to about 41%, or about 41% to about 42%. In some additional aspects, the percent substitution at the 3-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules may be about 36% to about 38%, about 36% to about 39%, about 36% to about 40%, about 36% to about 41%, about 37% to about 42%, about 38% to about 42%, about 39% to about 42%, about 40% to about 42%, about 37% to about 41%, or about 38% to about 40%. In an exemplary embodiment, the percent substitution at the 3-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 39.00%.
[0327] In some embodiments, about 58% to about 64% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecule are located at the 2-O-position. In some aspects, the substitution percentage at the 2-O-position in the mixture of the hydroxypropyl-β-cyclodextrin molecules is about 58% to about 59%, about 59% to about 60%, about 60% to about 61%, about 61% to about 62%, about 62% to about 63%, or about 63% to about 64%. In some additional aspects, the substitution percentage at the 2-O-position in the mixture of the hydroxypropyl-β-cyclodextrin molecules is about 58% to about 60%, about 58% to about 61%, about 58% to about 62%, about 58% to about 63%, about 59% to about 64%, about 60% to about 64%, about 61% to about 64%, about 62% to about 64%, about 59% to about 63%, or about 60% to about 62%. In an exemplary embodiment, the percent substitution at the 2-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 61.14%.
[0328] In some embodiments, the percent substitution at the 6-O-position in the mixture of hydroxypropyl-β-cyclodextrin molecules is about 0%.
[0329] In some embodiments, the composition may have Figure 13 HPLC-CAD chromatogram. In some aspects, the average retention time of the composition, as measured by HPLC-CAD, can be from about 11 minutes to about 13 minutes. In some additional aspects, the average retention time of the composition can be from about 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9 or about 13.0 minutes. In an exemplary embodiment, the average retention time is about 11.9 minutes.
[0330] In some embodiments, the composition may have a -ESI-MS spectrum with peaks at about 682 m / z, about 712 m / z, about 740 m / z, about 770 m / z, about 798 m / z, about 828 m / z, about 856 m / z, and about 886 m / z. In some embodiments, the composition may have a +ESI-MS spectrum with peaks at about 744 m / z, about 773 m / z, about 803 m / z, about 832 m / z, about 860 m / z, about 889 m / z, and about 919 m / z. In an exemplary embodiment, the composition has Figure 14 ESI-MS spectra shown in .
[0331] The percentage of hydroxypropyl-β-cyclodextrin can be based on the area percentage of the MALDI-TOF-MS spectrum. In some embodiments, the composition can have a MALDI-TOF-MS spectrum with peaks at about 1497 m / z, about 1557 m / z, about 1616 m / z, about 1675 m / z, about 1734 m / z, about 1794 m / z, and about 1914 m / z. In an exemplary embodiment, the composition has Figure 15 In one exemplary embodiment, the composition has a MALDI-TOF-MS spectrum in which DS-6 has an area of 2.91%, DS-7 has an area of 10.93%, DS-8 has an area of 22.52%, DS-9 has an area of 26.42%, DS-10 has an area of 20.35%, DS-11 has an area of 12.02%, and DS-12 has an area of 4.85%.
[0332] In some embodiments, the composition may have a true density of about 1.095 g / cm 3to about 1.100g / cm 3 In some aspects, the composition may have a true density of about 1.095 g / cm 3 to about 1.096 g / cm 3 , about 1.096g / cm 3 to about 1.097 g / cm 3 , about 1.097g / cm 3 to about 1.098 g / cm 3 , about 1.098g / cm 3 to about 1.099 g / cm 3 , about 1.099g / cm 3 to about 1.100g / cm 3 , about 1.095g / cm 3 to about 1.097 g / cm 3 , about 1.095g / cm 3 to about 1.098 g / cm 3 , about 1.095g / cm 3 to about 1.099 g / cm 3 , about 1.096g / cm 3 to about 1.100g / cm 3 , about 1.097g / cm 3 to about 1.100g / cm 3 , about 1.098g / cm 3 to about 1.100g / cm 3 , about 1.096g / cm 3 to about 1.098 g / cm 3 or about 1.096 g / cm 3 to about 1.099 g / cm 3 In some additional aspects, the composition may have a true density of about 1.095 g / cm 3 , 1.096g / cm 3 , 1.097g / cm 3 , 1.098g / cm 3 , 1.099g / cm 3 or about 1.100g / cm 3 In one exemplary embodiment, the composition has a true density of about 1.096 g / cm 3 to about 1.098 g / cm 3 .
[0333] In some embodiments, the osmolality of the composition can be from about 600 mOs / kg to about 750 mOs / kg. In some aspects, the osmolality of the composition can be from about 600 mOs / kg to about 625 mOs / kg, from about 625 mOs / kg to about 650 mOs / kg, from about 650 mOs / kg to about 675 mOs / kg, from about 675 mOs / kg to about 700 mOs / kg, from about 700 mOs / kg to about 725 mOs / kg, or from about 725 mOs / kg to about 750 mOs / kg. In some additional aspects, the composition may have an osmolality of about 600 mOs / kg to about 650 mOs / kg, about 600 mOs / kg to about 675 mOs / kg, about 600 mOs / kg to about 700 mOs / kg, about 600 mOs / kg to about 725 mOs / kg, about 625 mOs / kg to about 750 mOs / kg, about 650 mOs / kg to about 750 mOs / kg, about 675 mOs / kg to about 750 mOs / kg, about 700 mOs / kg to about 750 mOs / kg, about 625 mOs / kg to about 725 mOs / kg, or about 650 mOs / kg to about 700 mOs / kg. In yet other embodiments, the composition can have an osmolality of about 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, or about 750 mOs / kg. In an exemplary embodiment, the composition has an osmolality of about 635 to about 695 mOs / kg.
[0334] In some embodiments, the composition may have a conductivity between about 0 and about 8 μS / cm. In some aspects, the composition may have a conductivity between about 0 and about 1 μS / cm, about 1 and about 2 μS / cm, about 3 and about 4 μS / cm, about 4 and about 5 μS / cm, about 5 and about 6 μS / cm, about 6 and about 7 μS / cm, or about 7 and about 8 μS / cm. In some additional embodiments, the electrical conductivity of the composition may be between about 0 μS / cm and about 1.5 μS / cm, about 0 μS / cm and about 2 μS / cm, about 0 μS / cm and about 2.5 μS / cm, about 0 μS / cm and about 3 μS / cm, about 0 and about 3.5 μS / cm, about 0 μS / cm and about 4 μS / cm, about 0 and about 4.5 μS / cm, about 0 μS / cm and about 5 μS / cm, about 0 and about 5.5 μS / cm, about 0 μS / cm and about 6 μS / cm, about 0 and about 6.5, about 0 μS / cm and about 7 μS / cm, about 0 and about 7.5, about 1 μS / cm and about 8 μS / cm, about 1.5 μS / cm and about 10 μS / cm. / cm and about 8 μS / cm, about 2 μS / cm and about 8 μS / cm, about 2.5 μS / cm and about 8 μS / cm, about 3 μS / cm and about 8 μS / cm, about 3.5 μS / cm and about 8 μS / cm, about 4 μS / cm and about 8 μS / cm, about 4.5 μS / cm and about 8 μS / cm, about 5 μS / cm and about 8 μS / cm, about 5.5 μS / cm and about 8 μS / cm, about 6 μS / cm and about 8 μS / cm, about 6.5 μS / cm and about 8 μS / cm, about 1 μS / cm and about 7 μS / cm, about 2 μS / cm and about 6 μS / cm, or about 3 μS / cm and about 5 μS / cm. In still other aspects, the composition can have a conductivity of about 0.5 μS / cm, 1.0 μS / cm, 1.5 μS / cm, 2.0 μS / cm, 2.5 μS / cm, 3.0 μS / cm, 3.5 μS / cm, 4.0 μS / cm, 4.5 μS / cm, 5.0 μS / cm, 5.5 μS / cm, 6.0 μS / cm, 6.5 μS / cm, 7.0 μS / cm, 7.5 μS / cm, or about 8.0 μS / cm.
[0335] In some embodiments, the pH of the composition can be from about 4.0 to about 8.0; for example, the pH of the composition can be about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or about 8.0. The pH of the composition can be within a range or sub-range comprising any of the above numbers, including but not limited to the following pH: about 4.0 to about 4.5, about 4.5 to about 5.0, about 5.0 to about 5.5, about 5.5 to about 6.0, about 6.0 to about 6.5, about 6.5 to about 7.0, about 7.0 to about 7.5, or about 7.5 to about 8.0. In some embodiments, the composition may also include a pH adjusting agent, such as hydrochloric acid or sodium hydroxide, to adjust the pH to the desired level. In some embodiments, the composition may also include a buffer. In some embodiments, the buffer may include sodium dihydrogen phosphate and disodium hydrogen phosphate.
[0336] In some embodiments, the composition can have a viscosity measured in centipoise (cP) at 20° C. For example, the composition can have a viscosity of about 1.5 cP to about 3.0 cP at 20° C. In some embodiments, the composition can have a viscosity of about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, , 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9 or about 10.0 cP. In other embodiments, the viscosity of the composition at 20°C may be from about 3.0 cP to about 5.0 cP, from about 5.0 cP to about 10.0 cP, from about 10 to about 15 cP, from about 15 to about 20 cP, from about 20 cP to about 25 cP, from about 25 cP to about 50 cP, from about 50 cP to about 80 cP, from about 80 cP to about 150 cP, from about 150 cP to about 250 cP, from about 250 cP to about 500 cP, from about 500 cP to about 1,000 cP, from about 1,000 cP to about 2,000 cP, from about 2,000 cP to about 3,000 cP, from about 3,000 cP to about 5,000 cP, or from about 5,000 cP to about 10,000 cP.
[0337] The composition can be substantially free of impurities. Impurities include particles having a diameter greater than or equal to 25 microns, particles having a diameter greater than or equal to 10 microns, chlorides, propylene glycol, propylene oxide, and other unspecified impurities. In some embodiments, the composition can include less than or equal to about 0.05% impurities; for example, the composition can include less than or equal to about 0.05%, 0.04%, 0.03%, 0.02%, or less than or equal to about 0.01% impurities.
[0338] In some embodiments, the composition may further comprise a container and non-visible particulate matter. In some embodiments, the composition may be provided in a container. In some embodiments, the composition may further comprise non-visible particulate matter.
[0339] In some embodiments, the composition can include less than 600 particles / container having a diameter greater than or equal to 25 microns. In some aspects, the composition can include less than 500, less than 400, less than 300, less than 200, or less than 100 particles / container having a diameter greater than or equal to 25 microns.
[0340] In some embodiments, the composition may include less than 6,000 particles having a diameter greater than or equal to 10 microns per container. In some aspects, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, or less than 100 particles having a diameter greater than or equal to 10 microns per container. In another aspect, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, or less than 100 particles having a diameter greater than or equal to 10 microns per container, wherein the container is ≤ 100 mL. In another aspect, the composition may include less than 5,000, less than 4,000, less than 3,000, less than 2,000, less than 1,000, less than 500, less than 100, less than 50, less than 25, less than 10, less than 5, or less than 3 particles having a diameter greater than or equal to 10 microns per container, wherein the container is > 100 mL.
[0341] In some embodiments, the composition may include no more than 10ppb propylene glycol. In some aspects, the composition may include no more than 9ppb, 8ppb, 7ppb, 6ppb, 5ppb, 4ppb, 3ppb, 2ppb or no more than 1ppb propylene glycol. In some aspects, the amount of the propylene glycol in the composition can be measured by HPLC. In some additional aspects, the amount of the propylene glycol in the composition can be measured by gas chromatography. In other aspects, the amount of the propylene glycol in the composition can be measured by measuring the PG / EG ratio of propylene glycol and ethylene glycol.
[0342] In some embodiments, the composition may include no more than 1ppm propylene oxide. In some aspects, the composition may include no more than 0.9ppm, 0.8ppm, 0.7ppm, 0.6ppm, 0.5ppm, 0.4ppm, 0.3ppm, 0.2ppm or 0.1ppm propylene oxide. In some aspects, the amount of propylene oxide in the composition can be measured by HPLC. In some additional aspects, the amount of propylene oxide in the composition can be measured by gas chromatography.
[0343] In some embodiments, the composition may include between about 0 ppm and about 10 ppm of chloride (e.g., Cl -ions). In some aspects, the composition may include about 0ppm chloride to about 2ppm chloride, about 2ppm chloride to about 4ppm chloride, about 4ppm chloride to about 6ppm chloride, about 6ppm chloride to about 8ppm chloride or about 8 to about 10ppm chloride. In some additional aspects, the composition may include about 0ppm chloride to about 4ppm chloride, about 0ppm chloride to about 6ppm chloride, about 0ppm chloride to about 8ppm chloride, about 2ppm chloride to about 1ppm chloride, about 4ppm chloride to about 1ppm chloride or about 6ppm chloride to about 1ppm chloride. In other aspects, the composition may include about 0ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm or about 10ppm chloride. In an exemplary embodiment, the composition may include the chloride between about 0ppm to about 1ppm.
[0344] In some embodiments, the composition may include between about 0 ppm and about 10 ppm of sodium (e.g., Na + ions). In some aspects, the composition can include about 0ppm sodium to about 2ppm sodium, about 2ppm sodium to about 4ppm sodium, about 4ppm sodium to about 6ppm sodium, about 6ppm sodium to about 8ppm sodium or about 8 to about 10ppm sodium. In some additional aspects, the composition can include about 0ppm sodium to about 4ppm sodium, about 0ppm sodium to about 6ppm sodium, about 0ppm sodium to about 8ppm sodium, about 2ppm sodium to about 1ppm sodium, about 4ppm sodium to about 1ppm sodium or about 6ppm sodium to about 1ppm sodium. In other aspects, the composition can include about 0ppm, 1ppm, 2ppm, 3ppm, 4ppm, 5ppm, 6ppm, 7ppm, 8ppm, 9ppm or about 10ppm sodium. In an exemplary embodiment, the composition can include the sodium between about 0ppm to about 1ppm.
[0345] In some embodiments, the composition can include less than or equal to 0.05% other unspecified impurities; for example, the composition can include less than or equal to 0.05%, 0.04%, 0.03%, 0.02%, or less than or equal to 0.01% other unspecified impurities.
[0346] In some embodiments, the composition can be stable for at least 6 months. For example, the composition can be stable for at least 3 months, 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 24 months, or at least 36 months.
[0347] The composition can be nanofiltered. In some embodiments, the concentration of the composition does not substantially change the time required for nanofiltration. Thus, the time required for nanofiltration does not increase or decrease as the concentration of the mixture of β-cyclodextrin molecules in the composition increases or decreases. In some aspects, the time required for nanofiltration of the composition is between about 1.04 and about 1.20 hours per diafiltration volume (kg soln / m 2 In some embodiments, no substantial differences are observed in the composition after nanofiltration by HPLC-ELSD compared to before nanofiltration. In some embodiments, no substantial differences are observed in the composition after nanofiltration by NMR compared to before nanofiltration.
[0348] In some embodiments, the composition can be terminally sterilized. Terminal sterilization methods are generally well known in the art. In some embodiments, the pH of the composition can be adjusted after terminal sterilization.
[0349] In some embodiments, the composition can include less than or equal to 10.0% w / w water. For example, the composition can include less than or equal to 10.0% w / w, 9.5% w / w, 9.0% w / w, 8.5% w / w, 8.0% w / w, 7.5% w / w, 7.0% w / w, 6.5% w / w, 6.0% w / w, 5.5% w / w, 5.0% w / w, 4.5% w / w, 4.0% w / w, 3.5% w / w, 3.0% w / w, 2.5% w / w, 2.0% w / w, 1.5% w / w, 1.0% w / w, 0.5% w / w, or less than or equal to 0.1% w / w water.
[0350] In some embodiments, the composition can be packaged in a vial suitable for injection into a human subject in need. The vial can be made of glass, plastic, or any other material known in the pharmaceutical art. The vial can be coated with a material such as silicon dioxide to prevent infiltration from the vial into the composition.
[0351] In some embodiments, the composition may be effective in treating Niemann-Pick disease. In some embodiments, the composition may be effective in treating Niemann-Pick disease type C. In some embodiments, the composition may be effective in treating liver disease. In some embodiments, the composition may be effective in treating cardiovascular disease. In some embodiments, the composition may be effective in treating familial hypercholesterolemia. In some embodiments, the composition may be effective in treating cholesterol deposition.
[0352] In some embodiments, the composition may further comprise a pharmaceutical excipient or carrier. In some embodiments, the composition may further comprise a pharmaceutically acceptable diluent. Examples of pharmaceutical excipients, carriers, and diluents are well known to those skilled in the art.
[0353] In some embodiments, the composition may exhibit Cyclo or In some embodiments, the composition may exhibit a lower toxicity than Cyclo or Substantially Low Ototoxicity. In some embodiments, the composition may exhibit substantially no ototoxicity.
[0354] Fraction 3HDS
[0355] Provided herein is a composition comprising a mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules, the mixture comprising less than 1% DS-6 and less than 1% DS-14. In some embodiments, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may comprise less than 1% DS-5, DS-4, DS-3, DS-2, and DS-1. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may comprise less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-5, DS-4, DS-3, DS-2, and DS-1. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules can include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-6, DS-5, DS-4, DS-3, DS-2, and / or DS- 1. In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules is free of DS-5, DS-4, DS-3, DS-2, and / or DS-1.
[0356] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules may include less than 1% DS- 14. In some aspects, the mixture of isomerically purified hydroxypropyl-β-cyclodextrin molecules may include less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, or less than 0.1% DS-14.
[0357] In some embodiments, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 1% to about 7% DS-7. In some aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 1% to about 1.5% DS-7, about 1.5% to about 2% DS-7, about 2% to about 2.5% DS-7, about 2.5% to about 3% DS-7, about 3% to about 3.5% DS-7, about 3.5% to about 4% DS-7, about 4% to about 4.5% DS-7, about 4.5% to about 5% DS-7, about 5% to about 5.5% DS-7, about 5.5% to about 6% DS-7, about 6% to about 6.5% DS-7, or about 6.5% to about 7% DS-7. In some additional aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 1% to about 2% DS-7, about 1% to about 2.5% DS-7, about 1% to about 3% DS-7, about 1% to about 3.5% DS-7, about 1% to about 4% DS-7, about 1% to about 4.5% DS-7, about 1% to about 5% DS-7, about 1% to about 5.5% DS-7, about 1% to about 6% DS-7, about 1% to about 6.5% DS-7, about 1.5% to about 7% DS-7, about 2% to about 7% DS-7, or about 2% to about 7% DS-7. S-7, about 2.5% to about 7% DS-7, about 3% to about 7% DS-7, about 3.5% to about 7% DS-7, about 4% to about 7% DS-7, about 4.5% to about 7% DS-7, about 5% to about 7% DS-7, about 5.5% to about 7% DS-7, about 6% to about 7% DS-7, about 1.5% to about 6.5% DS-7, about 2% to about 6% DS-7, about 2.5% to about 5.5% DS-7, about 3% to about 5% DS-7 or about 3.5% to about 4.5% DS-7. In still other aspects, the mixture of hydroxypropyl-β-cyclodextrin molecules can include about 1.0%, ...
Claims
1. A composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: Octa-hydroxypropyl-substituted β-cyclodextrin ("DS-8"); Nine hydroxypropyl substituted β-cyclodextrin ("DS-9"); β-cyclodextrin substituted with ten hydroxypropyl groups ("DS-10"); β-cyclodextrin substituted with eleven hydroxypropyl groups ("DS-11"); β-cyclodextrin substituted with twelve hydroxypropyl groups ("DS-12"); Thirteen hydroxypropyl substituted β-cyclodextrin ("DS-13"); and Fourteen hydroxypropyl substituted β-cyclodextrin ("DS-14"), wherein the composition comprises less than 1% seven hydroxypropyl substituted β-cyclodextrin ("DS-7").
2. The composition of claim 1, wherein the composition comprises less than 1% β-cyclodextrin substituted with six hydroxypropyl groups ("DS-6"), 1% β-cyclodextrin substituted with five hydroxypropyl groups ("DS-5"), β-cyclodextrin substituted with four hydroxypropyl groups ("DS-4"), β-cyclodextrin substituted with three hydroxypropyl groups ("DS-3"), β-cyclodextrin substituted with two hydroxypropyl groups ("DS-2"), and β-cyclodextrin substituted with one hydroxypropyl group ("DS-1").
3. The composition of claim 1 or 2, wherein the DS-10 has the highest concentration in the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules compared to DS-8, DS-9, DS-11, DS-12, DS-13, and DS-14.
4. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 6% to about 12% DS-8; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 7% to about 11% DS-8.
5. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 18% to about 24% DS-9; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 19% to about 23% DS-9.
6. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 24% to about 30% DS-10; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises about 25% to about 29% DS-10.
7. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 18% to about 24% DS-11; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 19% to about 23% DS-11.
8. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 10% to about 16% DS-12; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 11% to about 15% DS-12.
9. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 4% to about 10% DS-13; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 5% to about 9% DS-13.
10. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl beta-cyclodextrin molecules comprises from about 0% to about 6% DS-14; For example, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules comprises from about 1% to about 5% DS-14.
11. The composition of any of the preceding claims, wherein the mixture of isomerically purified hydroxypropyl β-cyclodextrins has an average degree of substitution of from about 9 to about 10; For example, the average degree of substitution of the isomerically purified hydroxypropyl β-cyclodextrin mixture is about 9.
65.
12. The composition of any of the preceding claims, wherein about 15% to about 21% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecules is at the 3-O-position; For example, about 16% to about 20% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecule is at the 3-O-position.
13. The composition of any of the preceding claims, wherein about 79% to about 85% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecule is at the 2-O-position; For example, about 80% to about 84% of the hydroxypropyl substitution in the hydroxypropyl β-cyclodextrin molecule is at the 2-O-position.
14. The composition of any of the preceding claims, wherein the composition has the HPLC-CAD chromatogram of Figure 28.
15. The composition of claim 14, wherein the composition has an average retention time of about 15.4 minutes.
16. The composition of any of the preceding claims, wherein the composition has an ESI-MS spectrum with peaks at about 770 m / z, about 798 m / z, about 828 m / z, about 857 m / z, about 885 m / z.
17. The composition of any of the preceding claims, wherein the composition has a +ESI-MS spectrum with peaks at about 803 m / z, about 831 m / z, about 861 m / z, about 889 m / z, and about 919 m / z.
18. The composition of any of the preceding claims, wherein the composition has the ESI-MS spectrum of Figure 29.
19. The composition of any of the preceding claims, having a MALDI-TOF spectrum with peaks at about 1614 m / z, about 1673 m / z, about 1733 m / z, about 1792 m / z, about 1852 m / z, about 1912 m / z, and about 1971 m / z.
20. The composition of any preceding claim having a MALDI-TOF spectrum of Figure 30.
21. The composition of claim 20, wherein the area percentage of DS-8 is 8.53%.
22. The composition of claim 20 or 21, wherein the area of DS-9 is 21.33%; and / or The area of DS-10 is 26.58%; and / or wherein the area of DS-11 is 20.90%; and / or wherein the area of DS-12 is 13.31%; and / or wherein the area of DS-13 is 6.74%; and / or wherein the area of DS-14 is 2.60%.
23. A composition as described in any of the preceding claims, which has the 1H-NMR spectrum of Figure 26.
24. The composition of any preceding claim having the DEPT-edited HSQC spectrum of Figure 27.
25. The composition of any of the preceding claims, wherein the composition has an osmolality of about 635-695 mOs / kg; And / or wherein the true density of the composition is about 1.096-1.098 g / cm 3 .
26. The composition of any one of the preceding claims, wherein the composition comprises no more than 10 ppb propylene glycol as measured by HPLC.
27. The composition of any one of the preceding claims, wherein the composition comprises no more than 10 ppb propylene glycol as measured by gas chromatography.
28. The composition of any preceding claim, wherein the composition comprises no more than 10 ppb propylene glycol as measured by the PG / EG ratio of propylene glycol to ethylene glycol.
29. The composition of any preceding claim, wherein the composition comprises no more than 1 ppm propylene oxide.
30. The composition of any of the preceding claims, wherein the total amount of other unspecified impurities is less than or equal to 0.05% as measured by HPLC.
31. A composition as claimed in any one of the preceding claims, wherein the composition comprises between 0 and 10 ppm chloride; For example, wherein the composition comprises between 0 and 1 ppm chloride.
32. A composition as claimed in any one of the preceding claims, wherein the conductivity of the composition is between 0 and 8 μS / cm; For example, wherein the conductivity of the composition is between 0 and 4.5 μS / cm; For example, wherein the conductivity of the composition is between 0 and 3 μS / cm; For example, the conductivity of the composition is between 0 and 1.5 μS / cm.
33. The composition of any one of the preceding claims, wherein the composition is nanofiltered.
34. The composition of claim 33, wherein no substantial difference is observed in HPLC-ELSD of the nanofiltered composition after nanofiltration compared to before nanofiltration.
35. The composition of claim 33, wherein no substantial difference is observed in the NMR of the nanofiltered composition after nanofiltration compared to before nanofiltration.
36. A composition comprising a mixture of isomerically purified hydroxypropyl β-cyclodextrin molecules, the mixture comprising: about 6% to about 12% eight hydroxypropyl substituted beta-cyclodextrin ("DS-8"); about 18% to about 24% nine hydroxypropyl substituted beta-cyclodextrin ("DS-9"); about 24% to about 30% ten hydroxypropyl substituted beta-cyclodextrin ("DS-10"); about 18% to about 24% eleven hydroxypropyl substituted beta-cyclodextrin ("DS-11"); about 10% to about 16% dodecahydroxypropyl-substituted β-cyclodextrin ("DS-12"); about 4% to about 10% thirteen hydroxypropyl substituted beta-cyclodextrin ("DS-13"); and From about 0% to about 6% fourteen hydroxypropyl substituted beta-cyclodextrin ("DS-14").
37. A composition according to any one of the preceding claims for use in a method of treating or preventing a disease or disorder, for example wherein the disease or disorder is Niemann-Pick disease type C, liver disease, cardiovascular disease, familial hypercholesterolemia and / or cholesterol deposition.
